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Introduction 
In the Netherlands, one in three persons is diagnosed with cancer at some point in their 
lives.1 Because of earlier detection and further developments in cancer treatment, cancer 
survival rates have increased in the past decades and the number of cancer survivors is 
growing. Therefore, long term side effects of cancer treatment are becoming more and 
more important. There are several known long term effects after cancer treatment, like 
fatigue, pain and cognitive complaints.2, 3 Weight gain has also been described as a 
possible long term concern in breast cancer patients that were treated with 
chemotherapy.4, 5 This gain in weight is associated with a decreased quality of life and an 
increased risk of comorbidities like cardiovascular disease and diabetes.5 Moreover, there 
are studies that suggest that this gain in weight in breast cancer patients is characterised 
by a change in body composition, with an increase in fat mass, and no change or 
decrease of lean mass.6, 7 It is currently unknown whether this increase in weight is due to 
lower energy expenditure, higher energy intake, a combination of the two, or influenced 
by other factors.  
One frequently observed side effect of chemotherapy is a change in taste and smell 
perception, with a prevalence of 45% to 85% for taste changes and 5% to 60% for smell 
changes.8 Possibly, these changes lead to a change in food preferences, and can thereby 
contribute to a changed dietary intake and play a role in weight gain and changing body 
composition in breast cancer patients (figure 1.1). However, the nature of these 
chemosensory changes and their impact on food preferences and dietary intake are not 
well documented in cancer patients undergoing chemotherapy. Furthermore the impact 
of chemosensory changes may go beyond nutritional consequences, as taste and smell 
also play an important role in everyday functioning and quality of life. 
 
 
Figure 1.1 Hypothetical chain of events for how taste and smell changes could contribute to weight 
change and body composition.  
 
Although weight gain may occur in breast cancer, not all cancer patients gain weight 
during chemotherapy. The way chemosensory changes impact food preferences and 
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dietary intake may potentially be different for different types of cancer. Patients with 
cancer in the upper gastrointestinal tract, like oesophagogastrc cancer patients, receive 
different types of chemotherapy than breast cancer patients, and may possibly experience 
different chemosensory alterations and food preferences. Moreover, oesophagogastric 
cancer patients are mostly diagnosed when the disease is already in an advanced stage 
and are often malnourished when they are diagnosed.9 In this thesis, chemosensory 
changes and food preferences will be investigated in two different patient groups, thereby 
possible differences and similarities will indicate to what extent chemosensory and food 
preference changes are patient group specific, and if these might play a differential role in 
nutritional status in cancer patients undergoing chemotherapy.  
This general introduction starts with an overview on the senses of taste and smell, after 
which taste and smell changes, food preferences and intake, and quality of life in patients 
with cancer undergoing chemotherapy will be discussed. The introduction ends with the 
aim and outline of this thesis. 
Taste 
The sense of taste, or gustation, is involved in the enjoyment and evaluation of nutritional 
content of food, and prevention of ingesting potentially toxic foods.10 Humans can 
perceive five distinct basic tastes: sweet, salt, bitter, sour and umami. Sweet and umami 
taste function to signal sugars and amino acids, salt functions to maintain electrolyte 
balance and bitter and sour signal potential poisonous and unripe foods.11 Furthermore, 
there are indications that fat could also be a basic taste, but this is still under debate.12  
Tastes are signalled when they activate taste receptor cells mostly on the tongue, soft 
palate, or oropharynx. These receptor cells constantly regenerate and are renewed every 
9 to 15 days.13 Taste receptor cells are clustered in taste buds, which are in turn located in 
gustatory papillae.13 Tastes are signalled through different types of receptors. Salty and 
sour tastes are signalled through ion channels, while sweet, bitter and umami are 
detected by G-protein-coupled receptors. When tastes are signalled, signals travel to the 
brain through the facial, glosso-pharyngeal and vagus nerve. Signals are first sent to the 
solitary tract of the brain stem after which signals are then synapsed to the thalamus, 
anterior insula and frontal operculum (primary taste cortex), and the orbitofrontal cortex 
(secondary taste cortex).14, 15 
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Smell 
The sense of smell, or olfaction, is much more complex than the sense of taste. Whereas 
there are five basic tastes, it was calculated that humans are able to detect and 
discriminate more than a trillion of different odorants.16 The olfactory system is not only 
important for food and flavour perception, but is also important in identifying potential 
hazards and interpersonal communication.17  
There are two routes whereby odorants can reach the olfactory epithelium, orthonasally 
and retronasally.18 The orthonasal route goes through the nose and gives information on 
ambient odours in the outside world. Before eating, the orthonasal route signals whether 
something is edible or not. Furthermore, external olfactory cues can stimulate appetite in 
the anticipatory phase of eating.19, 20 The retronasal route refers to foods present in the 
mouth. During eating and drinking, volatiles aromas from food are released and travel 
through the oral cavity and pharynx to the olfactory epithelium at the top of the nasal 
cavity, where olfactory receptor neurons are located. Olfactory receptor neurons also 
regularly regenerate, renewing approximately every month.21 When olfactory stimuli reach 
the olfactory receptors, action potentials are sent through the olfactory nerve through the 
cribriform plate to the olfactory bulb in the brain. Different from other senses, olfactory 
signals travel directly to the brain and do not relay through the thalamus. From the 
olfactory bulb, signals are further processed in amongst others the piriform cortex and 
orbitofrontal cortex.14 
When a food is eaten, the gustatory, olfactory and somatosensory (irritation, texture, 
temperature) signals of a food together determine the flavour of the food.22 Flavour is 
therefore a multimodal experience. In everyday life, it is difficult for humans to distinguish 
between the sense of taste and smell as they are so much intertwined. The “taste” of food, 
for most humans, is therefore strongly related to the flavour of a food and this also 
encompasses an olfactory component. 
Taste and smell during chemotherapy in cancer patients 
Many cancer patients undergoing chemotherapy report that their food does not taste the 
same.8 These chemosensory alterations have been reported as an absence of taste or 
smell, reduced or increased sensitivity, distortion of taste or smell, phantom tastes or 
odours and metallic sensations.8 
General introduction 
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There are several possible mechanisms through which chemotherapy could affect taste 
and smell function. The most generally accepted hypothesis is that as chemotherapy 
targets rapidly dividing cells, besides the tumour, taste and smell receptor cells can be 
affected as well. This may lead to a lower number of receptor cells, but possibly also to an 
altered cell structure, changed receptor surface or interrupted neural coding.23 Taste and 
smell changes can start during the first infusion of chemotherapy8, but longitudinal 
studies also show that these changes are transient and mostly recover after 
chemotherapy.24, 25 However, there are also reports of taste and smell changes well 
beyond the end of chemotherapy.26, 27 It is suggested that the nature of taste and smell 
changes may vary among different types of cancer and chemotherapy.28 However, often 
studies have used heterogeneous study populations in terms of types of cancer, types of 
chemotherapy and stage of disease. Therefore systematic reviews failed to draw firm 
conclusions on whether there are specific target groups that suffer most from 
chemosensory changes.8, 29 Therefore it is important to assess taste and smell changes in 
homogeneous groups in terms of types of cancer and chemotherapy, and identify 
potential (clinical) determinants.  
Many studies address taste and smell changes by self-report. However it should be noted 
that for most persons it is difficult to accurately judge their taste or smell function30, 31, let 
alone to actually distinguish taste and smell. As mentioned before, when one is asked 
about taste, the response will mostly involve flavour as a whole. Therefore, to understand 
more on what actually changes during chemotherapy, it also important to measure taste 
and smell function objectively. In this thesis, we use both objective and subjective 
measures of taste and smell, to get insight on whether actual taste and/or smell function 
is affected through chemotherapy and to get understanding of what patients actually 
experience during chemotherapy. 
The taste and smell of foods are important predictors for food preferences and food 
intake. Therefore, when a patients’ taste or smell perception is altered, this may have 
consequences for food preferences and intake. The next part of this introduction will go 
further into these factors. 
Food preferences and food intake 
Taste preferences form early in life. Humans have an innate preference for sweet taste, 
while having an innate aversion for sour and bitter.32 However, food preferences are 
subject to change upon life experience. E.g. although we have an innate aversion for 
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bitter, persons can learn to like coffee. In daily life, food preferences can differ depending 
on factors like the time of the day, the appropriateness of foods within a meal context and 
the meal or food eaten previously.33-35 
Taste and food preferences are related to macronutrient balance. There are studies that 
show that, when humans are brought in a protein-depleted status, their preferences shift 
towards more savoury, protein-rich products to meet the metabolic needs.36, 37 Potentially, 
when taste and/or smell function are changed, this elicits shifts in food preferences and 
thereby can influence food intake during chemotherapy. Assessment of food preferences 
during chemotherapy in cancer patients to date have mostly focussed on reporting food 
products that are experienced as aversive. Products that are frequently reported as 
aversive are meat, caffeinated foods and drinks, and citrus fruits.29 As breast cancer 
patients seem to gain weight, mainly in fat mass and stay stable, or decrease in muscle 
mass, in this thesis, we hypothesise that food preferences may shift from more protein 
rich (savoury) products towards fat and carbohydrate rich (sweet) products in breast 
cancer patients.   
Liking of foods measured on a scale is often used as a measure for food preferences, this 
can range from rating one product, to a questionnaire that includes over 100 food 
items.38, 39 However, it could be that two foods are liked the same, but a specific 
preference becomes apparent when being forced to choose. In addition, in daily life 
humans are exposed to many foods, and have the possibility to choose one product over 
the other. There are methods that assess food preferences with a forced-choice paradigm, 
like the Leeds Food Preference Questionnaire (LFPQ).40 The LFPQ uses food pictures from 
different categories (high or low fat and savoury or sweet). During the task participants 
choose their preferred food between two food products from different categories. This 
method has its limitations, as it only includes one macronutrient (e.g. high and low fat). In 
order to measure shifts for multiple macronutrients and tastes, we developed a new 
method to assess food which is described in chapter 2, and then used as a method to 
assess food preferences in chapter 3 and 4.  
Although food preferences are important predictors for food intake, it is not always 
directly related to food intake. Intake studies in breast cancer patients undergoing 
chemotherapy show conflicting results, with studies showing increases41, decreases42, 43, 
and no changes6, 7, 44 of total energy intake during chemotherapy. Potentially because of 
different methods used to assess dietary intake, and differences in the moment of 
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assessing dietary intake during chemotherapy. Furthermore, studies focussing on dietary 
intake in cancer patients undergoing chemotherapy are limited to reporting total energy 
intake, but information on macronutrient intake, or specific food groups is often lacking. 
Therefore, in chapter 5, the dietary intake of breast cancer patients before and during 
chemotherapy is described, in relation to symptom burden, including subjective taste and 
smell perception.  
Daily life and quality of life 
Taste and smell play a role in eating and drinking, but these senses also play a role in 
identifying potential hazards and social communication.45 Therefore these senses are 
important for everyday functioning, pleasure and enjoyment. Studies have shown that 
individuals who suffer from olfactory dysfunction have more depression and anxiety 
symptoms, feel more isolated and can have relationship difficulties.46, 47 Therefore, 
chemosensory dysfunction can have a serious impact on quality of life.  
Quality of life outcomes are becoming more and more important in oncology research. In 
clinical trials, quality of life outcomes give additional information to the clinical endpoints 
used for determining the patients’ benefits and toxicity of treatment.48 Several studies 
have shown that in cancer patients undergoing chemotherapy, patients that experience 
taste and/or smell changes have a lower quality of life.28, 49 However, studies are mostly 
conducted in heterogeneous study populations, while experiences may vary in different 
patient groups. To get a better understanding on how taste and smell changes may 
impact daily life and quality of life, we assess the impact of taste and smell changes on 
quality of life in this thesis, both in oesophagogastric cancer patients (chapter 6) and in 
breast cancer patients (chapter 7). 
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chemosensory dysfunction can have a serious impact on quality of life.  
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used for determining the patients’ benefits and toxicity of treatment.48 Several studies 
have shown that in cancer patients undergoing chemotherapy, patients that experience 
taste and/or smell changes have a lower quality of life.28, 49 However, studies are mostly 
conducted in heterogeneous study populations, while experiences may vary in different 
patient groups. To get a better understanding on how taste and smell changes may 
impact daily life and quality of life, we assess the impact of taste and smell changes on 
quality of life in this thesis, both in oesophagogastric cancer patients (chapter 6) and in 
breast cancer patients (chapter 7). 
  
Chapter 1 
14 
Aim and thesis outline 
Taste and smell changes during chemotherapy in cancer patient can have an impact on 
food preferences, food intake, daily life and quality of life. However, the direction of these 
relations is hardly studied and needs further investigation in specific cancer populations. 
The overall aim of this thesis is to assess how the sense of taste and smell change upon 
treatment with chemotherapy in two specific cancer populations, and to investigate their 
consequences in terms of food preferences, food intake and quality of life. For that, four 
research questions were defined: 
1. How can we systematically measure food preferences in terms of macronutrients 
and tastes? 
2. How do (objective and subjective) taste and smell perception change over the 
course of chemotherapy? 
3. How do food preferences and food intake change over the course of 
chemotherapy, and are they related to taste and smell perception? 
4. What are the consequences of chemosensory changes during chemotherapy for 
daily life and quality of life? 
The first research question is addressed in chapter 2, which shows the development and 
validation of the Macronutrient and Taste Preference Ranking Task (MTPRT). In chapter 3 
and 4, research question 2 and 3 are addressed, with two studies assessing objective and 
subjective taste and smell function, as well as food preferences assessed with the MTPRT, 
during chemotherapy in both oesophagogastric cancer patients and breast cancer 
patients. Chapter 5 investigates the actual dietary intake in detail during chemotherapy in 
breast cancer patients, and the association between chemotherapy related symptoms 
(including taste and smell) and dietary intake (question 3).  
To get more insight into the consequences of taste and smell changes during 
chemotherapy on daily life and quality of life (question 4), chapter 6 describes a 
qualitative study on the experience of chemosensory and food-related changes and their 
impact on daily life in oesophagogastric cancer patients. Then in chapter 7, we assess the 
association between taste and smell changes and quality of life after chemotherapy in 
breast cancer patients. 
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Finally, in chapter 8 of this thesis, the main findings of the studies are summarized and 
discussed. This discussion puts the findings in perspective and gives implications for 
practice and directions for future research. 
The chapters involving breast cancer patients (chapter 4, 5 and 7) were done within the 
COBRA-study (see box 1). 
 
 
  
Box 1. The COBRA-study stands for Change of Body composition in Breast cancer: All-in Assessment. 
In this prospective cohort, breast cancer patients are followed over the course of chemotherapy 
treatment, with measurements before, during, shortly after and 6 months after chemotherapy. These 
patients are compared to a similar group of women without cancer, who are followed over a similar 
time frame. Overall, the aim of the COBRA-study is to assess changes in body composition during and 
after treatment for breast cancer, and to study whether lifestyle, sensory perception, hormone levels, 
personal characteristics and treatment related factors have an impact on those changes. The study 
also includes a qualitative arm, to get insight into the perceptions of breast cancer patients on why 
potential changes in dietary intake, physical activity and quality of life occur. 
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Abstract 
Food preferences are for a large part determined by the macronutrient content and taste 
of foods, but may change depending on internal and external factors. Here, we discuss a 
newly developed food preference task, the Macronutrient and Taste Preference Ranking 
Task (MTPRT), in which participants rank groups of four food products according to how 
much they desire to eat the products. The MTPRT includes pictures of sweet and savoury 
food products from four categories: high-carbohydrate, high-fat, high-protein and low-
energy. A within-subjects study on sensory-specific satiety was conducted to assess the 
task’s reliability and validity. Sixty-nine healthy participants performed two test sessions 
that were at least one week apart. Participants ate either a sweet or a savoury meal, which 
were similar in macronutrient content. Before and after eating the meal participants rated 
appetite and completed the MTPRT. In hungry state, preference scores for all food 
categories were significantly correlated between the two test sessions (all r > 0.68, all p < 
0.001). Preference for sweet decreased after the sweet meal and increased after the 
savoury meal. In addition, preference for protein decreased more after consuming the 
savoury meal than it did after consuming the sweet meal. Preference for carbohydrate 
and fat decreased after meal consumption, regardless of taste. Preference for low-energy 
increased after meal consumption. These results show the MTPRT is a reliable and valid 
task for measuring food preferences. The MTPRT can be used for both hypothesis-driven 
and exploratory studies to examine the influence of different factors on changes in food 
preferences. 
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Introduction 
Sensory properties of foods play an important role in the preferences for and intake of 
food.1 The basic tastes seem to have specific signalling functions for the body, in that 
sweet taste signals carbohydrates, and salty and savoury taste signals protein and 
electrolytes.2 Indeed, various studies have demonstrated relations between sugar content 
and sweetness, and between protein content and salty and umami taste.3-5 The body uses 
these signalling cues to maintain macronutrient balance. Studies have shown that a 
protein-depleted state elicits a higher preference and reward for and intake of savoury 
foods in order to restore protein status.6, 7 Energy and macronutrient balance may be 
challenged in certain people, which may be related to changed preferences for foods. For 
instance after gastric bypass surgery preference for sweet and high-fat foods decreases8, 9, 
while other studies report an increased preference for high-protein foods.10 In cancer 
patients undergoing chemotherapy, a reduced taste and smell function is frequently 
reported, which has consequences for food preferences and food intake.11-13 However, it is 
important to note that also in the general population food preferences are influenced by 
many factors including the time of the day, the appropriateness of foods within a meal 
context and the meal eaten previously.14-16 This multitude of factors that influence food 
preferences makes measuring food preferences a challenge. To better understand how 
food preferences can shift in different situations, it is essential to include macronutrient 
and taste composition when measuring food preferences. However, few methods are 
available that capture both macronutrient and taste composition and that are able to 
assess shifts in food preferences by these factors. 
 
A questionnaire that takes both macronutrient and taste composition into account is the 
macronutrient preference checklist (MPC). The MPC is a list of foods divided over four 
macronutrient categories, including both sweet and savoury products. Participants are 
instructed to check off all foods in the MPC that one would like to eat right at that 
moment.17-19 This method results in frequencies of selected products from specific 
macronutrient or taste categories. Another method that includes different macronutrient 
and taste categories is the Leeds Food Preference Questionnaire (LFPQ).20 The 
questionnaire uses food pictures rather than words, which is of importance as visual cues 
are important factors in food selection and give input on the edibility, palatability and 
satiating properties of a food.1 The LFPQ is a computer-based food preference task in 
which participants make forced choices between two food products from four different 
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food products from four categories: high-carbohydrate, high-fat, high-protein and low-
energy. A within-subjects study on sensory-specific satiety was conducted to assess the 
task’s reliability and validity. Sixty-nine healthy participants performed two test sessions 
that were at least one week apart. Participants ate either a sweet or a savoury meal, which 
were similar in macronutrient content. Before and after eating the meal participants rated 
appetite and completed the MTPRT. In hungry state, preference scores for all food 
categories were significantly correlated between the two test sessions (all r > 0.68, all p < 
0.001). Preference for sweet decreased after the sweet meal and increased after the 
savoury meal. In addition, preference for protein decreased more after consuming the 
savoury meal than it did after consuming the sweet meal. Preference for carbohydrate 
and fat decreased after meal consumption, regardless of taste. Preference for low-energy 
increased after meal consumption. These results show the MTPRT is a reliable and valid 
task for measuring food preferences. The MTPRT can be used for both hypothesis-driven 
and exploratory studies to examine the influence of different factors on changes in food 
preferences. 
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Introduction 
Sensory properties of foods play an important role in the preferences for and intake of 
food.1 The basic tastes seem to have specific signalling functions for the body, in that 
sweet taste signals carbohydrates, and salty and savoury taste signals protein and 
electrolytes.2 Indeed, various studies have demonstrated relations between sugar content 
and sweetness, and between protein content and salty and umami taste.3-5 The body uses 
these signalling cues to maintain macronutrient balance. Studies have shown that a 
protein-depleted state elicits a higher preference and reward for and intake of savoury 
foods in order to restore protein status.6, 7 Energy and macronutrient balance may be 
challenged in certain people, which may be related to changed preferences for foods. For 
instance after gastric bypass surgery preference for sweet and high-fat foods decreases8, 9, 
while other studies report an increased preference for high-protein foods.10 In cancer 
patients undergoing chemotherapy, a reduced taste and smell function is frequently 
reported, which has consequences for food preferences and food intake.11-13 However, it is 
important to note that also in the general population food preferences are influenced by 
many factors including the time of the day, the appropriateness of foods within a meal 
context and the meal eaten previously.14-16 This multitude of factors that influence food 
preferences makes measuring food preferences a challenge. To better understand how 
food preferences can shift in different situations, it is essential to include macronutrient 
and taste composition when measuring food preferences. However, few methods are 
available that capture both macronutrient and taste composition and that are able to 
assess shifts in food preferences by these factors. 
 
A questionnaire that takes both macronutrient and taste composition into account is the 
macronutrient preference checklist (MPC). The MPC is a list of foods divided over four 
macronutrient categories, including both sweet and savoury products. Participants are 
instructed to check off all foods in the MPC that one would like to eat right at that 
moment.17-19 This method results in frequencies of selected products from specific 
macronutrient or taste categories. Another method that includes different macronutrient 
and taste categories is the Leeds Food Preference Questionnaire (LFPQ).20 The 
questionnaire uses food pictures rather than words, which is of importance as visual cues 
are important factors in food selection and give input on the edibility, palatability and 
satiating properties of a food.1 The LFPQ is a computer-based food preference task in 
which participants make forced choices between two food products from four different 
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food categories. Thereby, products are not just rated on their own. Instead, products from 
different product categories are directly compared and relative preferences for food 
categories are measured. These relative preferences provide insight in motivation for the 
chosen food category over the non-chosen food category.21 However, the LFPQ includes 
only two macronutrient-based categories divided over sweet and savoury taste. In the 
original LFPQ, Finlayson and colleagues used high- and low-fat foods.20, 21 Later studies 
adapted this to include high- and low-protein22 and to high- and low-energy.23 As it is 
essential to be able to assess preferences for a full range of macronutrients, we developed 
the Macronutrient and Taste Preference Ranking Task (MTPRT), which includes both 
macronutrient and taste categories. The task was developed based on the following 
criteria (1) foods included should be from multiple macronutrient categories and tastes, (2) 
the foods should be presented as pictures rather than words, and (3) should consist of a 
ranking paradigm in order to assess relative food preferences.  
 
The MTPRT consists of pictures of products from four macronutrient categories, i.e., high-
carbohydrate, high-fat, high-protein and low-energy, including both sweet and savoury 
products. Participants are asked to make rankings of four products based on how much 
they desire to eat the different products at that moment. These rankings are used to 
assess relative preferences for the four macronutrient categories and the two tastes sweet 
and savoury. In the current study we aim to show that the MTPRT is a reliable and valid 
task to measure food preferences: to demonstrate reliability of the task, we assessed test-
retest reliability. To demonstrate validity of the task, we assessed the discriminative ability 
of the task by assessing sensory-specific satiety; after eating a food to satiety, the 
pleasantness of sensory properties of that food is decreased more than of foods that have 
not been eaten.24 Based on previous studies we expect preference for sweet products to 
decrease after a sweet test meal and to increase after a savoury test meal. Furthermore 
we expect decreased preferences for high-carbohydrate and high-fat products after 
eating a meal in general, a decreased preference for high-protein products after a 
savoury test meal and an increased preference for low-energy products after eating a 
meal in general. 
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Materials and methods 
Products and categories of the MTPRT 
A total of 32 food products from four macronutrient categories, i.e., high-carbohydrate, 
high-fat, high-protein and low-energy was used in the MTPRT. Each category contained 
eight products, of which four products were sweet and four were savoury. The high-
protein category formed an exception and consisted of eight savoury products, as no 
products met all requirements to be included as high-protein sweet. A product had to 
meet the following requirements to be included in the MTPRT: 
- Commercially available. 
- High-fat, high-protein and high-carbohydrate foods contained at least 50% of 
total energy from their respective macronutrient category classification. 
- Low energy products contained less than 60 kcal/100 gram. 
Hill’s European MPC17, 18 and Brisbois-Clarkson’s North American MPC19 were used as 
starting point to select the food products. Products were replaced based on commercial 
availability in the Netherlands when needed. The Dutch Food Composition table was used 
to ensure appropriate macronutrient composition.25 The final list of products including 
their respective nutritional values can be found in Supplementary Table 2.1.  
For the products that were included in the MTPRT, standardized pictures were provided 
by the Image Sciences Institute, UMC Utrecht, and created as part of the Full4Health 
project (www.full4health.eu), funded by the European Union Seventh Framework Program 
(FP7/2007-2013) under grant agreement nr. 266408, and the I.Family project 
(http://www.ifamilystudy.eu), grant agreement nr. 266044.26 Pictures of foods were 
standardized by means of the plate on which products are presented, background colour, 
contrast, camera distance and angle (see Fig. 2.1 for examples). 
Task procedure 
The MTPRT consisted of three parts: practicing, liking and ranking.  
The practicing part was designed to familiarize participants with the ranking task. 
Participants were presented with four combinations of four pictures and asked to rank 
these pictures according to “what they most desire to eat at this moment”. The pictures 
2Chapter 2 
24 
food categories. Thereby, products are not just rated on their own. Instead, products from 
different product categories are directly compared and relative preferences for food 
categories are measured. These relative preferences provide insight in motivation for the 
chosen food category over the non-chosen food category.21 However, the LFPQ includes 
only two macronutrient-based categories divided over sweet and savoury taste. In the 
original LFPQ, Finlayson and colleagues used high- and low-fat foods.20, 21 Later studies 
adapted this to include high- and low-protein22 and to high- and low-energy.23 As it is 
essential to be able to assess preferences for a full range of macronutrients, we developed 
the Macronutrient and Taste Preference Ranking Task (MTPRT), which includes both 
macronutrient and taste categories. The task was developed based on the following 
criteria (1) foods included should be from multiple macronutrient categories and tastes, (2) 
the foods should be presented as pictures rather than words, and (3) should consist of a 
ranking paradigm in order to assess relative food preferences.  
 
The MTPRT consists of pictures of products from four macronutrient categories, i.e., high-
carbohydrate, high-fat, high-protein and low-energy, including both sweet and savoury 
products. Participants are asked to make rankings of four products based on how much 
they desire to eat the different products at that moment. These rankings are used to 
assess relative preferences for the four macronutrient categories and the two tastes sweet 
and savoury. In the current study we aim to show that the MTPRT is a reliable and valid 
task to measure food preferences: to demonstrate reliability of the task, we assessed test-
retest reliability. To demonstrate validity of the task, we assessed the discriminative ability 
of the task by assessing sensory-specific satiety; after eating a food to satiety, the 
pleasantness of sensory properties of that food is decreased more than of foods that have 
not been eaten.24 Based on previous studies we expect preference for sweet products to 
decrease after a sweet test meal and to increase after a savoury test meal. Furthermore 
we expect decreased preferences for high-carbohydrate and high-fat products after 
eating a meal in general, a decreased preference for high-protein products after a 
savoury test meal and an increased preference for low-energy products after eating a 
meal in general. 
 
  
Macronutrient and Taste Preference Ranking Task 
25 
Materials and methods 
Products and categories of the MTPRT 
A total of 32 food products from four macronutrient categories, i.e., high-carbohydrate, 
high-fat, high-protein and low-energy was used in the MTPRT. Each category contained 
eight products, of which four products were sweet and four were savoury. The high-
protein category formed an exception and consisted of eight savoury products, as no 
products met all requirements to be included as high-protein sweet. A product had to 
meet the following requirements to be included in the MTPRT: 
- Commercially available. 
- High-fat, high-protein and high-carbohydrate foods contained at least 50% of 
total energy from their respective macronutrient category classification. 
- Low energy products contained less than 60 kcal/100 gram. 
Hill’s European MPC17, 18 and Brisbois-Clarkson’s North American MPC19 were used as 
starting point to select the food products. Products were replaced based on commercial 
availability in the Netherlands when needed. The Dutch Food Composition table was used 
to ensure appropriate macronutrient composition.25 The final list of products including 
their respective nutritional values can be found in Supplementary Table 2.1.  
For the products that were included in the MTPRT, standardized pictures were provided 
by the Image Sciences Institute, UMC Utrecht, and created as part of the Full4Health 
project (www.full4health.eu), funded by the European Union Seventh Framework Program 
(FP7/2007-2013) under grant agreement nr. 266408, and the I.Family project 
(http://www.ifamilystudy.eu), grant agreement nr. 266044.26 Pictures of foods were 
standardized by means of the plate on which products are presented, background colour, 
contrast, camera distance and angle (see Fig. 2.1 for examples). 
Task procedure 
The MTPRT consisted of three parts: practicing, liking and ranking.  
The practicing part was designed to familiarize participants with the ranking task. 
Participants were presented with four combinations of four pictures and asked to rank 
these pictures according to “what they most desire to eat at this moment”. The pictures 
Chapter 2 
26 
used in the practicing part were not used in the main task and did not necessarily fit 
within one of the macronutrient categories. 
The liking part was designed to introduce participants to each product by name and 
picture. Liking was assessed by presenting pictures of all 32 products with the question: 
‘How much do you like [product name]?’ which was rated on a 100 point visual analogue 
scale (VAS) anchored by ‘do not like at all’ and ‘like extremely’.  
The ranking part consisted of two sections, one focused on macronutrients the other on 
taste, i.e., sweet and savoury. In both sections, participants were presented with four 
different pictures, which they had to rank according to “what they most desire to eat at 
this moment” (Fig. 2.1). Participants first clicked on the product they most desired to eat at 
the moment of completing the task, then they clicked on the second most desired 
product, followed by the third and the product they least desired to eat at the moment of 
completing the task. In the macronutrient section, each of the four pictures represented 
one of the macronutrient categories. In total sixteen combinations of pictures were 
presented, in which each picture was shown twice. In the taste section, the four pictures 
that were presented came from two macronutrient categories. Within each category, one 
picture represented a sweet food item, and the other a savoury one. For example, one 
sweet product and one savoury product were high in carbohydrate and one sweet 
product and one savoury product were high in fat. In the taste section, products from the 
high-protein category were excluded, as this category only contained savoury products. In 
total twelve rankings were made in the taste section. As in the macronutrient section, each 
picture was shown twice. 
For both sections, the order in which categories were presented on the screen was 
randomized and balanced across trials. For the macronutrient section, this meant that 
each macronutrient appeared four times on each of the four available positions. The same 
picture never appeared on the same position within this section. In the taste section, both 
tastes appeared six times on each of the four available positions. All pictures were 
presented twice, on two different positions.  
The task took approximately 10 minutes to complete and was executed in E-Prime 2.0 
(Psychology Software Tools, Pittsburgh, PA). The MTPRT can also be executed in 
EyeQuestion software (Logic8 BV), which facilitates participants to complete the task 
online. 
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Figure 2.1. Lay-out of the macronutrient section (A) and taste section (B) of the MTPRT.  
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Participants 
Healthy participants aged 18-35 years with a normal weight (BMI 18.5-25 kg/m2) were 
recruited. Exclusion criteria were restraint eating (DEBQ: men: >2.9, women >3.4) 27, lack 
of appetite, difficulties swallowing or eating, having taste or smell disorders (self-report), 
energy restricted diet two months prior to the study, weight loss or gain >5 kg during the 
two months prior to the study, being allergic or intolerant for the products under study, 
smoking, being vegetarian or vegan, and for women: being pregnant or lactating. 
Seventy-four participants were included in the study. Five participants were excluded from 
the analyses because they did not comply with study procedures. Analyses were done on 
data of the remaining 69 participants (16 male/53 female) with an average age of 21.3 
years (SD ± 2.9) and average BMI of 21.6 kg/m2 (SD ± 1.8). All participants received a 
financial compensation for participating. The study was exempt from formal ethical 
approval by the Medical ethical Committee of Wageningen University. All participants 
signed an informed consent form.  
Study design  
We used a randomized crossover design, in which participants were invited to attend two 
test sessions that were at least seven days apart. Participants were told that the purpose 
of the study was to examine the effect of a sweet and savoury lunch on preference for 
different food products. During both test sessions, participants were presented with either 
a sweet or a savoury test meal, the order of which was randomized and balanced across 
the participants. When participants arrived they were instructed to first fill out an appetite 
questionnaire with 5 questions, i.e., hunger, fullness, prospective consumption, appetite 
for something sweet and appetite for something savoury. Questions were rated on a 100 
point visual analogue scale (VAS) anchored by ‘not at all’ and ‘extremely’, except for 
prospective consumption which was anchored by ‘nothing at all’ and ‘a very large 
amount’. Next, participants completed the MTPRT, as described under ‘task procedure’. 
After finishing the MTPRT, participants were presented with the test meal and 150 ml 
water. They were instructed to finish the meal and water within 30 minutes. Next, 
participants rated the test meal for liking on a 100 point VAS anchored by ‘not at all’ and 
‘extremely’ and completed the appetite ratings and MTPRT again. 
To standardize hunger feelings for all participants in both test sessions, participants were 
instructed to standardize their breakfast and morning physical activity on both test days. 
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They were asked to refrain from eating and to drink only water or tea without sugar 
during the three hours prior to the test session. Test sessions started at 11:30, 11:45, 12:00, 
13:00, 13:15 and 13:30 and lasted approximately one hour. Both test sessions started at the 
same time for each individual participant. 
Test meals 
Participants received a standard amount of each test meal based on their energy 
requirements as calculated by the Schofield formula28 with a physical activity level of 1.6. 
The test meal contained 18% of participant’s daily required energy intake, rounded to the 
nearest 50 kcal, which is 81% of the amount of energy provided by an average lunch in 
the Netherlands.29 
Energy and macronutrient composition were similar for both meals and are shown in 
Table 2.1. The savoury meal consisted of risotto rice (Lassie, Wormer, The Netherlands) 
(65%), semi-skimmed milk (17%), crème fraiche (11%), bouillon (0.3%), garlic powder 
(0.02%), salt (0.8%) and maltodextrin (Fantomalt, Nutricia, The Netherlands) (6%). The 
sweet meal consisted of risotto rice (64%), semi-skimmed milk (21%), water (4%), 
margarine (4%), cinnamon (0.08%), sucralose (0.05%) and maltodextrin (7%). A standard 
protocol was used to make fresh meals on each test day. Meals were kept warm with an 
average temperature of 81 °C (range 69-89 °C). 
 
Table 2.1. Nutritional composition per 100 g of the sweet and savoury meal 
 Savoury meal Sweet meal 
Energy (kcal) 91 89 
Energy (kJ) 381 375 
Protein (g) 2 1.9 
Fat (g) 3.2 3.2 
Carbohydrates (g) 13.2 13.1 
Fiber (g) 0.2 0.2 
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 Data analysis 
Each product received a macronutrient preference score based on the place the product 
was ranked. The higher the rank, the higher the score. Scores for all 16 presentations 
added up to a total score that was divided by the 16 times a product from each category 
was presented. Preference scores can range from 1 to 4: 
𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟 𝑠𝑠𝑠𝑠𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑚𝑚𝑚𝑚𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑝𝑝𝑝𝑝𝑚𝑚𝑚𝑚𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟= 4 ∗ (# 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟 1) + 3 ∗ (# 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟 2) + 2 ∗ (# 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟 3) + 1 ∗ (# 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟 4)16  
Similarly a preference score was calculated based on taste rankings. As both sweet and 
savoury products were presented twice in all 12 rankings the ranks-based score is divided 
by 24 and this preference score can range from 1.5 to 3.5: 
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In case of no apparent preference for a specific category, all macronutrients would be 
ranked on each position twice and preference scores are 2.5.  
As the preference scores for sweet and savoury are each other’s opposites, i.e., savoury 
score = 5 - sweet score, we report only sweet preference scores in this article. 
Data are presented as means with standard deviation (SD) unless otherwise specified. 
Data was analysed using IBM SPSS 21 (IBM Corporation, Armonk, New York, USA). Results 
were considered statistically significant at p<0.05. 
To compare liking of both test meals a paired-samples T-test was conducted. Repeated 
measures ANOVA was used to analyse appetite ratings and the preference scores with 
hunger state (before and after a meal) and taste of the test meal (sweet and savoury) as 
factors. 
Non-parametric tests were used to determine relative preference for the different 
macronutrient and taste categories. To compare preference scores for macronutrient 
categories within conditions, e.g., before the sweet meal, Friedman ANOVA was used. 
Post-hoc analyses were done using Wilcoxon signed rank tests with Bonferroni correction. 
To determine relative preference for taste, sweet and savoury preference scores were 
compared using Wilcoxon signed rank tests. Pearson’s correlations were determined to 
assess reproducibility of food preferences measured with the MTPRT. 
Liking scores were calculated by using the average liking rating within a category. These 
were analysed with repeated measures ANOVA to compare liking scores before and after 
the two different test meals. Post-hoc analyses were done using Bonferroni correction. 
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Results 
Liking of test meals 
Average liking of the sweet test meal was 40.7 (SD = 27.7), compared to 45.3 (SD = 23.2) 
for the savoury meal. Liking of both meals did not differ significantly, T(1,68) = 1.12, p = 
0.27. 
Appetite ratings 
Regardless of taste, eating a test meal decreased hunger, prospective consumption, 
appetite for something sweet and appetite for something savoury, but increased fullness 
(all p < 0.001, Table 2.2). The interaction between hunger state and taste of the test meal 
showed that appetite for something sweet decreased more after eating the sweet test 
meal than after eating the savoury test meal, F(1,68) = 27.92, p < 0.001. Similarly, appetite 
for something savoury decreased more after eating the savoury test meal than after 
eating the sweet test meal, F(1,68) = 34.31, p < 0.001. 
Table 2.2. Pre and post meal appetite ratings per type of meal 
 Sweet meal Savoury meal 
 Pre Post* Pre Post* 
Hunger 71±16 19±19 67±15 20±18 
Fullness 22±13 72±20 28±17 76±18 
Prospective consumption 66±14 27±20 64±15 25±19 
Appetite for sweet1 58±23 21±26 55±23 44±28 
Appetite for savoury1 73±15 48±24 68±18 23±22 
Ratings performed on a 100-unit VAS. Values are means±SD.  
*Post meal ratings are significantly different from pre meal ratings.  
1Significant difference between post meal ratings between sweet and savoury meal. 
 
Test-retest reliability of preference scores 
The preference scores in hungry state on the two test days did not significantly differ from 
each other (all p > 0.05). In addition, these preference scores significantly correlated with 
each other within all macronutrient categories and the sweet category, r = 0.77, 0.68, 0.78, 
0.69, 0.74 for high-carbohydrate, high-fat, high-protein, low-energy, and sweet 
respectively, all p < 0.001 (Fig. 2.2). 
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 Data analysis 
Each product received a macronutrient preference score based on the place the product 
was ranked. The higher the rank, the higher the score. Scores for all 16 presentations 
added up to a total score that was divided by the 16 times a product from each category 
was presented. Preference scores can range from 1 to 4: 
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Similarly a preference score was calculated based on taste rankings. As both sweet and 
savoury products were presented twice in all 12 rankings the ranks-based score is divided 
by 24 and this preference score can range from 1.5 to 3.5: 
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In case of no apparent preference for a specific category, all macronutrients would be 
ranked on each position twice and preference scores are 2.5.  
As the preference scores for sweet and savoury are each other’s opposites, i.e., savoury 
score = 5 - sweet score, we report only sweet preference scores in this article. 
Data are presented as means with standard deviation (SD) unless otherwise specified. 
Data was analysed using IBM SPSS 21 (IBM Corporation, Armonk, New York, USA). Results 
were considered statistically significant at p<0.05. 
To compare liking of both test meals a paired-samples T-test was conducted. Repeated 
measures ANOVA was used to analyse appetite ratings and the preference scores with 
hunger state (before and after a meal) and taste of the test meal (sweet and savoury) as 
factors. 
Non-parametric tests were used to determine relative preference for the different 
macronutrient and taste categories. To compare preference scores for macronutrient 
categories within conditions, e.g., before the sweet meal, Friedman ANOVA was used. 
Post-hoc analyses were done using Wilcoxon signed rank tests with Bonferroni correction. 
To determine relative preference for taste, sweet and savoury preference scores were 
compared using Wilcoxon signed rank tests. Pearson’s correlations were determined to 
assess reproducibility of food preferences measured with the MTPRT. 
Liking scores were calculated by using the average liking rating within a category. These 
were analysed with repeated measures ANOVA to compare liking scores before and after 
the two different test meals. Post-hoc analyses were done using Bonferroni correction. 
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Results 
Liking of test meals 
Average liking of the sweet test meal was 40.7 (SD = 27.7), compared to 45.3 (SD = 23.2) 
for the savoury meal. Liking of both meals did not differ significantly, T(1,68) = 1.12, p = 
0.27. 
Appetite ratings 
Regardless of taste, eating a test meal decreased hunger, prospective consumption, 
appetite for something sweet and appetite for something savoury, but increased fullness 
(all p < 0.001, Table 2.2). The interaction between hunger state and taste of the test meal 
showed that appetite for something sweet decreased more after eating the sweet test 
meal than after eating the savoury test meal, F(1,68) = 27.92, p < 0.001. Similarly, appetite 
for something savoury decreased more after eating the savoury test meal than after 
eating the sweet test meal, F(1,68) = 34.31, p < 0.001. 
Table 2.2. Pre and post meal appetite ratings per type of meal 
 Sweet meal Savoury meal 
 Pre Post* Pre Post* 
Hunger 71±16 19±19 67±15 20±18 
Fullness 22±13 72±20 28±17 76±18 
Prospective consumption 66±14 27±20 64±15 25±19 
Appetite for sweet1 58±23 21±26 55±23 44±28 
Appetite for savoury1 73±15 48±24 68±18 23±22 
Ratings performed on a 100-unit VAS. Values are means±SD.  
*Post meal ratings are significantly different from pre meal ratings.  
1Significant difference between post meal ratings between sweet and savoury meal. 
 
Test-retest reliability of preference scores 
The preference scores in hungry state on the two test days did not significantly differ from 
each other (all p > 0.05). In addition, these preference scores significantly correlated with 
each other within all macronutrient categories and the sweet category, r = 0.77, 0.68, 0.78, 
0.69, 0.74 for high-carbohydrate, high-fat, high-protein, low-energy, and sweet 
respectively, all p < 0.001 (Fig. 2.2). 
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Figure 2.2. Correlation preference scores for sweet (A), high-carbohydrate (B), high-fat (C), high-
protein (D) and low-energy (E) products in hungry condition between test day 1 and test day 2.  
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Food preferences 
Before consumption, preference scores for all categories did not differ between the sweet 
and savoury test meal conditions (all p > 0.05). In both conditions, participants showed a 
relative preference for sweet over savoury (both p < 0.001), but no relative preference for 
one of the macronutrient categories (Fig. 2.3). 
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Figure 2.3. Preferences for high-carbohydrate (A), high-fat (B), high-protein (C) and low-energy (D) 
products (mean ± SD). Dotted line represents chance level. * indicates significant change 
compared to pre meal at p < 0.05 level, ** indicates significant difference at p < 0.05 level. 
After consumption of the test meal, sweet preference shifted dependent on taste of the 
meal as shown by the interaction between hunger state and taste of the test meal: F(1,68) 
= 53.26, p < 0.001, partial η2 = 0.44. Sweet preference decreased after the sweet meal and 
increased after the savoury meal (Fig. 2.4). After consumption of the sweet test meal, 
participants lost their relative preference for sweet products over savoury products, Z = -
1.53, p = 0.127. 
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Figure 2.2. Correlation preference scores for sweet (A), high-carbohydrate (B), high-fat (C), high-
protein (D) and low-energy (E) products in hungry condition between test day 1 and test day 2.  
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Food preferences 
Before consumption, preference scores for all categories did not differ between the sweet 
and savoury test meal conditions (all p > 0.05). In both conditions, participants showed a 
relative preference for sweet over savoury (both p < 0.001), but no relative preference for 
one of the macronutrient categories (Fig. 2.3). 
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Figure 2.3. Preferences for high-carbohydrate (A), high-fat (B), high-protein (C) and low-energy (D) 
products (mean ± SD). Dotted line represents chance level. * indicates significant change 
compared to pre meal at p < 0.05 level, ** indicates significant difference at p < 0.05 level. 
After consumption of the test meal, sweet preference shifted dependent on taste of the 
meal as shown by the interaction between hunger state and taste of the test meal: F(1,68) 
= 53.26, p < 0.001, partial η2 = 0.44. Sweet preference decreased after the sweet meal and 
increased after the savoury meal (Fig. 2.4). After consumption of the sweet test meal, 
participants lost their relative preference for sweet products over savoury products, Z = -
1.53, p = 0.127. 
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Figure 2.4. Preferences for sweet products before and after the sweet and savoury meal (mean ± 
SD). Dotted line represents chance level. * indicates significant change compared to pre meal at p 
< 0.05 level, ** indicates significant difference at p < 0.05 level. 
Fig. 2.3 shows the preferences for the four macronutrient categories. Preference for high-
carbohydrate and for high-fat products decreased after meal consumption, regardless of 
taste, main effect carbohydrate: F(1,68) = 18.87, p < 0.001, partial η2 = 0.22; fat: F(1,68) = 
38.92, p < 0.001, partial η2 = 0.36. Hunger state interacted with taste of the test meal for 
high protein foods, F(1,68) = 22.13, p < 0.001, partial η2 = 0.25. This was explained by a 
decrease for high protein products after the savoury meal, but no change in preference 
for high protein products after the sweet meal. Preference for low-energy products 
increased after eating a meal, main effect: F(1,68) = 85,30, p < 0.001, partial η2 = 0.56. 
Hunger state interacted with taste of the test meal; low-energy preference increased more 
after the savoury meal than after the sweet meal F(1,68) = 22.13, p < 0.001, partial η2 = 
0.11. After both meals, participants showed a relative preference for low-energy products 
compared to the other macronutrient categories (all p < 0.01). After the savoury meal, 
high-fat products were preferred over high-protein products (p < 0.05). 
Liking of food categories 
Fig. 2.5 shows the liking ratings for the different food categories. After eating both test 
meals, liking of the sweet, savoury, high-carbohydrate, high-fat and high-protein products 
decreased (all p < 0.05), but liking of the low-energy products did not change (p = 0.832). 
For savoury, F(1,68) = 10.96, p = 0.001, and for high-protein, F(1.68) = 8.49, p = 0.005, 
hunger state interacted with taste of meal. For both categories, liking decreased more 
after the savoury meal than after the sweet meal. 
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Figure 2.5. Liking ratings (0-100 VAS) for sweet (A), savoury (B), high-carbohydrate (C), high-fat (D), 
high-protein (E) and low-energy (F) products (mean ± SD). * indicates significant change compared 
to before meal at p < 0.05 level. ** indicates significant difference at p < 0.05 level.  
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Figure 2.4. Preferences for sweet products before and after the sweet and savoury meal (mean ± 
SD). Dotted line represents chance level. * indicates significant change compared to pre meal at p 
< 0.05 level, ** indicates significant difference at p < 0.05 level. 
Fig. 2.3 shows the preferences for the four macronutrient categories. Preference for high-
carbohydrate and for high-fat products decreased after meal consumption, regardless of 
taste, main effect carbohydrate: F(1,68) = 18.87, p < 0.001, partial η2 = 0.22; fat: F(1,68) = 
38.92, p < 0.001, partial η2 = 0.36. Hunger state interacted with taste of the test meal for 
high protein foods, F(1,68) = 22.13, p < 0.001, partial η2 = 0.25. This was explained by a 
decrease for high protein products after the savoury meal, but no change in preference 
for high protein products after the sweet meal. Preference for low-energy products 
increased after eating a meal, main effect: F(1,68) = 85,30, p < 0.001, partial η2 = 0.56. 
Hunger state interacted with taste of the test meal; low-energy preference increased more 
after the savoury meal than after the sweet meal F(1,68) = 22.13, p < 0.001, partial η2 = 
0.11. After both meals, participants showed a relative preference for low-energy products 
compared to the other macronutrient categories (all p < 0.01). After the savoury meal, 
high-fat products were preferred over high-protein products (p < 0.05). 
Liking of food categories 
Fig. 2.5 shows the liking ratings for the different food categories. After eating both test 
meals, liking of the sweet, savoury, high-carbohydrate, high-fat and high-protein products 
decreased (all p < 0.05), but liking of the low-energy products did not change (p = 0.832). 
For savoury, F(1,68) = 10.96, p = 0.001, and for high-protein, F(1.68) = 8.49, p = 0.005, 
hunger state interacted with taste of meal. For both categories, liking decreased more 
after the savoury meal than after the sweet meal. 
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Figure 2.5. Liking ratings (0-100 VAS) for sweet (A), savoury (B), high-carbohydrate (C), high-fat (D), 
high-protein (E) and low-energy (F) products (mean ± SD). * indicates significant change compared 
to before meal at p < 0.05 level. ** indicates significant difference at p < 0.05 level.  
Chapter 2 
36 
Discussion 
The current study demonstrates the reliability and validity of the Macronutrient and Taste 
Preference Ranking Task, the first food preference ranking task that includes both taste 
and four macronutrient dimensions. First, we showed that food preference scores for all 
categories in a hungry condition were highly correlated over two test sessions indicating 
test-retest reliability. Second, we showed a decreased preference for sweet products after 
eating a sweet meal and an increased preference for sweet products after eating a 
savoury meal. Preference for high-protein products decreased more after eating a 
savoury meal than it did after eating a sweet meal. Preferences for high-carbohydrate and 
high-fat products decreased after eating a meal, regardless of the taste of the meal. 
Preferences for low energy products increased after eating a meal, and this increase was 
most pronounced after the savoury meal. These results indicate that the MTPRT is a valid 
task to detect changes in food preferences. 
Food preferences as measured with the MTPRT were shown to be reproducible. 
Correlations of preference scores for the different food categories as measured under 
similar circumstances were comparable to those found in previous studies that assessed 
test-retest reliability of methods to measure food preferences.19, 30, 31 Given the 
reproducibility and the high variation in individual food preference scores between 
participants, the MTPRT may be able to identify individuals with specific preferences. 
Further studies are needed to assess whether there are specific individual characteristics 
that determine these individual food preferences.  
In addition, the discriminative ability of the MTPRT was successfully demonstrated by 
assessing the effect of sensory-specific satiety. Similar to other methods used in previous 
studies, preferences for sweet decreased after the sweet meal and increased after the 
savoury meal.16, 32 Moreover, we were able to discriminate preferences between four 
different macronutrient categories, i.e., high-carbohydrate, high-fat, high-protein and 
low-energy. Preferences for high-carbohydrate and high-fat products decreased after 
eating a meal, regardless of the taste of the meal. Conversely, preference for low-energy 
products increased after meal consumption. This increased preference for low-energy 
products can be explained by the fact that participants were feeling full after the meal. 
This induced a shift from energy-dense to low-energy products and is consistent with 
other studies.23, 33 Preferences for high-protein products decreased after consumption of 
the savoury meal, but not after consumption of the sweet meal. This finding can be 
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explained by the fact that savoury products are generally associated with high protein 
content.3, 5 Contrarily, a previous study into the effects of taste of a 24-hour diet on food 
preferences did not find a difference in preference for protein.34 However in that study, 
protein content of high-protein products was at most 26 energy percent and included 
both sweet and savoury products. This difference between high-protein products could 
explain these different findings. Another possible explanation could be that the 
preference for protein was confounded by preference for savoury. In that case, we would 
have expected an increased preference for protein after the sweet meal, similar to the 
increased preference for savoury. However, preference for protein did not change after 
the sweet meal. We therefore consider this explanation unlikely. 
The meals in our study were carefully composed to be similar with regard to nutritional 
content, and only differed in the taste, sweet and savoury. Therefore we mainly observe 
effects which can be explained by the taste and detect less differentiation on the 
macronutrients. Most likely, when varying meals in macronutrient content pronounced 
changes in macronutrient preferences would become apparent.31, 35, 36 Compared to the 
LFPQ, the MTPRT has more macronutrient categories and can therefore be used in a wide 
range of studies that assess the influence of different factors on changes in preferences 
for different macronutrients and tastes in a variety of populations.    
By using a ranking procedure, we can assess food preferences for categories of foods 
relative to other categories. In our study, we detected changes in preference for all food 
categories included in the MTPRT, while we did not detect these for all categories in the 
liking part. One important difference is that liking of sweet products decreased in a similar 
fashion after both the sweet and the savoury meal, whereas the preference score for 
sweet increased after the savoury meal. Furthermore, the ranking showed an increased 
preference for low-energy products after eating the meals, while liking of low-energy 
products did not change. Therefore, the ranking procedure is more sensitive compared to 
the liking procedure, and is thus able to detect more subtle shifts in food preferences.  
The ranking method makes the MTPRT an easy and quick tool for evaluating food 
preferences over a wide range of food categories, i.e., high-carbohydrate, high-fat, high-
protein and low-energy, both sweet and savoury. Because of this range, the food 
preference task can be used in a variety of studies without changing food categories 
based on the research question. In the current study the experiment was focused on 
assessing sensory-specific satiety in a controlled setting and within subjects. However 
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food preferences are influenced by many factors and further research is needed to assess 
the use of the task in a less controlled, more natural setting, and to assess the effect of 
time of day, meal context and person characteristics like gender, age and eating type.  
The current study did not measure actual food intake and thus cannot compare 
preference scores with actual intake. No conclusions can be drawn, therefore, on how 
food preferences as assessed with the MTPRT translate into actual behaviour. Based on 
previous comparisons of a forced-choice procedure with actual food intake,16, 22 where 
strong correlations were found between relative food preference and food intake, we 
would hypothesize that the preference scores as measured with the MTPRT correlate with 
actual food choice behaviour. 
It is important to note that the MTPRT does not include sweet high-protein products. 
Within the range of products that contain at least 50 energy percent of protein, there are 
no sweet products. The same applies to other food preference measures19, 36 and 
therefore we do believe that the products in the high-protein category are a good 
representation of this macronutrient. In addition, the food products currently included in 
the task are chosen based on their commercial availability in the Netherlands. As Dutch 
consumption patterns may differ from consumption patterns in other countries, it might 
be necessary to exchange a few individual food products in the MTPRT when using the 
task in other countries. 
The MTPRT is the first food preference task that uses a ranking procedure and can detect 
shifts in preferences for both taste and macronutrients. The MTPRT was shown to be a 
reliable and valid method to measure food preferences, as results were reproducible 
under similar conditions, and differentiated food preferences based on macronutrients 
and taste in an experimental setting. The task can be used to examine the effect of 
internal and external factors that influence food preferences. 
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Supplementary table 2.1. Nutritional values for the selected 32 products 
  Energy 
(kJ/100 
grams) 
Energy 
(kcal/100 
grams) 
Protein 
(en%) 
CHO 
(en%) 
Fat  
(en%) 
High carbohydrate 
Sweet Ginger bread 1346 318 3.4 88.9 5.9 
 Syrup waffles  (Dutch: Stroopwafels) 1985 473 3.1 59.4 36.7 
 Pancakes 826 196 16.9 59.6 22.5 
 Wine gums 1481 349 6.3 92.8 0.8 
Savoury Tortilla chips 2039 487 5.7 51.3 41.2 
 French fries 1282 306 5.9 50.1 42.1 
 Nibbits 1989 475 3.4 53.9 41.7 
 Salty sticks 1654 395 9.4 81.0 8.2 
High fat 
Sweet Chocolate bar  (milk chocolate) 2278 546 5.1 40.2 53.6 
 Cream pie 1465 350 4.0 33.1 64.3 
 Apple turnover  (Dutch: Appelflap) 1506 361 3.9 39.3 55.8 
 Large chocolate eclair (Dutch: Bossche bol) 1275 307 5.9 23.6 70.1 
Savoury Salted peanuts 2390 577 16.6 7.6 73.3 
 Sausage roll 1596 382 12.4 35.8 51.4 
 Chips (salted) 2254 541 4.7 37.9 55.7 
 Cheese cubes 1508 363 25.0 0.0 73.4 
High protein 
 Chicken satay 667 158 78.2 0.0 21.6 
 Cod fillet 498 118 72.9 2.0 25.2 
 Pork chop 743 177 64.0 0.0 35.6 
 Turkey fillet (cold cut) 479 113 69.7 11.0 19.1 
 Roast beef 656 156 69.7 0.5 29.4 
 Gammon (cold cut) 569 136 53.5 7.1 38.4 
 Shrimps 397 94 84.3 0.4 15.3 
 Steak 616 146 80.3 0.0 19.7 
Low energy 
Sweet Peach 172 41 9.8 77.1 0.0 
 Strawberries 123 29 9.7 70.3 0.0 
 Apple 254 60 1.3 86.7 3.0 
 Melon galia 107 25 0.0 96.0 0.0 
Savoury Tomato 96 23 12.2 53.9 19.6 
 Cucumber 55 13 18.5 58.5 13.8 
 Pickles 44 11 36.4 36.4 0.0 
 Celery sticks 60 14 28.6 57.1 0.0 
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Supplementary table 2.1. Nutritional values for the selected 32 products 
  Energy 
(kJ/100 
grams) 
Energy 
(kcal/100 
grams) 
Protein 
(en%) 
CHO 
(en%) 
Fat  
(en%) 
High carbohydrate 
Sweet Ginger bread 1346 318 3.4 88.9 5.9 
 Syrup waffles  (Dutch: Stroopwafels) 1985 473 3.1 59.4 36.7 
 Pancakes 826 196 16.9 59.6 22.5 
 Wine gums 1481 349 6.3 92.8 0.8 
Savoury Tortilla chips 2039 487 5.7 51.3 41.2 
 French fries 1282 306 5.9 50.1 42.1 
 Nibbits 1989 475 3.4 53.9 41.7 
 Salty sticks 1654 395 9.4 81.0 8.2 
High fat 
Sweet Chocolate bar  (milk chocolate) 2278 546 5.1 40.2 53.6 
 Cream pie 1465 350 4.0 33.1 64.3 
 Apple turnover  (Dutch: Appelflap) 1506 361 3.9 39.3 55.8 
 Large chocolate eclair (Dutch: Bossche bol) 1275 307 5.9 23.6 70.1 
Savoury Salted peanuts 2390 577 16.6 7.6 73.3 
 Sausage roll 1596 382 12.4 35.8 51.4 
 Chips (salted) 2254 541 4.7 37.9 55.7 
 Cheese cubes 1508 363 25.0 0.0 73.4 
High protein 
 Chicken satay 667 158 78.2 0.0 21.6 
 Cod fillet 498 118 72.9 2.0 25.2 
 Pork chop 743 177 64.0 0.0 35.6 
 Turkey fillet (cold cut) 479 113 69.7 11.0 19.1 
 Roast beef 656 156 69.7 0.5 29.4 
 Gammon (cold cut) 569 136 53.5 7.1 38.4 
 Shrimps 397 94 84.3 0.4 15.3 
 Steak 616 146 80.3 0.0 19.7 
Low energy 
Sweet Peach 172 41 9.8 77.1 0.0 
 Strawberries 123 29 9.7 70.3 0.0 
 Apple 254 60 1.3 86.7 3.0 
 Melon galia 107 25 0.0 96.0 0.0 
Savoury Tomato 96 23 12.2 53.9 19.6 
 Cucumber 55 13 18.5 58.5 13.8 
 Pickles 44 11 36.4 36.4 0.0 
 Celery sticks 60 14 28.6 57.1 0.0 
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Abstract  
Background & aims: Cancer patients undergoing palliative chemotherapy can experience 
a variety of chemosensory and food preference changes which may impact their 
nutritional status and quality of life. However, evidence of these changes in 
oesophagogastric cancer patients is currently mostly qualitative and not supported by 
quantitative data. The aim of this study was to assess the influence of palliative 
chemotherapy on both objective and self-reported taste and smell function and food 
preferences in oesophagogastric cancer patients. 
Methods: This observational study included 15 advanced oesophagogastric cancer 
patients planned for first line treatment with capecitabine and oxaliplatin. Participants 
completed two test sessions scheduled before start of cytotoxic treatment and after two 
cycles. Objective tests and self-reported taste and smell function and the macronutrient 
and taste preference ranking task were conducted at each test session. 
Results: Self-reported taste and smell did not change upon chemotherapy. Objective 
smell function did not change, but objective taste function decreased during 
chemotherapy, although this was not statistically significant (p=0.06). Before and during 
chemotherapy, high protein foods were preferred over high carbohydrate and over low 
energy products, but food preferences did not change over time. A lower self-reported 
taste function correlated with a lower preference for high-protein products (ρ=0.526, 
p=0.003).  
Conclusion: This study suggests that objective taste function decreases during 
chemotherapy in OGC patients, but not olfactory function. A low reported taste function 
was related to a lower preference for high-protein products. This highlights the 
importance of monitoring chemosensory function when giving nutritional advice in 
advanced OGC patients. 
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Introduction 
Oesophagogastric cancer (OGC) is a highly lethal disease. The overall 5-year survival rate 
for OGC is approximately 26%, as the majority of patients is diagnosed with advanced 
disease. For these patients, the benefit of palliative chemotherapy compared with best 
supportive care has been established both in terms of overall survival and quality of life.1-3 
However, cytotoxic treatment is often accompanied by side effects including alterations in 
taste and smell that may impact food preferences and quality of life.4-7 A previous 
qualitative study of our group in OGC patients undergoing chemotherapy showed a large 
variation in the experience and impact of changes in taste and smell perception.4 These 
chemosensory changes had consequences in terms of food preferences, with a change in 
food preferences and avoidance of specific products like meat. Taste and smell changes, 
and eating problems related to the location of the tumour affected daily life and social 
life. For humans it is difficult to distinguish taste and smell, as these systems are highly 
related in the perception of food. Therefore it is important to objectively assess taste and 
smell function to understand the nature of these changes. Thus far, it is unknown how 
reported subjective chemosensory changes and changes in food preferences relate to 
actual objective measures of taste, smell and food preferences in oesophagogastric 
cancer patients undergoing chemotherapy. Therefore, the aim of the current study is to 
measure the influence of chemotherapy on both objective and self-reported taste and 
smell function and food preferences in OGC patients.  
Materials and methods 
Patients 
Twenty-three patients with metastatic or irresectable carcinoma of the stomach or 
oesophagus were included. All patients were scheduled to start cytotoxic treatment with 
capecitabine (Xeloda®) 1000 mg/m2 days 1-14 and oxaliplatin (Eloxatin®) 130 mg/m2 day 
1 of three-weekly cycles and had a WHO performance status of 0 - 2. Treatment and 
tumour characteristics were obtained from medical records.  
Study design 
This observational study included test sessions before the first chemotherapy cycle 
(baseline) and shortly before the third chemotherapy cycle (follow-up). Objective and self-
reported chemosensory function and food preferences were assessed during each test 
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session. The study was exempted from formal ethical approval by the medical ethics 
committee of the Academic Medical Centre.  
Measurements 
Taste function was assessed using the Taste Strips (Burghart, Wedel, Germany) to assess 
sensitivity for sweet, salty, bitter and sour. Scores for each taste ranged from 0 to 4, and 
total taste scores range from 0-16, which was the sum of the four basic taste scores.8, 9 
Olfactory function was measured using the Sniffin’ Sticks. The test consists of three parts: 
odour threshold (THR, range 1-16), odour discrimination (DIS, range 0-16) and odour 
identification (ID, range 0-16). Overall olfactory function (TDI) was the sum of the three 
subtests.10, 11 The Appetite Hunger and Sensory Perception questionnaire (AHSP) was used 
to assess reported taste, smell, appetite and hunger feelings.12 Food preferences were 
assessed using the Macronutrient and Taste Preference Ranking Task, a computer-based 
food preference task with food pictures from four food categories high-protein, high-
carbohydrate, high-fat and low-energy, divided over sweet and savoury products.13 
Relative preferences were calculated for each category.  
Data analysis 
Differences for olfactory, gustatory scores and food preferences within macronutrient and 
taste categories between baseline and follow up were analysed with Wilcoxons Signed 
Rank test. Preferences between food categories at baseline and follow-up were assessed 
using Friedman ANOVA with Dunn-Bonferroni test to assess post hoc differences. 
Spearman correlations were done to correlate reported taste and smell perception with 
objective taste and smell function, and to correlate reported and measured taste and 
smell with food preferences. Data were analysed using IBM SPSS version 23.0, a p-value of 
<0.05 was considered statistically significant. 
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Results 
Twenty-three patients were included, of which 8 dropped out because of early 
discontinuation of treatment (n=3), feeling too ill to undergo the tests (n=3), and death 
before the second measurement (n=2). Table 3.1 shows demographic and clinical 
characteristics of the 15 OGC patients who completed baseline and follow-up 
measurements.  
Table 3.1. Sociodemographic and tumour characteristics of the included OGC patients (n=15) 
n (%) or 
mean ± SD 
Gender Male 14 (93) 
Female 1 (7) 
61  ± 9.3 
24.4  ± 2.7 
Age (years) 
BMI (kg/m2) 
WHO performance status 1 0 8 (53) 
1 5 (33) 
2 2 (13) 
Tumour characteristics 
Location Oesophagus 10 (67) 
Gastroesophageal junction 2 (13) 
Stomach 3 (20) 
Tumour type Adenocarcinoma  13 (87) 
Large cell undifferentiated carcinoma 2 (13) 
Stage I-II 2 (13) 
III 8 (53) 
IV 5 (33) 
Resectable status Locally resectable 6 (40) 
Locally irresectable 4 (26) 
Metastatic disease 5 (33) 
1 World Health Organisation(WHO) performance status is a tool to assess a patient’s general health. 
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We observed no differences in the objective measurements of olfactory function (TDI), 
threshold, discrimination or identification of odours between baseline and follow up (table 
3.2). Objective taste function at follow up was lower than at baseline (median 9 vs. 6), 
which was borderline statistically significant (p=0.06). For the separate tastes, salt taste 
decreased the most, although all tastes (salt, sweet, sour and bitter) were not statistically 
significantly different (table 3.2). Self-reported taste, smell, appetite and hunger feelings 
did not differ between baseline and follow-up. 
Table 3.2. Median (IQR) scores of taste and smell function in oesophagogastric cancer patients 
before chemotherapy (baseline) and after two cycles chemotherapy (follow up), n=15. 
Baseline Follow up P-value 
Objective taste function 
Total taste 9 (5-12) 6 (5-11) 0.06 
Sweet 3 (1-4) 3 (2-4) 0.21 
Sour 1 (1-2) 1 (1-2) 0.71 
Salty 3 (2-4) 2 (1-4) 0.08 
Bitter 1 (0-3) 1 (0-2) 0.45 
Objective smell function 
TDI 28.3 (22.0-34.8) 27.3 (21.7 – 34.5) 0.57 
Threshold 6.3 (4-7) 6.5 (5-8) 0.09 
Discrimination 10 (9-14) 10 (7-13) 0.23 
Identification 12 (9-13) 11 (8-14) 0.15 
Self-report 
Taste 28 (23-29) 28 (27-28) 0.42 
Smell 22 (19-22) 22 (20-22) 0.78 
Appetite 21 (19-22) 22 (20-22) 0.59 
Hunger 35 (33-38) 34 (30-40) 0.45 
IQR = Interquartile range, TDI =Threshold Discrimination Identification score 
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Both at baseline and at follow-up, high protein products were preferred over high 
carbohydrate and low energy products (all p<0.05), but no differences were observed in 
preferences for the macronutrient categories between baseline and follow up (figure 3.1a). 
There were no differences in preferences for sweet and savoury products between 
baseline and follow up, nor was there a specific preference for either sweet or savoury 
products (figure 3.1b).  
A lower self-reported taste perception was correlated with a lower preference for high-
protein products (ρ=0.526, p=0.003). Reported taste and smell perception were not 
significantly correlated with objective taste and smell function. 
a. Macronutrient preferences
Sc
or
e 
(1
-4
)
1
2
3
4
HC HF HP LE
Category
b. Taste preference
Sc
or
e 
(1
.5
 - 
3.
5)
1.5
2.0
2.5
3.0
3.5
Sweet Savoury
Baseline
Follow up
Baseline
Follow up
Figure 3.1. Boxplot of baseline and follow-up measurements a. macronutrient preferences and b. 
taste preferences. Whiskers represent minimum and maximum. (HC: high carbohydrate; HF: high 
fat; HP: high protein; LE: low energy) 
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Discussion 
This is the first study that used both self-reported and objective methods to assess 
olfactory and gustatory sensitivity and food preferences in oesophagogastric cancer 
patients undergoing palliative chemotherapy. Although the sample size of the study is 
small, our results suggest that objective taste function decreases during chemotherapy in 
OGC patients, while objective olfactory function remains unchanged. Furthermore, self-
reported taste and smell function did not change upon chemotherapy treatment. A recent 
qualitative study of our group in this patient group showed that OGC patients undergoing 
chemotherapy do experience chemosensory changes.4 It could be argued that the 
reported  changes in the qualitative study are more hedonic in nature, related to the 
appreciation of tastes or smells, rather than reflecting an actual decrease in chemosensory 
function.5  
Although food preferences did not change during chemotherapy, there was a preference 
for high protein products over low energy and high carbohydrate products both before 
and during chemotherapy. This preference for high-protein products was not seen 
previously in a sample of young healthy adults.13 Weight loss and malnutrition prevails in 
the majority of patients with oesophageal cancer before treatment.14 This weight loss is 
often accompanied with a loss of muscle mass, indicating a poor protein status. Studies 
have shown that humans develop compensatory preferences for protein-rich food when 
being brought into a low protein status by a low-protein diet.15, 16 Therefore, the 
preference for high-protein products in our study could be the result of a low protein 
status in oesophagogastric cancer patients. Unfortunately, no data were available on 
weight loss of the patients before start of the study. Studies on the relation between body 
composition and food preferences should be done to further explore the potential 
relationship between weight change, protein status and food preferences in cancer 
patients.  
Importantly, we observed that a low self-reported taste function was correlated with a low 
preference for high-protein products. Dietary advice in oesophagogastric cancer patients 
is directed at enhancing protein intake.17 Potentially, patients with a lower reported taste 
function have more difficulties to comply to a higher protein intake, as their preference 
for high-protein products is lower. Therefore it is important to consider the patient’s taste 
function, when providing dietary advice to OGC patients.  
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Conclusion 
This study suggests that olfactory function in oesophagogastric cancer patients 
undergoing palliative chemotherapy does not change, but objective taste function 
decreases.  A low reported taste function was related to a lower preference for high-
protein products. Given the importance of maintaining a good nutritional status, these 
findings highlight the importance of asking about chemosensory function when giving 
nutritional advice in advanced OGC patients. 
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Abstract  
Changes in food preferences and chemosensory function are frequently reported during 
chemotherapy, but the nature of these changes are largely unknown. We aimed to follow 
and characterize food preferences, taste and smell function over treatment with 
chemotherapy in breast cancer patients and compared to women without cancer. 
Furthermore, we assessed associations between taste and smell function and food 
preferences in breast cancer patients.  
Women with newly diagnosed breast cancer (n=28) completed test sessions before, 
halfway, shortly after, and six months after chemotherapy. Twenty-eight women without 
cancer were tested at similar time points as control. During each test session, food 
preferences were assessed with the Macronutrient and Taste Preference Ranking Task 
(MTPRT). Self-reported taste and smell function were tested on a visual analogue scale. 
Objective taste and smell function were assessed with Taste Strips and Sniffin’ Sticks.  
Breast cancer patients liked high-protein, high-fat, sweet, and savoury products less 
during chemotherapy, which returned to baseline half a year after chemotherapy, while 
the control group was stable over time. Chemotherapy led to a decreased taste and smell 
function which recovered six months after chemotherapy. A better self-reported taste was 
associated with higher liking of high-protein, low-energy, savoury and sweet products.  
Breast cancer patients undergoing chemotherapy have altered food preferences for 
macronutrients, but not specifically for sweet or savoury tastes. Chemotherapy has a 
transient influence on food preferences and chemosensory function, of which patients 
should be informed prior to treatment, and which should be monitored during treatment 
due to the consequences for nutritional intake and quality of life. 
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Introduction 
Cancer patients undergoing chemotherapy treatment experience many side effects, 
including changes in taste, smell and food preferences. The prevalence of these changes 
vary from 45 to 84% for self-reported taste and 5 to 60% for smell.1 These changes are 
amongst the most troublesome side effects of chemotherapy,2, 3 and can have a 
substantial impact on the daily life of cancer patients by reducing food enjoyment, 
nutritional intake and quality of life.4-7 However, the nature of changes in food preferences 
and changed chemosensory function is largely unknown. 
Our recent study showed that breast cancer patients have a lower intake of total energy, 
protein and fat during chemotherapy compared to a group of women without cancer, but 
a similar intake of carbohydrates.8 A lower self-reported taste perception was associated 
with this decreased intake of energy, protein and fat. Possibly, this association reflects the 
nutrient-signalling function of taste, where sweet taste signals carbohydrates, salt taste 
signals sodium content which is important for the bodies electrolyte balance, and savoury 
(umami) taste signals protein content.9 The body uses these signals to maintain 
macronutrient balance. Experimental studies have shown that in humans, a protein-
depleted state elicits a higher preference for savoury foods to restore protein status.10, 11 
Possibly a dysfunctional taste system might elicit different preferences for food and 
thereby influence food intake during chemotherapy in cancer patients. However, there is 
little known on macronutrient preferences during chemotherapy and whether this is 
influenced by actual changes in taste or smell function. 
Several studies have assessed food preferences during chemotherapy, but mostly in terms 
of food aversions, with foods such as meat, coffee and chocolate frequently  being 
reported as aversive.12-15 However, there are no quantitative studies available that 
specifically assessed food preferences in terms of macronutrients in breast cancer 
patients. Recently, the Macronutrient and Taste Preference Ranking Task (MTPRT) was 
developed in our group.16 This task assesses food preferences for four macronutrient 
categories (high-fat, high-protein, high-carbohydrate and low-energy) and two tastes 
(sweet and savoury), with both liking and relative preferences (ranking) of these food 
categories. This task could therefore give more systematic insights in how food 
preferences might change over chemotherapy treatment.  
To explore the possible relation between taste, smell and food preferences, it is important 
to assess chemosensory function both subjectively and objectively. As reported 
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chemosensory changes do not always correspond to objective measures of taste or smell 
function,17 these measures give information on the actual changed during chemotherapy. 
Studies using objective measures thus far suggest that chemotherapy lowers taste 
sensitivity in cancer patients.18 For objective olfactory function studies have different 
findings, some suggesting a decreased olfactory function, while others report unchanged 
olfactory function during chemotherapy.18 This heterogeneity in findings is partly 
attributed to studies that are performed in populations with different types of cancer, 
treatments and disease phases.12 Interestingly, to date there are no prospective studies in 
cancer patients that included a control group that was followed over the course of the 
study, thus excluding the effect of normal fluctuations or repeated testing over time. 
To better understand the relation between altered food preferences and chemosensory 
function over chemotherapy treatment, we followed and characterized food preferences, 
taste and smell function before, during and after chemotherapy in  breast cancer patients 
and compared women without cancer. Furthermore, in breast cancer patients, we 
assessed the associations between subjective and objective taste and smell and food 
preferences. 
Materials and Methods 
Study population 
This study involves a sub-group of an ongoing observational multi-centre study among 
breast cancer patients during chemotherapy and a control group of women without 
cancer of similar age (COBRA-study).8 In the COBRA-study, women with newly diagnosed, 
stage I-IIIB, operable breast cancer, who were scheduled for 2nd or 3rd generation 
chemotherapy were compared with women without cancer of similar age (range within 2 
years). Eligible patients were recruited by the staff of 11 participating hospitals in the 
Netherlands prior to commencement of chemotherapy. The control group was recruited 
via patients, who were asked to distribute information about the study to friends, 
acquaintances and colleagues. Women without cancer could contact the researchers if 
they were interested in participating in the study. All study participants needed to be at 
least 18 years old and be able to communicate in Dutch. Exclusion criteria were: history of 
cancer, previous treatment with chemotherapy, pregnancy or the intention to get 
pregnant during the study period, dementia or other mental conditions that made it 
impossible to comply with study procedures. The protocol was approved by the Medical 
Ethical Committee of Wageningen University (ABR NL40666.081.12). All participants 
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provided written informed consent before enrolment. For the current sub-study we 
included 33 breast cancer patients and 30 controls between February 2014 and December 
2015. There were no additional in- or exclusion criteria to participate in this sub-study. 
Five patients and two controls dropped out for various reasons: lack of sufficient time to 
participate (n=1), participants wanted to focus solely on treatment (n = 1), receiving 
palliative treatment (n=1), medical reasons (n=2) or no specific reason (n=2). 
Study design 
Assessment of taste and smell function, and food preferences was done at four time 
points for all study participants. For patients this was before start of chemotherapy (T1), 
during chemotherapy (T2), 1-3 weeks after the last chemotherapy cycle (T3) and 6 months 
after end of chemotherapy (T4). The measurement during chemotherapy was scheduled 
halfway the scheduled chemotherapy cycles, mostly in the week before administration of 
the next cycle. For the comparison group measurements were done over a similar time 
frame; baseline (T1), 3 months (T2), 6 months (T3) and 12 months (T4) after baseline. All 
tests were done at participants’ homes by trained researchers. Measurements took place 
at approximately the same time of the day for each participant, either in the morning or 
during the afternoon. Participants were instructed not to wear perfume, not to smoke, 
and not to eat or drink anything other than water or unsweetened tea 15 minutes prior to 
testing. The measurements were completed in the same order during each test session: 
subjective taste and smell perception, olfactory function, taste function, hedonic taste 
intensity ranking and food preference task. Demographic information regarding age, BMI, 
education level and smoking status was derived from a questionnaire at study onset. 
Information regarding disease stage and treatment was derived from medical records. 
Measurements 
Macronutrient and Taste Preference Ranking Task 
Food preferences were assessed using the Macronutrient and Taste Preference Ranking 
Task, a computer-based preference task with food pictures from four food categories: 
high-protein, high-carbohydrate, high-fat and low-energy products.16 Each macronutrient 
category consisted of 8 products, with both sweet and savoury products, except the high-
protein category, which only consisted of savoury products. First, liking was assessed for 
each product on a 100 point VAS anchored: ‘do not like at all’ and ‘like extremely’.  
Next, participants were presented with the ranking procedure of the MTPRT, which 
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consisted of a macronutrient and a taste section. In both sections, participants were 
presented with four different pictures which they had to rank according to “what they 
most desire to eat at this moment”. In the macronutrient section, each of the four pictures 
represented one of the macronutrient categories, with 16 combinations in total. In the 
taste section, the four pictures that were presented came from two macronutrient 
categories, with twelve combinations in total. Within each category, one picture 
represented a sweet food item, and the other a savoury one. In this section, products 
from the high-protein category were excluded. Liking for the macronutrient and taste 
categories were calculated by using the mean liking for each category. Relative 
preferences were calculated for the macronutrient and taste categories as described 
elsewhere.16 Preference scores for the macronutrient categories can range from 1-4, with a 
higher score indicating a higher preference for a category. Preference scores for sweet 
and savoury can range from 1.5 to 3.5. Because preference scores for sweet and savoury 
are each other’s opposite in this task, we only report preference scores for savoury in this 
article. 
Taste intensity preferences  
Taste intensity preferences were evaluated with lemonade and tomato juice, with five 
different concentrations of sucrose and salt 19, 20. Sucrose was added to peach mango 
flavoured beverage (Kool-Aid® drink mix, Kraft Foods Canada Inc., Ontario, Canada), 
prepared in water according to manufacturer’s instructions. The sucrose concentrations 
ranged from 0.0625 M to 1M, with a twofold increase between every concentration. 
Tomato juice was made by diluting tomato paste without added sodium chloride (Albert 
Heijn, Zaandam, Netherlands) in water (215g/L). Sodium chloride was added to the 
tomato juice, with a concentration range of 0.3125 M to 0.5 M with a twofold increase 
between every concentration. Solutions were stored frozen in lidded containers (30ml) 
and brought to room temperature on the day of testing. For each taste, the five 
concentrations were presented in random order. Participants had to taste the 
concentrations, with a sip of water in between, and rank order the samples from least 
liked to most liked. Scores were ranged 1-5, with 1 being the least liked and 5 the most 
liked sample. 
Self-reported taste and smell perception 
Self-reported taste and smell function were assessed by asking response to the following 
statements: ‘At this moment I can taste’ and ‘At this moment I can smell’. Responses were 
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measured on a 100 point visual analogue scale (VAS), anchored from ‘not good at all’ to 
‘very good’.  
Taste 
Taste function was assessed using the Taste Strips (Burghart, Wedel, Germany). This 
validated test uses filter-paper taste strips impregnated with different concentrations of 
the basic tastes sweet, salty, bitter and sour 21, 22. The filter papers are impregnated with 
four concentrations of sweet (0.05, 0.1, 0.2 or 0.4 g/ml sucrose), salty (0.016, 0.04, 0.1 or 
0.25 g/ml sodium chloride), sour (0.05, 0.09, 0.165 or 0.3 g/ml citric acid) or bitter (0.0004, 
0.0009, 0.0024, 0.006 g/ml quinine hydrochloride) taste. After placing a paper on the 
tongue, patients were asked to identify the taste stimulus with five possible answers 
(sweet, sour, salty, bitter or no taste). Taste strips were presented in a semi-randomized 
forced choice procedure. Patients rinsed their mouth with water before each taste strip. 
Scores for each taste range from 0 to 4, and total taste scores range from 0-16, which is 
the sum of the four basic taste scores. Higher scores indicate a better taste function. 
Smell 
Olfactory function was measured using the Sniffin’ Sticks.23 This validated test battery 
examines nasal chemosensory performance using pen-like odour devices. The test 
consists of three parts: a detection threshold (THR), discrimination (DIS) test and odour 
identification (ID) test. The THR was measured with a standard series of pens with 
different concentrations of n-butanol. With a staircase procedure, three pens were 
presented to participants in a randomized order. Of these pens, one contained the odour 
and two contained solvent. Participants had to indicate which pen contained the odorant.  
To measure DIS ability, 16 triplets of odorants were presented to participants. The triplet 
contained two pens with the same odour and one with a different odour. Participants had 
to discriminate which pen smelled differently. During the ID test, 16 pens with common 
odours were presented. Participants had to choose the correct descriptor from a list of 
four descriptors for each pen. For the THR, scores range from 1 to 16, for the ID and DIS 
test scores ranged from 0 to 16. A score for overall olfactory function (TDI) was calculated 
by taking the sum of the THR, DIS and ID. Higher scores indicate a better olfactory 
function. To limit potential learning effects over the sessions, the extended version of the 
Sniffin’ Sticks was used, which contains 32 odour combinations for the DIS-test and 32 
odours for the ID-test.24 Combinations of pens were randomized across participants and 
test sessions. 
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taste section, the four pictures that were presented came from two macronutrient 
categories, with twelve combinations in total. Within each category, one picture 
represented a sweet food item, and the other a savoury one. In this section, products 
from the high-protein category were excluded. Liking for the macronutrient and taste 
categories were calculated by using the mean liking for each category. Relative 
preferences were calculated for the macronutrient and taste categories as described 
elsewhere.16 Preference scores for the macronutrient categories can range from 1-4, with a 
higher score indicating a higher preference for a category. Preference scores for sweet 
and savoury can range from 1.5 to 3.5. Because preference scores for sweet and savoury 
are each other’s opposite in this task, we only report preference scores for savoury in this 
article. 
Taste intensity preferences  
Taste intensity preferences were evaluated with lemonade and tomato juice, with five 
different concentrations of sucrose and salt 19, 20. Sucrose was added to peach mango 
flavoured beverage (Kool-Aid® drink mix, Kraft Foods Canada Inc., Ontario, Canada), 
prepared in water according to manufacturer’s instructions. The sucrose concentrations 
ranged from 0.0625 M to 1M, with a twofold increase between every concentration. 
Tomato juice was made by diluting tomato paste without added sodium chloride (Albert 
Heijn, Zaandam, Netherlands) in water (215g/L). Sodium chloride was added to the 
tomato juice, with a concentration range of 0.3125 M to 0.5 M with a twofold increase 
between every concentration. Solutions were stored frozen in lidded containers (30ml) 
and brought to room temperature on the day of testing. For each taste, the five 
concentrations were presented in random order. Participants had to taste the 
concentrations, with a sip of water in between, and rank order the samples from least 
liked to most liked. Scores were ranged 1-5, with 1 being the least liked and 5 the most 
liked sample. 
Self-reported taste and smell perception 
Self-reported taste and smell function were assessed by asking response to the following 
statements: ‘At this moment I can taste’ and ‘At this moment I can smell’. Responses were 
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measured on a 100 point visual analogue scale (VAS), anchored from ‘not good at all’ to 
‘very good’.  
Taste 
Taste function was assessed using the Taste Strips (Burghart, Wedel, Germany). This 
validated test uses filter-paper taste strips impregnated with different concentrations of 
the basic tastes sweet, salty, bitter and sour 21, 22. The filter papers are impregnated with 
four concentrations of sweet (0.05, 0.1, 0.2 or 0.4 g/ml sucrose), salty (0.016, 0.04, 0.1 or 
0.25 g/ml sodium chloride), sour (0.05, 0.09, 0.165 or 0.3 g/ml citric acid) or bitter (0.0004, 
0.0009, 0.0024, 0.006 g/ml quinine hydrochloride) taste. After placing a paper on the 
tongue, patients were asked to identify the taste stimulus with five possible answers 
(sweet, sour, salty, bitter or no taste). Taste strips were presented in a semi-randomized 
forced choice procedure. Patients rinsed their mouth with water before each taste strip. 
Scores for each taste range from 0 to 4, and total taste scores range from 0-16, which is 
the sum of the four basic taste scores. Higher scores indicate a better taste function. 
Smell 
Olfactory function was measured using the Sniffin’ Sticks.23 This validated test battery 
examines nasal chemosensory performance using pen-like odour devices. The test 
consists of three parts: a detection threshold (THR), discrimination (DIS) test and odour 
identification (ID) test. The THR was measured with a standard series of pens with 
different concentrations of n-butanol. With a staircase procedure, three pens were 
presented to participants in a randomized order. Of these pens, one contained the odour 
and two contained solvent. Participants had to indicate which pen contained the odorant.  
To measure DIS ability, 16 triplets of odorants were presented to participants. The triplet 
contained two pens with the same odour and one with a different odour. Participants had 
to discriminate which pen smelled differently. During the ID test, 16 pens with common 
odours were presented. Participants had to choose the correct descriptor from a list of 
four descriptors for each pen. For the THR, scores range from 1 to 16, for the ID and DIS 
test scores ranged from 0 to 16. A score for overall olfactory function (TDI) was calculated 
by taking the sum of the THR, DIS and ID. Higher scores indicate a better olfactory 
function. To limit potential learning effects over the sessions, the extended version of the 
Sniffin’ Sticks was used, which contains 32 odour combinations for the DIS-test and 32 
odours for the ID-test.24 Combinations of pens were randomized across participants and 
test sessions. 
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Data analysis 
Baseline characteristics (age, BMI, smoking and education level) are presented as mean ± 
SD or percentages. For 8 out of 28 patients, baseline measurements of taste and smell 
and food preferences were missing because the inclusion date was too close to the start 
of the first chemotherapy cycle to schedule the first test session.  
Linear mixed models were used to analyse liking and ranking of high-fat, high-protein, 
high-carbohydrate, low-energy, sweet and savoury products, reported and measured 
taste and smell function, over time and differences between groups. Test session (T1-T4) 
and group (patient and control) and their interaction were included as fixed factors in the 
model and participants were included as random factors. When significant main effects or 
a significant interaction was found, post hoc analyses were performed to further explore 
the effects. For the liking of high-protein and savoury products, and ranking of the four 
macronutrient categories, vegetarian and vegan participants (n=3.) were excluded from 
the analyses. 
Differences in preference for each lemonade and tomato juice concentration between the 
four test sessions were assessed for patients and controls separately with Friedman 
ANOVA and Dunn-Bonferroni test to assess post hoc differences. Pearson correlations 
were done to correlate self-reported taste and smell function with objectively measured 
taste and smell function, and to correlate reported and measured taste and smell with 
liking food preferences in patients. All time points were included in these analyses. 
Statistical analyses were performed using SPSS statistics version 23 (IBM Corporation, 
Armonk, New York, USA). A p-value ≤0.05 was considered statistically significant. 
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Results 
Twenty eight breast cancer patients and 28 women in the control group completed all 
four test sessions (table 4.1). The two groups were similar in age and BMI, while there 
were more smokers and less former smokers in the patient group than in the control 
group. The control group had a higher education level than the patient group. Most 
patients had a stage II tumour and received adjuvant chemotherapy containing 
anthracyclines and taxanes. 
Table 4.1. Demographic and clinical characteristics of the participants in the study presented as 
mean (SD) or n (%) 
Control 
n=28 
Patients 
n=28 
Age (years) 51.8 ± 7.6 51.0 ± 8.1 
BMI (kg/m2) 25.0 ± 4.8 25.1 ± 4.5 
Smoking 
 Current 
 Former 
 Never 
0 (0) 
17 (61) 
11 (39) 
5 (18) 
13 (46) 
10 (36) 
Education 
 Lower 
 Middle 
 Higher 
0 (0) 
8 (29) 
20 (71) 
4 (14) 
11 (39) 
13 (47) 
22 (79) 
6 (21) 
Adjuvant chemotherapy 
Neo-adjuvant chemotherapy 
Stage  
I   
II   
III 
9 (32) 
17 (61) 
2 (7) 
Chemotherapy 
Taxanes  
Anthracyclines + taxanes  
Platinum containing 
1 (4) 
26 (92) 
1 (4) 
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Food preferences  
Macronutrient and Taste Preference Ranking Task 
For all analyses on the MTPRT, liking and ranking the control group did not significantly 
change over time unless specified otherwise. 
In patients, liking of high-fat products was significantly lower shortly after chemotherapy 
(T3) compared to baseline, but not for other time points (T1: 60 ± 17.3, T2: 56 ± 15.7, T3: 
54 ± 16.9, T4: 59 ± 16.7). For high-protein products (figure 4.1b), liking was higher in the 
patient group compared to the control group at baseline (67 ± 12.1 vs. 60 ± 14.8). 
Furthermore, patients liked high-protein products less during (T2) and shortly after 
chemotherapy (T3) compared to baseline (T1: 67 ± 12.1, T2: 62 ± 14.2, T3: 60 ± 14.8, T4: 66 
± 12.2). There were no significant differences between the groups and over time for liking 
of high carbohydrate products and low energy products (figure 4.1c-d).  
Patients liked savoury products more than controls at baseline (65 ± 7.6 vs. 58 ± 10.6) and 
T4 (64 ± 9.7vs. 58 ± 9.4) (figure 4.1e). Furthermore, patients liked savoury products less 
shortly after chemotherapy compared to baseline (T1: 65 ± 7.6, T2: 62 ± 10.5, T3: 58 ± 10.1, 
T4: 64 ± 9.7). Sweet products were liked less during and shortly after chemotherapy 
compared to baseline in the patient group (T1: 64 ± 14.3, T2: 61 ± 13.1, T3: 60 ± 12.3, T4:64 
± 12.8) (figure 4.1f). 
For all data of the liking and ranking scores of the MTPRT, see Supplementary material 4.1. 
Ranking scores for high-fat, high-protein, high-carbohydrate and low-energy products 
did not differ over time within or between the groups. Preferences for savoury products 
changed over time in both the patient and the control group. In the patient group, 
preference for savoury products was significantly higher during chemotherapy compared 
to baseline (T1: 2.4 ± 0.4, T2: 2.5 ± 0.37, T3: 2.4 ± 0.33, T4: 2.4 ± 0.39). In the control 
group preference for savoury products was significantly higher at T2 and T3 compared to 
T1 (T1: 2.2 ± 0.34, T2: 2.3 ± 0.34, T3: 2.3 ± 0.38). 
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Figure 4.1. Liking of high-fat (a), high-protein (b), high-carbohydrate (c) and low energy (d), 
savoury (e) and sweet (f) products over time in breast cancer patients and controls (mean ± SD). T1 
represents before chemotherapy (patients) or baseline (control), T2 halfway chemotherapy 
(patients) or three months (controls), T3 shortly after chemotherapy (patients) or six months 
(controls) and T4 represents ½ year after chemotherapy (patients) or 12 months (controls).  
* indicates a significant difference at p<0.05. 
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Figure 4.1. Liking of high-fat (a), high-protein (b), high-carbohydrate (c) and low energy (d), 
savoury (e) and sweet (f) products over time in breast cancer patients and controls (mean ± SD). T1 
represents before chemotherapy (patients) or baseline (control), T2 halfway chemotherapy 
(patients) or three months (controls), T3 shortly after chemotherapy (patients) or six months 
(controls) and T4 represents ½ year after chemotherapy (patients) or 12 months (controls).  
* indicates a significant difference at p<0.05. 
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Taste intensity preferences  
Preferences for the lemonades with different concentrations of sucrose were similar over 
time in the control group (figure 4.2a). In the patient group, the lemonade with the 
second lowest concentration was less preferred during chemotherapy compared to 
baseline (figure 4.2b). Furthermore, the sweetest lemonade was more preferred, indicating 
a greater preference for highly intense sweet, albeit not statistically significant. 
For the tomato juices, there were significant differences in salt intensity preferences over 
time, but mainly in the control group (figure 4.2c). In the patient group there were no 
significantly changed preferences for the different concentrations of salt in tomato juice 
(figure 4.2d). 
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Figure 4.2. Hedonic ranking of lemonades and tomato juice over time in breast cancer patients and 
control group. T1 represents before chemotherapy (patients) or baseline (control), T2 halfway 
chemotherapy (patients) or three months (controls), T3 shortly after chemotherapy (patients) or six 
months (controls) and T4 represents ½ year after chemotherapy (patients) or 12 months (controls). 
Sample 1 presents the lowest concentration of sugar or salt, sample 5 the highest concentration. 
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Taste and smell function 
For reported and objective taste and smell function measures, the control group 
remained stable over time. 
Taste  
Patients reported their taste function significantly lower during (T2) and shortly after 
chemotherapy (T3) compared to baseline (T1: 78 ± 19.2, T2: 56 ± 25.1, T3: 55 ± 27.4, T4: 
76 ± 17.1) and compared to the control group (T2: 74 ± 15.5, T3: 76 ± 15.8) (figure 4.3a). 
The self-reported taste function of breast cancer patients was recovered half a year after 
chemotherapy (T4).  
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Figure 4.3. Self-reported taste (a), objective taste (b) and self-reported and objective smell function 
(c-d) over time in breast cancer patients and controls (mean ± SD). T1 represents before 
chemotherapy (patients) or baseline (control), T2 halfway chemotherapy (patients) or three months 
(controls), T3 shortly after chemotherapy (patients) or six months (controls) and T4 represents ½ 
year after chemotherapy (patients) or 12 months (controls). * indicates a significant difference at 
p<0.05. 
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Figure 4.3. Self-reported taste (a), objective taste (b) and self-reported and objective smell function 
(c-d) over time in breast cancer patients and controls (mean ± SD). T1 represents before 
chemotherapy (patients) or baseline (control), T2 halfway chemotherapy (patients) or three months 
(controls), T3 shortly after chemotherapy (patients) or six months (controls) and T4 represents ½ 
year after chemotherapy (patients) or 12 months (controls). * indicates a significant difference at 
p<0.05. 
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Objective taste function (figure 4.3b) was lower during and shortly after chemotherapy 
compared to baseline, and also recovered half a year after chemotherapy (T1: 11.3 ± 2.41, 
T2: 9.6 ± 3.6, T3: 10.0 ± 3.22, T4: 11.5 ± 3.32). Similarly, during and shortly after 
chemotherapy objective taste function was significantly lower than the control group (T2: 
11.4 ± 2.92, T3: 11.9 ± 2.36). 
For data on the separate tastes in both groups see supplementary material 4.2. Patients 
had a significantly lower sensitivity for sweet during chemotherapy (T2) compared to 
baseline (T1: 3.2 ± 1.1, T2: 2.7 ± 1.3, T3: 2.9 ± 1.2, T4: 3.4 ± 1.1). 
 During (T2) and shortly after chemotherapy (T3) the patient group had a significantly 
lower sensitivity for sweet compared to the control group (T2: 3.4 ± 0.6, T3: 3.5 ± 0.6). 
Similarly, sensitivity for salt taste was lower during (T2) and shortly after chemotherapy 
(T3) compared to baseline in the patient group (T1: 3.1 ± 0.8, T2: 2.4 ± 1.4, T3: 2.3 ± 1.2, 
T4: 2.8 ± 1.2). Shortly after chemotherapy this was significantly different from the control 
group (T3: 3.0 ± 1.1). Sensitivity for sour and bitter taste were not significantly different 
over time, nor between the groups.  
Smell 
Patients reported their smell function significantly lower shortly after chemotherapy (T3) 
(T1: 68 ± 24.5, T2: 62 ± 22.8, T3: 59 ± 26.5, T4: 69 ± 23.8) (figure 4.3c). For overall 
olfactory function (TDI, figure 4.3d), patients scored lower during chemotherapy (T2) 
compared to baseline (T1: 32.9 ± 5.46, T2: 31.4 ± 5.06, T3: 33.3 ± 3.82, T4: 33.4 ± 3.74). 
For odour thresholds (THR), patients had the lowest THR during chemotherapy, which was 
which was significantly different from shortly after chemotherapy and half a year after 
chemotherapy, but not from baseline (T1: 7.5 ± 2.41, T2: 6.4 ± 2.16, T3: 7.5 ± 2.08 , T4: 
7.9 ± 1.66). The DIS and ID test did not show changes over time within or between the 
groups. For all data on separate olfactory tests in both groups see Supplementary 
material 4.2. 
Correlations between subjective, objective taste and smell function, and 
food preferences 
Subjective taste was significantly correlated with subjective smell function in both the 
patient and the control group (patients: r=0.73, p<0.001; control: r=0.59, p<0.001). 
Furthermore, subjective smell function was significantly correlated with objective smell 
function in both groups (patients: r=0.31, p=0.001; control: r=0.25, p<0.01), while 
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subjective and objective taste function were not significantly correlated in either of the 
groups (patients: r=0.12, p=0.22; control: r=-0.06, p=0.54). Objective taste function was 
significantly correlated with objective smell function in the patient group (r=0.21, p=0.03), 
but not in the control group (r=0.05, p=0.60). 
A higher rating of taste function was significantly correlated with a higher liking of high 
protein (r=0.32, p<0.01), low energy (r=0.27, p<0.01), savoury (r=0.32, p<0.01) and sweet 
products (r=0.21, p=0.04), but not with liking of high carbohydrate or high fat products. A 
higher rating of subjective smell function was significantly correlated with a higher liking 
of low energy (r=0.29, p<0.01) and sweet products (r=0.24, p=0.01), but not with liking of 
high carbohydrate, high fat, high protein and savoury products. Objective taste and smell 
function were not significantly correlated with any of the liking of the macronutrient and 
taste categories (all p>0.05).   
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Objective taste function (figure 4.3b) was lower during and shortly after chemotherapy 
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material 4.2. 
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food preferences 
Subjective taste was significantly correlated with subjective smell function in both the 
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high carbohydrate, high fat, high protein and savoury products. Objective taste and smell 
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taste categories (all p>0.05).   
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Discussion 
In this study we assessed food preferences, taste and smell function before, during and 
after chemotherapy in  breast cancer patients and compared women without cancer. 
Furthermore, in breast cancer patients, we assessed the associations between subjective 
and objective taste and smell and food preferences. 
Altered preferences for macronutrients were expressed in a lower liking of high-fat and 
high protein products during chemotherapy, but was not shown in changed ranking 
scores in the MTPRT. The changed liking for these macronutrient categories are in line 
with the actual dietary intake of breast cancer patients during chemotherapy, where we 
found a lower intake of protein and fat, but not for carbohydrates.8 Probably, the lower 
liking for high-protein and high-fat products results in a lower intake of protein and fat 
during chemotherapy. This corresponds to literature frequently reporting meat as being 
aversive during chemotherapy, as it is high in protein and fat.12-14 
Our results for sweet and savoury preferences do not suggest a specific change in 
preference for either of the tastes, as the results for sweet and savoury preferences were 
not consistent over the different methods used. Liking of both sweet and savoury 
products in the MTPRT decreased during chemotherapy. In the ranking procedure of the 
MTPRT, we found a higher preference of savoury products over sweet products during 
chemotherapy. However, the control group showed a similar change in preference during 
the study period. Therefore the shift in ranking of sweet and savoury products in breast 
cancer patients cannot specifically be attributed to chemotherapy. Furthermore, the 
intensity preference ranking of the lemonades suggest a higher preference for more 
intense sweet taste during chemotherapy, but the results from the salt intensity 
preferences were difficult to interpret, as there were also fluctuations of preferences in the 
control group. Possibly, the preferences for the tomato juices were more difficult to 
assess, as tomato juice is less frequently consumed in the Netherlands and was less liked 
in general. These results highlight the importance of including a control group in these 
types of observational studies. Without a control group, changes in cancer patients could 
be falsely attributed to influences of chemotherapy, while these could also be natural 
fluctuations in eating behaviour. 
Generally, the ranking methods used for tastes in our study indicated fluctuations in both 
the patient and the control group, while the liking scores indicated a stable pattern over 
time in the control group, and changes in the patient group during chemotherapy. 
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Possibly, the liking measures give information on liking over a longer period of time, while 
the ranking measures are more susceptible to daily fluctuations, like time and previous 
meals, which was difficult to standardize in our study setting. 
Our study shows that chemotherapy induced taste changes, both measured subjectively 
and objectively. These changes were transient and recover after the end of chemotherapy, 
which has also been reported by several other studies.13, 25, 26 However, it should be noted 
that on average objective taste function during chemotherapy was still considered to be 
within the normal range.22 With regard to specific tastes, changes were mostly measured 
for sweet and salt taste, but not for sour and bitter taste. However, other studies 
investigating separate tastes during chemotherapy show varying results, with all tastes 
affected during chemotherapy13, only salt, umami and sour25, only sweet and bitter27 and 
only salt being affected.26 Results may vary with methods used to assess taste sensitivity, 
but also due to variations in the moment of assessing taste function during 
chemotherapy. Recent studies show that taste changes are largest early in the 
chemotherapy cycle25, 26, while most studies, including ours, assess taste function later in 
the cycle. Potentially, the taste changes we found would be greater when measurements 
were done early cycle.  
Smell function was less affected by chemotherapy than taste function. The decrease in 
total olfactory function score was small (1.5), and is not considered a clinically relevant 
difference.28 Furthermore, the odour threshold score was decreased, while odour 
identification and discrimination were unaffected by chemotherapy. This suggests that 
olfactory function is mostly affected by chemotherapy on peripheral level, but that supra-
threshold perception and cognitive processing of odours remain unaffected.29 
Chemotherapy targets rapidly dividing cells and as a consequence, next to tumour cells, 
also smell and taste receptor cells are likely to be affected. This also explains why the 
effects on chemosensory perception are transient and recover after the end of 
chemotherapy. 
In terms of self-reported taste and smell function, there was a more prominent decrease 
during chemotherapy for taste than for smell, in line with the objectively measured data. 
However, it is difficult for humans to distinguish between taste and smell. When people 
are asked about taste, they mostly refer to the overall flavour of food which also includes 
a large olfactory component.30 This was also reflected in the lack of correlation between 
self-reported taste and objective taste function, while self-reported smell was significantly 
4Chapter 4 
72 
Discussion 
In this study we assessed food preferences, taste and smell function before, during and 
after chemotherapy in  breast cancer patients and compared women without cancer. 
Furthermore, in breast cancer patients, we assessed the associations between subjective 
and objective taste and smell and food preferences. 
Altered preferences for macronutrients were expressed in a lower liking of high-fat and 
high protein products during chemotherapy, but was not shown in changed ranking 
scores in the MTPRT. The changed liking for these macronutrient categories are in line 
with the actual dietary intake of breast cancer patients during chemotherapy, where we 
found a lower intake of protein and fat, but not for carbohydrates.8 Probably, the lower 
liking for high-protein and high-fat products results in a lower intake of protein and fat 
during chemotherapy. This corresponds to literature frequently reporting meat as being 
aversive during chemotherapy, as it is high in protein and fat.12-14 
Our results for sweet and savoury preferences do not suggest a specific change in 
preference for either of the tastes, as the results for sweet and savoury preferences were 
not consistent over the different methods used. Liking of both sweet and savoury 
products in the MTPRT decreased during chemotherapy. In the ranking procedure of the 
MTPRT, we found a higher preference of savoury products over sweet products during 
chemotherapy. However, the control group showed a similar change in preference during 
the study period. Therefore the shift in ranking of sweet and savoury products in breast 
cancer patients cannot specifically be attributed to chemotherapy. Furthermore, the 
intensity preference ranking of the lemonades suggest a higher preference for more 
intense sweet taste during chemotherapy, but the results from the salt intensity 
preferences were difficult to interpret, as there were also fluctuations of preferences in the 
control group. Possibly, the preferences for the tomato juices were more difficult to 
assess, as tomato juice is less frequently consumed in the Netherlands and was less liked 
in general. These results highlight the importance of including a control group in these 
types of observational studies. Without a control group, changes in cancer patients could 
be falsely attributed to influences of chemotherapy, while these could also be natural 
fluctuations in eating behaviour. 
Generally, the ranking methods used for tastes in our study indicated fluctuations in both 
the patient and the control group, while the liking scores indicated a stable pattern over 
time in the control group, and changes in the patient group during chemotherapy. 
Chemosensory changes and food preferences in breast cancer patients 
73 
Possibly, the liking measures give information on liking over a longer period of time, while 
the ranking measures are more susceptible to daily fluctuations, like time and previous 
meals, which was difficult to standardize in our study setting. 
Our study shows that chemotherapy induced taste changes, both measured subjectively 
and objectively. These changes were transient and recover after the end of chemotherapy, 
which has also been reported by several other studies.13, 25, 26 However, it should be noted 
that on average objective taste function during chemotherapy was still considered to be 
within the normal range.22 With regard to specific tastes, changes were mostly measured 
for sweet and salt taste, but not for sour and bitter taste. However, other studies 
investigating separate tastes during chemotherapy show varying results, with all tastes 
affected during chemotherapy13, only salt, umami and sour25, only sweet and bitter27 and 
only salt being affected.26 Results may vary with methods used to assess taste sensitivity, 
but also due to variations in the moment of assessing taste function during 
chemotherapy. Recent studies show that taste changes are largest early in the 
chemotherapy cycle25, 26, while most studies, including ours, assess taste function later in 
the cycle. Potentially, the taste changes we found would be greater when measurements 
were done early cycle.  
Smell function was less affected by chemotherapy than taste function. The decrease in 
total olfactory function score was small (1.5), and is not considered a clinically relevant 
difference.28 Furthermore, the odour threshold score was decreased, while odour 
identification and discrimination were unaffected by chemotherapy. This suggests that 
olfactory function is mostly affected by chemotherapy on peripheral level, but that supra-
threshold perception and cognitive processing of odours remain unaffected.29 
Chemotherapy targets rapidly dividing cells and as a consequence, next to tumour cells, 
also smell and taste receptor cells are likely to be affected. This also explains why the 
effects on chemosensory perception are transient and recover after the end of 
chemotherapy. 
In terms of self-reported taste and smell function, there was a more prominent decrease 
during chemotherapy for taste than for smell, in line with the objectively measured data. 
However, it is difficult for humans to distinguish between taste and smell. When people 
are asked about taste, they mostly refer to the overall flavour of food which also includes 
a large olfactory component.30 This was also reflected in the lack of correlation between 
self-reported taste and objective taste function, while self-reported smell was significantly 
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correlated with objective smell function. Furthermore, self-reported taste may also reflect 
hedonic changes, rather than an actual taste change. Which means that food is not 
enjoyed anymore, but it might taste the same. This could also explain the lack of 
associations between objective measures of taste and smell and the liking measures of 
the MTPRT, while subjective measures were associated. Subjective taste function was most 
often correlated to liking of foods. Self-reported measures may therefore be more 
relevant in a clinical context, as a lower self-reported taste function was related to a lower 
liking of foods in this study, and a lower dietary intake in our previous study.8  
In conclusion, this is the first study that longitudinally assessed food preference and 
chemosensory perception in breast cancer patients undergoing chemotherapy and a 
healthy control group. Breast cancer patients undergoing chemotherapy have altered 
food preferences for macronutrients, but not specifically for sweet or savoury tastes. 
Chemotherapy has a transient influence on food preferences and chemosensory function, 
on which patients should be informed prior to treatment, and monitored during 
treatment due to the consequences for nutritional intake and quality of life. 
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Abstract 
Purpose: Breast cancer patients receiving chemotherapy often experience symptoms such 
as nausea, vomiting and loss of appetite that potentially affect dietary habits. This study 
assessed the intake of energy, macronutrients and food groups before and during 
chemotherapy in breast cancer patients compared  with women without cancer, and 
determined the association between symptoms and energy and macronutrient intake. 
Methods: This study included 117 newly diagnosed breast cancer patients scheduled for 
chemotherapy and 88 women without cancer. Habitual intake before chemotherapy was 
assessed with a food frequency questionnaire. Two 24h dietary recalls were completed on 
random days for each participant during the whole chemotherapy treatment for patients 
and within 6 months after recruitment for women without cancer. Shortly after the dietary 
recall, participants filled out questionnaires on symptoms.  
Results: Before chemotherapy, habitual energy and macronutrient intake was similar for 
breast cancer patients and women without cancer. During chemotherapy, breast cancer 
patients reported a significantly lower total energy, fat, protein and alcohol intake than 
women without cancer, as shown by a lower intake of pastry and biscuits; cheese; 
legumes; and meat products. A decline in subjective taste perception, appetite, hunger, 
and experiencing a dry mouth, difficulty chewing, lack of energy and nausea were 
associated with a lower energy intake.   
Conclusions: Symptoms induced by chemotherapy are associated with lower dietary 
intake, and manifested by a lower intake of specific food groups. To ensure an optimal 
dietary intake during chemotherapy, it is important to monitor nutritional status and 
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Introduction 
The majority of women with breast cancer is treated with chemotherapy.1 Treatment with 
cytotoxic drugs is often accompanied with symptoms such as nausea, vomiting, loss of 
appetite, dry mouth and changes in taste or smell perception. These symptoms can be 
very disturbing and can significantly impact quality of life.2, 3 In types of cancer where the 
gastro-intestinal tract is affected, such as head and neck cancer, the impact of these 
symptoms on dietary intake and nutritional status is well established.4, 5 However, for 
breast cancer patients the experience of symptoms during cancer treatment may differ 
and the extent to which symptoms specifically affect dietary intake in breast cancer 
patients is less clear.  
Previous studies that investigated whether dietary intake changed during chemotherapy 
in breast cancer patients are inconsistent in their findings. They either showed increases,6 
decreases7, 8 or no changes9-11 in energy intake during chemotherapy, possibly because 
different studies used different methods and different time points during the course of 
chemotherapy to assess dietary intake. Most studies in breast cancer patients assessed 
dietary intake only in the week prior to a next chemotherapy cycle, while dietary intake is 
suggested to vary during a cycle.12 Most importantly, earlier studies did not compare 
dietary intake in breast cancer patients to a comparable group of women without breast 
cancer, limiting the possibility to assess whether changes in intake deviate from normal 
fluctuations in intake over time. Additionally, most studies are limited by only focussing on 
energy and macronutrient intake, and not on food items or food groups. Thereby it is 
unknown whether changes in dietary intake during chemotherapy are due to changes in 
intake of specific food groups.  
There are studies that suggest that breast cancer patients gain weight during and after 
chemotherapy, which may be associated with an increased risk of comorbidities like 
cardiovascular disease and diabetes.13, 14 Therefore it is important to give breast cancer 
patients well-grounded advice on their lifestyle and dietary habits before, during and after 
treatment. Especially since breast cancer patients have expressed a need for dietary 
support during treatment with chemotherapy;15 unmet supportive care needs in cancer 
patients are highest during treatment.16 However, in order to give specific dietary advice it 
is important to first know what the actual change in dietary intake of breast cancer 
patients is and which symptoms are associated with dietary changes during 
chemotherapy.  
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Therefore, the aim of this observational study was to assess the intake of energy, 
macronutrients and food groups before and during chemotherapy in breast cancer 
patients in comparison with a group of women without cancer, and to determine the 
association between the experience of specific symptoms and energy and macronutrient 
intake.  
Materials and Methods 
Participants 
This study is part of an ongoing observational multi-centre study among breast cancer 
patients during chemotherapy and a comparison group of women of similar age without 
cancer (COBRA-study). Women with newly diagnosed, incident, stage I-IIIB, operable 
breast cancer, scheduled for 2nd or 3rd generation chemotherapy were compared with 
women without cancer of similar age (range within 2 years). Eligible patients were 
recruited by the staff of 11 participating hospitals prior to commencement of 
chemotherapy. The comparison group was recruited via the women with breast cancer, 
who were asked to distribute information about the study to female friends, 
acquaintances and colleagues. This approach was chosen to maximize the comparability 
of groups with respect to possible confounding factors, and thus to minimize the risk that 
other factors than chemotherapy influenced our findings on dietary intake. Women 
without cancer contacted the researchers if they were interested in participating in the 
study. All study participants needed to be at least 18 years old and be able to 
communicate in Dutch. Exclusion criteria were: history of cancer, previous treatment with 
chemotherapy, pregnancy or the intention to get pregnant during the study period, 
dementia or other mental conditions that made it impossible to comply with the study 
procedures. The protocol was approved by the Medical Ethical Committee of Wageningen 
University (ABR NL40666.081.12). All participants provided written informed consent 
before enrolment. 
Measurements  
Dietary intake 
Upon recruitment, all participants filled out a food frequency questionnaire (FFQ) to 
assess habitual intake before chemotherapy (patient group) or start of the study 
(comparison group).17, 18 During chemotherapy, actual dietary intake was assessed using 
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two telephone-based 24h dietary recalls, because of the expected high day to day 
variation during chemotherapy. The recalls were planned on two random days during 
chemotherapy, during all weeks within a chemotherapy cycle and over all chemotherapy 
cycles administered. Recalls were planned between the day of the first chemotherapy 
infusion and three weeks after the last chemotherapy infusion. Women in the comparison 
group also completed two recalls, which were planned on two random days within 6 
months after recruitment. This was a comparable time-frame, as current oncological 
guidelines for chemotherapy for breast cancer in the Netherlands encompass schemes 
which mostly take 4.5 to 6 months to complete. Randomization of the recall days was 
done for each participant separately. The two recalls were scheduled at least 7 days apart. 
If it was not possible to complete the recall on the scheduled day, a new day was planned 
randomly within 2 weeks. The 24h-recalls were performed using a standardized protocol 
and conducted by trained dietitians. The recalls were at least one week apart and were 
conducted both on week and weekend days. Dietary recall data were coded and entered, 
after which the intake of total energy, protein, carbohydrate, fat, alcohol and fibre were 
calculated in the computation module of Compl-eat™ using the Dutch food composition 
table 2013.19 A data check was performed by the dietitians. The highest and lowest ten 
values for energy, macronutrients, and fruit and vegetables intake were checked for errors 
in coding or amounts. Food items were grouped into food groups for both the food 
frequency questionnaire and 24h dietary recall.19 These food groups were: bread; cereal 
and cereal products; fruit; vegetables; legumes; nuts, seeds and snacks; soups; soy 
products and vegetarian products; pastry and biscuits; sugar, candy sweet toppings and 
sweet sauces; milk and dairy products; cheese; eggs; meat and meat products; and fish. 
Symptoms  
After being called for each 24-h recall, participants were instructed to fill out 
questionnaires on sensory perception and experienced symptoms. The Appetite, Hunger 
feelings and Sensory Perception (AHSP) questionnaire was used to assess self-judgement 
of taste, smell and appetite.20 The questionnaire consisted of 29 questions answered on a 
5 point Likert scale, concerning four categories; taste (8 items, score range 8-40), smell (6 
items, range 6-30), appetite (6 items, range 6-30) and hunger (9 items, range 9-45). An 
example of a question for taste was: In former days the taste of food was: 1. much better 
than nowadays, 2. better than nowadays, 3. the same as nowadays, 4. worse than 
nowadays, 5. much worse than nowadays. For the patient group, ‘former days’ was 
referenced as the situation before chemotherapy and for the comparison group as the 
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situation one year ago. A higher score corresponds to a more positive judgement about 
current taste and smell perception, appetite and hunger. The severity of 13 additional 
symptoms was assessed: pain; dry mouth; feeling depressed; thick saliva; diarrhoea; sore 
mouth; lack of energy; nausea; difficulty chewing; difficulty swallowing; anxiety; 
constipation and vomiting. For each symptom the question was asked: ‘How often have 
you experienced this symptom during the past three days?’, scored on a 5 point Likert 
scale, ranging from 1=“not at all” to 5=“a lot”. If participants did not answer the symptoms 
questionnaires within 3 days after complete the 24h dietary recall, we did not include their 
data in the analyses. In total, we collected n=274 recalls from patients and n=205 recalls 
from women without breast cancer. A number of n=205 recalls from breast cancer 
patients and n=152 recalls from women without cancer were used in the analyses in this 
paper. Excluding participants who did not complete the questionnaires within 3 days from 
analysis did not significantly influence the results on energy and macronutrient intake. 
Demographics and medical information 
All participants filled out a baseline questionnaire for demographic information, including 
age, smoking status and educational level. Information on stage of cancer at diagnosis 
and treatment were obtained from reviewing patients’ medical records. Dates of 
chemotherapy cycles were compared with the dates of the 24h-recalls to classify the 
recalls into the week within a chemotherapy cycle and to the number of cycles that was 
administered at the date of the 24h recalls.  
Data analysis 
Population characteristics were described as medians with interquartile range (IQR) or 
percentages of the patient and comparison group separately. To assess differences in the 
population characteristics between the groups, the Mann-Witney U-test was used for 
continuous data and the Chi Square test for categorical data. Differences in dietary intake 
at study onset (FFQ) between the women with and without breast cancer were analysed 
with Linear Regression. Mixed Model analysis was used to assess differences in energy, 
macronutrient and food group intake between the patient and comparison group. For the 
analysis of differences in dietary intake within a chemotherapy cycle for patients receiving 
a three weekly scheme of chemotherapy, recalls were classified according to the week 
within a chemotherapy cycle a 24h-recall was administered (week 1, week 2 or week 3) 
and to the number of cycles administered. Patients with weekly chemotherapy cycles were 
excluded from this analysis (n=22 recalls). Mixed models were also used to assess the 
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association between symptoms and energy intake. Interactions between each symptom 
and group (patient and comparison group) were evaluated to test whether associations 
between symptoms and energy intake were different between the two groups. For 
significant interactions (p-value ≤0.1), stratified results for patients and the comparison 
group are shown. For symptoms with a significant association with energy intake, data 
was also analysed for the macronutrients protein, carbohydrates and fat. Covariates 
considered as potential confounders were included in the regression and mixed models 
analyses based on literature and change of regression coefficient. Variables that changed 
the regression coefficient ≥ 10% in the adjusted model compared to the crude model 
were included in the final model. Final regression and mixed models analyses were 
adjusted for: age at inclusion, BMI at inclusion, education level, and smoking status at 
inclusion. Statistical analyses were performed using SPSS, version 21 (SPSS inc. Chicago, 
IL). A p-value < 0.05 was considered as statistically significant. 
Results 
Patient characteristics 
Data were collected for 117 breast cancer patients and 88 women in the comparison 
group, see table 5.1. BMI was higher in women with breast cancer than in women without 
breast cancer. In the patient group, fewer women had a high educational level than in the 
comparison group. There were no differences for age, smoking status and menopausal 
status between the groups. The majority of the breast cancer patients had a stage 2 
tumour, and received adjuvant chemotherapy combining taxanes and anthracyclines.  
Dietary intake at study onset 
At study onset, mean energy, protein, fat and carbohydrate intakes were similar between 
the patient and comparison group as assessed with a food frequency questionnaire (table 
5.2). Women with breast cancer reported to consume less alcohol than women in the 
comparison group. Intake for the various food groups was similar between the two 
groups, with the exception of cheese intake, which was slightly higher in breast cancer 
patients compared to the women without cancer. 
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Table 5.1. Demographic and clinical characteristics of the patient and comparison group included 
in the study. 
Characteristic Comparison group (n=88) 
Patient group 
(n=117) 
Demographics    
Age, years (median, IQR)  53.5 (46.1 – 60.9) 51.0 (46.8 – 55.3) 
Education level  (n, %) * 
  Low 
  Medium 
  High  
   
4 (4.5) 
18 (20.5) 
66 (75.0) 
12 (10.4) 
35 (30.4) 
68 (59.1) 
Lifestyle   
BMI, kg/m2 (median, IQR) * 23.8 (22.1 – 26.7) 25.2 (22.3 – 28.4) 
Smoking status (n, %) 
   Current 
   Former 
   Never 
9 (10.2) 
40 (45.5) 
39 (44.3) 
21 (18.1) 
49 (42.2) 
46 (39.7) 
Medical profile   
Tumor Stage (n, %) 
  I 
 II 
 III 
 
 
25 (21.4) 
70 (59.8) 
22 (18.8) 
Adjuvant chemotherapy (n, %) 
Neo adjuvant chemotherapy (n, %) 
 
 
68 (58.1) 
49 (41.9) 
 
Chemotherapy regimen (n, %) 
  Taxanes only 
  Anthracyclines only 
 Taxanes + Anthracyclines  
 
 
4 (3.4) 
4 (3.4) 
109 (93.2) 
Abbreviations: IQR, Interquartile range;  
Missings per variable : education, 2; smoking, 1. 
* p <0.05  
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Table 5.2. Habitual intake of energy, macronutrients and food groups for the patient and 
comparison group (mean ± SE) and differences in intake between the groups at study onset, 
assessed by a food frequency questionnaire. 
Intake in kcal (mean ± SE) 
Comparison group 
(N=88) 
Patient group 
(N=114) 
Differencea 
[95% CI] 
Energy 2069 ± 69.2 2070 ± 59.7 1 [-181 ; 184] 
Protein 318 ± 10.1 315 ± 8.7 -3 [-30 ; 24] 
Carbohydrate 859 ± 31.3 870 ± 27.0 11 [-71 ; 93] 
Fat 761 ± 32.3 779 ± 27.8 18 [-67 ; 103] 
Alcohol* 75 ± 7.5 51 ± 6.5 -24 [-44 ; -4] 
Fibre 46 ± 1.6 45 ± 1.4 -1 [-5 ; 3] 
Food groups 
Bread 256 ± 16.7 256 ± 14.4 0 [-44 ; 44] 
Cereal and cereal products 139 ± 10.9 131 ± 9.4 -8 [-37 ; 21] 
Fruit 134 ± 8.3 118 ± 7.2 -16 [-37 ; 7] 
Vegetables 50 ± 3.5 53 ± 3.0 3 [-6 ; 12] 
Legumes 10 ± 1.6 11 ± 1.4 1 [-4 ; 5] 
Nuts, seeds and snacks 168 ± 15.7 146 ± 13.5 -22 [-63 ; 19] 
Soups 24 ± 3.3 22 ± 2.8 -2 [-11 ; 6] 
Soy products and 
vegetarian products 
18 ± 5.3 16 ± 4.5 -2 [-15 ; 12] 
Pastry and biscuits 119 ± 11.3 136 ± 9.7 17 
[-13 ; 47] 
Sugar, candy, sweet toppings 
and sweet sauces 
110 ± 10.6 120 ± 9.2 10 [-18 ; 38] 
Milk and dairy products 195 ± 13.9 173 ± 12.0 -22 [-58 ; 15] 
Cheese* 105 ± 13.8 145 ± 11.9 40 
[3 ; 76] 
Eggs 25 ± 2.6 24 ±2.3 -1 [-8 ; 6] 
Meat, meat products 
and poultry 
153 ± 9.3 159 ± 8.0 6 [-19 ; 30] 
Fish 36 ± 3.1 29 ± 2.7 -7 [-15 ; 1] 
a Adjusted for age, BMI, education level, smoking status * p <0.05 
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Milk and dairy products 195 ± 13.9 173 ± 12.0 -22 [-58 ; 15] 
Cheese* 105 ± 13.8 145 ± 11.9 40 
[3 ; 76] 
Eggs 25 ± 2.6 24 ±2.3 -1 [-8 ; 6] 
Meat, meat products 
and poultry 
153 ± 9.3 159 ± 8.0 6 [-19 ; 30] 
Fish 36 ± 3.1 29 ± 2.7 -7 [-15 ; 1] 
a Adjusted for age, BMI, education level, smoking status * p <0.05 
Chapter 5 
90 
Dietary intake during chemotherapy 
In total, 357 recalls were collected, 205 in the patient group and 152 in the comparison 
group. During chemotherapy, breast cancer patients had a significantly lower energy 
intake than the women without cancer as assessed with 24-h dietary recalls, 1779 ± 56 vs 
1993 ± 68 kcal (table 5.3). Breast cancer patients reported a significant lower absolute 
intake of protein, fat, and alcohol, but not of carbohydrates and fibre than women without 
cancer.  Expressed as energy percentages, during chemotherapy women with breast 
cancer consumed relatively more energy from carbohydrates and less energy from 
alcohol compared to women without cancer. 
During chemotherapy, women with breast cancer consumed less energy from the food 
groups legumes; pastry and biscuits; cheese; and meat than the women without cancer 
(table 5.4). The intake of other food groups: bread; cereal and cereal products; fruit; 
vegetables; nuts, seeds and snacks; soups; soy and vegetarian products; sugar, sweets, 
sweet toppings and sweet sauces; milk and dairy products; cheese; eggs; and fish was 
similar between breast cancer patients during chemotherapy and women without cancer. 
Results expressed in grams/day can be found in Supplementary table 5.1. The main 
sources of total protein, fat and carbohydrate intake were similar for the patient and the 
comparison group. The main sources of protein intake were meat, bread and milk and 
dairy products. For fat the main sources were fats, oils and savoury sauces, cheese and 
meat, Carbohydrates came mostly from the food groups bread, alcoholic and non-
alcoholic drinks, milk and dairy products and fruit. 
Dietary intake in the patient group was lower compared to the women without cancer in 
all three weeks after chemotherapy was administered, and was lowest in each first week 
However, there were no statistically significant  differences in energy and macronutrient 
intake between the first, second and third week within a chemotherapy (Supplementary 
table 5.2). In addition, there was no association between dietary intake and the number of 
chemotherapy cycles administered. 
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Table 5.3. Energy and macronutrient intake in kcal and energy percentages (en%) for the breast 
cancer patients during chemotherapy and comparison group during follow up (mean ± SE) and 
the differences in intake between the groups. 
Intake in kcal* 
(mean ± SE) 
Comparison group Patient group Difference
a 
[95% CI] 
Energy* 1993 ± 68.3 1779 ± 55.7 -214 [-353 ; -76] 
Protein* 313 ± 10.7 270 ± 8.8 -43 [-64 ; -21] 
Carbohydrate 844± 34.4 815± 28.0 -29 [-99 ; 41] 
Fat* 734 ± 32.0 633± 26.1 -101 [-166 ; -37] 
Alcohol* 54 ± 9.4 17 ± 7.7 -37 [-57 ; -19] 
Dietary fibre 38 ± 1.8 35 ± 1.4 -3 [-7 ; 1] 
Intake in en%* 
(mean ± SE) 
Protein 16.3 ± 0.45 15.5 ± 0.37 -0.8 [-1.6 ; 0.2] 
Carbohydrate* 41.9 ± 1.0 46.2 ± 0.82 4.3 
[2.2 ; 6.3] 
Fat 36.6 ± 0.85 35.0 ± 0.70 -1.6 [-3.4 : 0.1] 
Alcohol* 2.8 ± 0.47 0.8 ± 0.38 -2.0 [-2.9 ; -1.0] 
Dietary fibre 2.0 ± 0.09 2.0 ± 0.07 0.0 [-0.1 ; 0.2] 
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Table 5.4. Intake per food group for the breast cancer patients during chemotherapy and 
comparison group during follow up (mean ± SE) and the differences in intake between the groups 
in kcal. 
Intake in kcal* (mean ± SE) 
Comparison group Patient group 
Difference 
[95% CI]a 
Bread 332 ± 39.5 291 ± 37.2 -41 [-81 ; 2] 
Cereal and cereal products 68 ± 29.4 67 ± 27.7 -1 [-32 ; 31] 
Fruit 98 ± 26.5 86 ± 24.9 -121 [-40 ; 16] 
Vegetables 41 ± 9.4 33 ± 8.9 -8 [-17 ; 3] 
Legumes* 136 ± 39.2 83  ± 36.9 -53 [-95 ; -12] 
Nuts seeds and snacks 7 ± 11.8 9 ± 11.1 2 [-11 ; 14] 
35 ± 28.5 22 ± 26.8 -13 [-43 ; 18] 
29 ± 14.9 31 ± 14.0 2 [-14 ; 18] 
131 ± 36.6 84 ± 34.4 -47 [-86 ; -8] 
90 ± 28.7 86 ± 27.0 -4 [-34 ; 26] 
Soups 
Soy products and vegetarian 
products 
Pastry and biscuits* 
Sugar, candy, sweet toppings, 
and sweet sauces 
Milk and dairy products 164 ± 36.6 170 ± 34.5 6 [-33 ; 44] 
Cheese* 140 ± 22.4 112 ± 21.1 -28 [-52 ; -4] 
35 ± 9.1 39 ± 8.6 4 [-6 ; 14] 
190 ± 31.8 150 ± 29.9 -40 [-74 ; -6] 
Eggs 
Meat, meat products 
and poultry* 
Fish 25 ± 22.3 42 ± 20.95 17 [-8 ; 40] 
a Adjusted for age, BMI, education level, smoking status 
*p < 0.05
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Symptoms 
During chemotherapy, the patient group scored significantly lower on their self-reported 
taste, smell, appetite and hunger, compared to the women without cancer (table 5.5). 
Furthermore, breast cancer patients undergoing chemotherapy experienced more often 
anxiety, dry mouth, constipation, feeling depressed, thick saliva, diarrhoea, sore mouth, 
lack of energy, nausea, difficulty chewing and difficulty swallowing than women in the 
comparison group (table 5.6). Scores were not different for the symptoms pain and 
vomiting between the patient and the comparison group. Only 3 women with breast 
cancer and 1 woman without breast cancer reported vomiting as a symptom they 
experienced that day, therefore vomiting was not analysed for its association with energy 
intake. 
Table 5.5. Taste, smell, appetite and hunger scores from AHSP questionnaire for the breast cancer 
patients during chemotherapy and comparison group during follow up (mean ± SE) and the 
association of AHSP categories with energy intake (kcal). Higher scores indicate a more positive 
self-judgement on the categories of the questionnaire. β for energy intake is the difference in 
energy intake (kcal) per 1 unit higher score within ASHP category. 
Score questionnaire 
(mean ± SE) 
Category Range 
Comparison 
group 
Patient group Difference 
Estimate (β) for 
energy intake (kcal)a 
[95% CI] 
Taste 8-40 30.9 ± 0.71 22.0 ± 0.57 -8.9* [-10.4 ; -7.5] 
16.4* 
[7.0 ; 25.8] 
Smell 6-30 23.3 ± 0.42 20.6 ± 0.42 -2.7 * [-3.7 ; -1.8] 
11.9 
[-5.0 ; 28.7] 
Appetite 6-30 24.7 ± 0.40 18.7 ± 0.50 -6.0* [-7.0 ; -5.0] 
26.5* 
[14.4 ; 38.5] 
Hunger 9-45 38.3 ± 0.70 32.5 ± 0.70 -5.8* [-7.4 ; -4.3] 
24.5* 
[15.1 ; 33.9] 
a Adjusted for age, BMI, education level, smoking status 
*p < 0.05
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Symptoms and dietary intake 
A higher self-judgement of taste perception, better appetite and more hunger were 
significantly associated with a higher energy intake (table 5.5). Self-judgement of smell 
was not significantly associated with energy intake.  
Having a dry mouth, lack of energy, nausea and having difficulty chewing were 
significantly associated with a lower energy intake (table 5.6). The associations between 
anxiety and energy intake and between constipation and energy intake were different for 
the patient and the comparison group (interaction anxiety p=0.02, constipation p=0.03): 
anxiety was not associated with energy intake in breast cancer patients, while it was 
associated with a lower energy intake in the comparison group. Constipation was 
associated with a higher energy intake in the patient group and with a lower energy 
intake in the comparison group, but these associations were not statistically significant 
(table 5.6).  
For the symptoms that were significantly associated with energy intake, we additionally 
assessed whether those symptoms  were associated with protein, carbohydrate and fat 
intake. Briefly, those associations were in the same direction as how the intake of 
macronutrients differed during chemotherapy between the patients and the comparison 
group: symptoms were associated with a lower protein and fat intake, and not associated 
with the intake of carbohydrates (Supplementary table 5.3). 
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Table 5.6. Results of the symptom questionnaire for the breast cancer patients during 
chemotherapy and comparison group during follow up (mean ± SE) and the association between 
symptoms and energy intake (kcal). Symptom severity was assessed on a 5 point Likert scale (1=not 
at all, 5=a lot). β for energy intake indicates the difference in energy intake (kcal) per 1 unit higher 
score in the symptom. 
Symptom 
Score questionnaire 
(mean ± SE) 
Estimate (β) for 
energy intake 
(kcal)a 
[95%CI] 
Comparison 
group 
Patient group Difference 
Pain 1.6 ± 0.13 1.9 ± 0.11 0.3 [-0.005 ; 0.520] 
54.2 
[-2.8 ; 111.2] 
Dry mouth 1.3 ± 0.15 2.9 ± 0.12 1.6 [1.3 ; 1.9]* -47.1* [-92.5 ; -1.8] 
Depressed 1.3 ± 0.1 1.6 ± 0.08 0.3 [0.1 ; 0.5]* 5.4 [-68.4 ; 79.1] 
Thick saliva 1.1 ± 0.12 1.9 ± 0.10 0.8 [0.6 ; 1.1]* -56.3 [-114.1 ; 1.5] 
Diarrhoea 1.0 ± 0.09 1.5 ± 0.07 0.5 [0.2 ; 0.6]* -3.1 [-75.9 ; 69.6] 
Sore mouth 1.3 ± 0.13 2.2 ± 0.11 0.9 [0.7 ; 1.2]* -35.7 [-86.0 ; 14.6] 
Lack of energy 1.6 ± 0.14 3.3 ± 0.12 1.7 [1.5 ; 2.0]* -55.5* [-99.0 ; -12.1] 
Nausea 1.1 ± 0.1 1.7 ± 0.08 0.6 [0.4 ; 0.8]* -77.7* [-139.4 ; -16.0] 
Difficulty 
chewing 
1.1 ± 0.09 1.5 ± 0.07 0.4 [0.2 ; 0.6]* -102.6* [-180.3 ; -24.9] 
Difficulty 
swallowing 
1.1 ± 0.08 1.5 ± 0.06 0.4 [ 0.2 ; 0.6]* -33.6 [-117.1 ; 49.8] 
Constipationb 1.3 ± 0.12 1.8 ± 0.09 0.5 [0.2 ; 0.7]* 
Constipation 
control
-103.3 
[-228.8 ; 22.3] 
Constipation 
patient 
42.1 
[-34.1 ; 118.5] 
Anxietyb 1.2 ± 0.08 1.5 ± 0.07 0.3 [0.1 ; 0.4]* 
Anxiety 
Control
-208.7* 
[-384.1 ; -33.3] 
Anxiety Patient 
83.1 
[-18.2 ; 184.5] 
Vomitingc 1.0 ± 0.04 1.1 ± 0.03 0.04 [-0.04 ; 0.12] 
a Adjusted for age, BMI, education level, smoking status 
b For anxiety and constipation significant interactions were found on the association with energy intake, 
therefore stratified results are shown. 
c For vomiting only 1 control and 3 patients reported a score of 2 or higher on the questionnaire, therefore this 
symptom was not analysed for the association with energy intake. 
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Discussion 
To date, this is the largest study that examined energy, macronutrient and food group 
intake in breast cancer patients during chemotherapy compared to a group of women 
without cancer. We showed that breast cancer patients had a significantly lower energy 
intake during chemotherapy compared with a group of women without cancer. Since 
habitual intake of breast cancer patients before start of chemotherapy was comparable to 
the women without cancer in our study, we can assume that the differences found 
between the groups were mostly due to the consequences of chemotherapy. These 
findings are  in accordance with two other studies that observed a lower energy intake in 
breast cancer patients during chemotherapy compared to before chemotherapy.7, 8 Only 
one previous study, published in 1987, suggested a higher dietary intake during 
chemotherapy in breast cancer patients compared with controls.6 However, that study had 
a control group which already had a lower intake at baseline, limiting the reliability of 
those conclusions.  
The lower energy intake that we observed during chemotherapy was not caused by a 
lower intake of all macronutrients. The intakes of fat, protein and alcohol were lower 
during chemotherapy in breast cancer patients than in women without cancer, while 
intakes of carbohydrates and dietary fibre were similar. The lower protein and fat intake 
can be explained by the food groups that were consumed less during chemotherapy: 
meat and cheese are mostly high in protein and fat, and may thereby partially account for 
the different intakes of macronutrients. Habitual alcohol intake was lower in breast cancer 
patients before chemotherapy than women without cancer, and the intake remained 
lower during chemotherapy. As alcohol is a known risk factor for breast cancer,21 a higher 
or comparable alcohol intake could be expected in the patient group compared wo the 
women without cancer. Possibly, breast cancer patients underreported their alcohol intake 
due to social desirability bias. However, it is also possible that breast cancer patients 
changed their dietary habits due do cancer diagnosis. Cancer diagnosis has been referred 
to as a ‘teachable moment’ for lifestyle changes and may motivate patients to change 
their dietary habits.22  
Patients in our study experienced a variety of symptoms during chemotherapy, but not all 
were associated with energy intake. Specifically, the symptoms of lower self-reported 
taste, lower appetite, less hunger, dry mouth, lack of energy, nausea and difficulty 
chewing were associated with a lower energy intake. These symptoms are known to limit 
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the enjoyment of eating as they make eating more difficult. It is thus not surprising that 
they have been previously related to a lower energy intake.4, 23 Interestingly, self-
judgement of taste was significantly associated with energy intake, but self-judgement of 
smell was not, while smell function is generally recognized as an important factor for food 
intake.24 We must consider that humans are generally not well able to rate their own smell 
sensitivity.25 Therefore, we cannot exclude that reduced smell function influences energy 
intake. The experience of symptoms does not only have an effect on dietary intake, 
symptoms also negatively impact quality of life.26 Therefore it is important to monitor 
symptoms during chemotherapy, and to treat symptoms where possible. Furthermore, 
given the associations of symptoms with dietary intake, it is important to monitor 
nutritional status to ensure an adequate intake of energy and nutrients during 
chemotherapy.  
In addition to experienced symptoms, changed preferences for foods may be related to 
the changed food choices we observed during chemotherapy. Aversions for meat are 
commonly reported during chemotherapy,27, 28 and may thereby underlie the lower intake 
of this food group that we observed in breast cancer patients during chemotherapy 
compared to the women without cancer. However, research on food preferences during 
chemotherapy is mostly anecdotal and scarcely measured quantitatively and should be 
taken into account in future studies.  
Studies suggest that breast cancer patients gain weight during and after chemotherapy.13, 
14 To date, it is not clear which factors underlie these weight changes. However, our study 
does not suggest nutritional intake as a contributing factor for this weight gain, as we 
observe a decreased energy intake of patients during chemotherapy. However, breast 
cancer patients may have a lower energy requirement, as physical activity may be lower.9, 
29 Additionally, reductions in resting energy expenditure have been reported during and 
after chemotherapy.13, 14 Therefore, studies assessing weight change during chemotherapy 
should take changes in dietary intake, physical activity and resting energy expenditure 
into account to assess the contribution of these factors on weight change. 
Previous studies investigating dietary intake during chemotherapy in breast cancer 
patients were heterogeneous in the time points dietary intake was assessed. Mostly, it was 
assessed the week before a next cycle would be administered. In our study, we 
deliberately chose to assess dietary intake at random days during the full cycle of 
chemotherapy, thereby capturing the full variation in dietary intake over chemotherapy. 
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lower during chemotherapy. As alcohol is a known risk factor for breast cancer,21 a higher 
or comparable alcohol intake could be expected in the patient group compared wo the 
women without cancer. Possibly, breast cancer patients underreported their alcohol intake 
due to social desirability bias. However, it is also possible that breast cancer patients 
changed their dietary habits due do cancer diagnosis. Cancer diagnosis has been referred 
to as a ‘teachable moment’ for lifestyle changes and may motivate patients to change 
their dietary habits.22  
Patients in our study experienced a variety of symptoms during chemotherapy, but not all 
were associated with energy intake. Specifically, the symptoms of lower self-reported 
taste, lower appetite, less hunger, dry mouth, lack of energy, nausea and difficulty 
chewing were associated with a lower energy intake. These symptoms are known to limit 
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the enjoyment of eating as they make eating more difficult. It is thus not surprising that 
they have been previously related to a lower energy intake.4, 23 Interestingly, self-
judgement of taste was significantly associated with energy intake, but self-judgement of 
smell was not, while smell function is generally recognized as an important factor for food 
intake.24 We must consider that humans are generally not well able to rate their own smell 
sensitivity.25 Therefore, we cannot exclude that reduced smell function influences energy 
intake. The experience of symptoms does not only have an effect on dietary intake, 
symptoms also negatively impact quality of life.26 Therefore it is important to monitor 
symptoms during chemotherapy, and to treat symptoms where possible. Furthermore, 
given the associations of symptoms with dietary intake, it is important to monitor 
nutritional status to ensure an adequate intake of energy and nutrients during 
chemotherapy.  
In addition to experienced symptoms, changed preferences for foods may be related to 
the changed food choices we observed during chemotherapy. Aversions for meat are 
commonly reported during chemotherapy,27, 28 and may thereby underlie the lower intake 
of this food group that we observed in breast cancer patients during chemotherapy 
compared to the women without cancer. However, research on food preferences during 
chemotherapy is mostly anecdotal and scarcely measured quantitatively and should be 
taken into account in future studies.  
Studies suggest that breast cancer patients gain weight during and after chemotherapy.13, 
14 To date, it is not clear which factors underlie these weight changes. However, our study 
does not suggest nutritional intake as a contributing factor for this weight gain, as we 
observe a decreased energy intake of patients during chemotherapy. However, breast 
cancer patients may have a lower energy requirement, as physical activity may be lower.9, 
29 Additionally, reductions in resting energy expenditure have been reported during and 
after chemotherapy.13, 14 Therefore, studies assessing weight change during chemotherapy 
should take changes in dietary intake, physical activity and resting energy expenditure 
into account to assess the contribution of these factors on weight change. 
Previous studies investigating dietary intake during chemotherapy in breast cancer 
patients were heterogeneous in the time points dietary intake was assessed. Mostly, it was 
assessed the week before a next cycle would be administered. In our study, we 
deliberately chose to assess dietary intake at random days during the full cycle of 
chemotherapy, thereby capturing the full variation in dietary intake over chemotherapy. 
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Although there were no significant differences between the weeks within chemotherapy 
cycles, there was variation within the weeks; dietary intake was lowest in the first week 
after a cycle was administered. This renders the importance to take into account all weeks 
within chemotherapy cycles to give a correct representation of dietary intake during 
chemotherapy. 
It cannot be excluded that differential reporting of dietary intake between patients and 
the comparison group influenced the results of our study. Differential reporting may be 
influenced by differences in BMI.30 BMI was slightly higher in the patient group than the 
comparison group at the start of our study. As persons with higher BMI tend to 
underestimate dietary intake,  the patient group may have underestimated their intake, 
explaining the difference in intake between women with breast cancer and women 
without cancer observed during chemotherapy. However, habitual intake was similar 
between patients and the comparison group at baseline and analyses were adjusted for 
BMI. Therefore, we do not expect that differential reporting substantially influenced our 
results. 
In conclusion, our study is the largest study to date showing that breast cancer patients 
have a lower dietary intake during chemotherapy, which is expressed in a lower intake of 
specific food groups. The lower intake was associated with specific symptoms. These 
finding can guide clinicians to inform patients about the potential impact of 
chemotherapy and related symptoms on dietary intake and to ensure an adequate intake 
of energy and nutrients during chemotherapy.  
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Supplementary table 5.1. Intake per food group for the breast cancer patients during 
chemotherapy and comparison group during follow up (mean ± SE) and the differences in intake 
between the groups in grams. 
Intake in gram* 
(mean ± SE) 
Comparison group Patient group 
Difference 
[95% CI]a 
Bread 124 ± 15.3 110 ± 14.4 -14 [-31 ; 2] 
Cereal and thickeners 35 ± 17.4 37 ± 16.4 2 [-16 ; 21] 
Fruit 131 ± 34.8 125 ± 32.8 -6 [-43  ; 31] 
Vegetables 152 ± 29.1 125 ± 27.4 -27 [-58 ; 4] 
Legumes* 33  ± 10.4 19  ± 9.8 -14 [-25 ; -3] 
Nuts seeds and snacks 14 ± 18.1 8 ± 17.1 -6 [-25 ; 13] 
25 ± 19.5 21 ± 18.4 -4 [-25 ; 17] 
76 ± 29.9 77 ± 28.1 1 [-31 ; 33] 
Soups 
Soy products and 
vegetarian products 
Pastry and biscuits* 40 ± 11.2 25 ± 10.5 -15 [-27 ; -3] 
Sugar, candy, sweet 
toppings, and sweet sauces 
22 ± 6.4 21 ± 6.0 -1 [-7 ± 6] 
Milk and dairy products 260 ± 54.8 247 ± 51.7 -13 [-70 ; 44] 
Cheese* 39 ± 6.5 31 ± 6.1 -8 [-15 ; -1] 
27 ± 6.6 30 ± 6.2 3 [-5 ; 9] Eggs 
Meat, meat products 
and poultry* 
92 ± 14.4 76 ± 13.6 -16 [-32 ; -1] 
Fish 18 ± 12.4 20 ± 11.7 2 [-11 ± 16] 
a Adjusted for age, BMI, education level, smoking status 
*p < 0.05
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Supplementary table 5.2. Energy and macronutrient intake per week within the chemotherapy 
cycle. Week 1: n=90 recalls, week 2: n= 60 recalls, week 3: n=42 recalls. 
a Adjusted for age, BMI, education level, smoking status 
Intake in kcal* 
(mean ± SE) 
Difference 
[95% CI]a 
Energy 
 Week 1 1751 ± 74.1 Ref 
 Week 2 1883 ± 84.0 132 [-54 ; 318 
 Week 3 1861 ± 95.6 110 [-96 ; 315] 
Protein 
 Week 1 267 ± 12.6 Ref 
 Week 2 286 ± 14.4 19 [-14 ; 52] 
 Week 3 283 ± 16.5 16 [-21 ; 53] 
Fat 
 Week 1 621 ± 34.2 Ref 
 Week 2 665 ± 39.0 43 [-44 ; 130] 
 Week 3 671 ± 44.3 50 [-47 ; 146] 
Carbohydrate 
 Week 1 816 ± 38.1 Ref 
 Week 2 863 ± 42.9 47 [-45 ; 139] 
 Week 3 847 ± 48.1 30 [-71 ; 131] 
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Supplementary table 5.3. The association of AHSP and symptom categories and intake of protein, 
carbohydrate and fat (kcal) for the categories that were significantly associated with energy intake.  
Symptom 
Estimate (β) for protein 
intake (kcal)1 
[95%CI] 
Estimate (β) for 
carbohydrate intake 
(kcal)a 
[95%CI] 
Estimate (β) for fat 
intake (kcal)a 
[95%CI] 
3.5* 
[2.0 ; 5.0] 
2.6 
[-2.1 ; 7.3] 
7.7* 
[3.3 ; 12.1] 
5.1* 
[3.1 ; 7.1] 
5.5* 
[0.6 ; 11.5] 
12.6* 
[6.9 ; 18.3] 
4.2* 
[2.7 ; 5.7] 
8.5* 
[3.8 ; 13.2] 
10.2* 
[5.7 ; 14.7] 
-8.0* 
[-15.7; -0.4] 
-7.9 
[-30.3; 14.5] 
-21.0 
[-42.6; 0.7] 
-12.2* 
[-19.5 ; -4.8] 
-12.0 
[-33.5 ; 9.5] 
-22.6* 
[-43.4 ; -1.8] 
-11.1* 
[-21.9 ; -0.2] 
-8.6 
[-39.1 ; 21.9] 
-42.4* 
[-72.3 ; -12.5] 
Tasteb 
Appetiteb 
Hungerb
Dry mouthc 
Lack of energyc 
Nauseac 
Difficulty chewingc
-14.9* 
[-28.4 ; -1.3] 
-20.2 
[-58.6 ; 18.2] 
-61.6* 
[-99.0 ; -24.2] 
a Adjusted for age, BMI, education level, smoking status 
b β for macronutrient intake is the difference in macronutrient intake (kcal) per 1 unit higher score within ASHP 
category. 
c β for macronutrient intake indicates the difference in macronutrient intake (kcal) per 1 unit higher score in 
the symptom.
*p < 0.05
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2.6 
[-2.1 ; 7.3] 
7.7* 
[3.3 ; 12.1] 
5.1* 
[3.1 ; 7.1] 
5.5* 
[0.6 ; 11.5] 
12.6* 
[6.9 ; 18.3] 
4.2* 
[2.7 ; 5.7] 
8.5* 
[3.8 ; 13.2] 
10.2* 
[5.7 ; 14.7] 
-8.0* 
[-15.7; -0.4] 
-7.9 
[-30.3; 14.5] 
-21.0 
[-42.6; 0.7] 
-12.2* 
[-19.5 ; -4.8] 
-12.0 
[-33.5 ; 9.5] 
-22.6* 
[-43.4 ; -1.8] 
-11.1* 
[-21.9 ; -0.2] 
-8.6 
[-39.1 ; 21.9] 
-42.4* 
[-72.3 ; -12.5] 
Tasteb 
Appetiteb 
Hungerb
Dry mouthc 
Lack of energyc 
Nauseac 
Difficulty chewingc
-14.9* 
[-28.4 ; -1.3] 
-20.2 
[-58.6 ; 18.2] 
-61.6* 
[-99.0 ; -24.2] 
a Adjusted for age, BMI, education level, smoking status 
b β for macronutrient intake is the difference in macronutrient intake (kcal) per 1 unit higher score within ASHP 
category. 
c β for macronutrient intake indicates the difference in macronutrient intake (kcal) per 1 unit higher score in 
the symptom.
*p < 0.05
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Abstract  
Purpose: Chemosensory changes are frequently observed side effects of cytotoxic 
treatment and have an impact on daily life by altering food-related behaviour and daily 
practices. For oesophagogastric cancer patients these changes can be particularly 
important as they may have specific needs with regard to eating, due to obstruction of 
the upper intestinal tract. The purpose of this study was to gain insight into the impact of 
chemosensory and food-related changes in oesophagogastric cancer patients undergoing 
chemotherapy and how this may influence the practical and social aspects of food-related 
behaviour of patients and their relatives. 
Methods: We used a qualitative interview approach with a cross-sectional design using 
semi-structured interviews. Template analysis was used to analyse patients' experiences 
with and the impact of chemosensory changes on daily life. Thirteen advanced 
oesophagogastric cancer (OGC) patients treated with capecitabine and oxaliplatin were 
included by convenience sampling, recruited from one academic hospital, and interviewed 
at home or in the hospital. 
Results: There was a large variation in the impact of chemosensory changes in OGC 
patients, though daily life was impacted substantially when chemosensory and/or food-
related changes were experienced. Three main themes emerged from the interviews: 
altered food preferences, practical constraints in daily life, and impact on social 
functioning.  
Conclusion: Chemosensory and food-related changes significantly influenced food 
preferences and had practical and social consequences in daily life of patients and their 
relatives. Specific nutritional care for these patients should be directed towards enhancing 
food enjoyment and should take the specific needs, related to the location of the tumour, 
into account. 
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Introduction  
Taste and smell alterations are among the most common side effects in cancer patients 
undergoing cytotoxic treatment.1-3 Studies have reported a prevalence of 45 to 84% for 
self-reported taste changes and 5 to 60% for smell changes among cancer patients 
undergoing chemotherapy.2 These changes can lead to a decreased appetite, liking and 
enjoyment of food, food avoidance, altered food preferences, food aversions, a reduction 
in food intake and eventually malnutrition in cancer patients.1, 4-10 These different 
alterations in taste and smell may seriously impact patients’ daily life and quality of life. 11-
13 For instance, taste and smell changes can affect daily living, change practical routines 
and may also have an impact on social functioning related to cooking and rituals of 
eating, such as eating together with family and friends.11, 14, 15 In order to support patients 
in the course of their anti-cancer treatment, it is important to further explore these 
experienced chemosensory changes. 
To date, most studies assessing chemosensory changes during chemotherapy were 
executed in heterogeneous study populations undergoing a variety of chemotherapeutic 
regimens.2 However, it has been suggested that the experience of taste and smell 
changes may depend on specific cytotoxic agents used.16 Additionally, patients with 
certain cancer types may experience specific difficulties with respect to eating. For 
instance, in patients with oesophagogastric cancer (OGC), eating may be particularly 
complicated by obstruction of the upper intestinal tract, potentially resulting in a poor 
nutritional status.17 Therefore, it is of specific interest to study how patients and their 
families experience the interactions of these complications with chemosensory alterations 
resulting from cytotoxic treatment.   
So far, no studies have focussed on the impact and consequences of chemosensory 
changes within advanced OGC patients receiving chemotherapy. In order to improve 
supportive care, in particular nutritional advice and management strategies for OGC 
patients with chemosensory changes, a better understanding of the experiences of 
patients is needed. Not only the experience of chemosensory changes and dietary itself 
are of interest, but also the impact of these experiences and the consequences of these 
changes in daily life. 
In this study, we use a qualitative approach to explore the impact of chemosensory and 
food-related changes in advanced oesophagogastric cancer patients undergoing 
chemotherapy with two specific cytotoxic agents, capecitabine and oxaliplatin, and study 
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how this influences the practical and social aspects of food-related behaviour of patients 
and their relatives.  
Methods  
Study design 
We adopted qualitative approach, applying template analysis to describe and interpret 
the lived experience of patients in order to get a deep understanding of these experiences 
at both a general and individual level.18 The study was exempt from formal ethical 
approval by the institutional medical ethics committee of the Academic Medical Centre 
(W14_010). 
Participants 
We included a convenience sample of patients with OGC diagnosed in the Academic 
Medical Centre (AMC) in Amsterdam, the Netherlands. The following inclusion criteria 
were applied: patients with diagnosed oesophageal and stomach cancer who had a 
metastatic or irresectable carcinoma at the time of diagnosis with a WHO performance 
status of 0 to 2,19 who were currently receiving palliative chemotherapy with capecitabine 
(Xeloda®) and oxaliplatin (Eloxatin®) (CAPOX) and had completed at least two cycles of 
chemotherapy. We considered convenience sampling to be adequate for broadly 
exploring the experiences of chemosensory changes following chemotherapy. Patients 
were not purposefully selected on reporting an altered chemosensory perception.  
Data collection 
MK, a clinical dietician and MSc student Nutrition and Health at the time of the study, 
carried out semi-structured interviews. She had no prior relationship with the participants. 
Interviews were held at home or in the hospital, following patients’ preference, and lasted 
approximately 15 - 60 minutes. In the hospital, rooms could be private or shared with 
other patients. During the interviews, patients were often accompanied by a close relative 
or friend, who was allowed to participate in the conversation. The interview guide was 
developed based on key topics from literature and investigators’ knowledge and 
experiences from clinical practice, and further adapted in the course of the study. 
Interviews covered changes in taste and smell, appetite, enjoyment of food, food 
preferences, practical and social consequences, strategies to handle changes, the impact 
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of changes in smell, taste on daily life and the impact of such changes upon diagnosis. 
Interviews were audio recorded.  
Data analysis 
Interviews were transcribed and coded according to the template analysis as described by 
King.20 Template analysis is a thematic analysis where, to analyse the data, the researcher 
identifies a number of codes or themes that summarize key ideas, concepts, actions or 
experiences extracted from the interviews by reading and re-reading the text. Codes are 
organized hierarchically with the highest level codes representing broad themes in the 
data and lower-level codes representing more narrow or specified themes in the data. 
When patients did not experience any changes in chemosensory function, interviews were 
not or only partly transcribed, although all interviews were reviewed for the final template. 
The first two interviews were coded for main themes by MK, together with and YV, a PhD 
student in the field of sensory science and eating behaviour and studies chemosensory 
changes during chemotherapy in cancer patients. The template was further developed in 
discussion with EH, an elderly care physician with specific expertise in qualitative research, 
who was working on separate transcripts. MK and YV constructed the final template on 
the basis of detailed re-reading of the full set of transcripts and discussed their 
interpretations with EH and HvL, a medical oncologist specialized in the treatment of OGC 
patients. 
Results  
Thirteen patients were interviewed for this study, of whom demographic and diagnostic 
data are summarized in Table 6.1. We defined nine themes, each divided into further sub-
themes (Table 6.2). Three main themes pertained strongly to the experience of patients 
and are fully described: altered food preferences, practical constraints in daily life and the 
meaning of chemosensory and food-related changes for social life.  
General findings 
We found a large individual variation in the perceived degree and impact of 
chemosensory changes and other side effects of chemotherapy in patients. Patients who 
experienced mild or few side effects mostly did not experience alterations in their sense of 
smell or taste either. In contrast to other side effects of chemotherapy, patients did not 
always mention changes in taste and smell spontaneously. Nevertheless, these changes 
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were described as important or as having a substantial impact on their daily lives. Some 
patients reported that their daily lives were greatly impacted by chemosensory changes, 
while others experienced the impact as less significant. Two extremes are mentioned; 
Sam, a patient with only minor chemosensory complaints, said:  
‘I do find them noticeable [changes in taste and smell], but I think it’s more important to 
live than to hand in some of the sensory stimuli.’ (Sam) 
Charles, a patient with severe complaints, believes that these chemosensory changes do 
not outweigh the benefits of chemotherapy. 
‘I would not do it again [chemotherapy] if I knew what I know now. (…) Should I be 
severely ill for nine or ten weeks for just a few months extension of my life?’ (Charles) 
Patients found it difficult to describe changes in taste and smell perception as distinct 
features and referred to changes in flavour as a whole or instead jointly ascribed these to 
changes in taste perception. They were, however, perfectly able to articulate what these 
changes entailed: 
‘I used to love cheese, but if I eat cheese now, I cannot taste it. I only taste the saltiness. I 
also used to love quark with blueberries.(...) If you would close your eyes and take a bite it 
just doesn’t taste the way that it used to do.’ (Nicole) 
Patients described changes in taste or smell in terms of having a reduced enjoyment of 
food. 
‘You just hope that it’s over soon, because you don’t enjoy food whatsoever. You just eat 
because you have to, but there is no pleasure in it. You just hope that it will improve 
soon.’ (Jacob) 
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were described as important or as having a substantial impact on their daily lives. Some 
patients reported that their daily lives were greatly impacted by chemosensory changes, 
while others experienced the impact as less significant. Two extremes are mentioned; 
Sam, a patient with only minor chemosensory complaints, said:  
‘I do find them noticeable [changes in taste and smell], but I think it’s more important to 
live than to hand in some of the sensory stimuli.’ (Sam) 
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not outweigh the benefits of chemotherapy. 
‘I would not do it again [chemotherapy] if I knew what I know now. (…) Should I be 
severely ill for nine or ten weeks for just a few months extension of my life?’ (Charles) 
Patients found it difficult to describe changes in taste and smell perception as distinct 
features and referred to changes in flavour as a whole or instead jointly ascribed these to 
changes in taste perception. They were, however, perfectly able to articulate what these 
changes entailed: 
‘I used to love cheese, but if I eat cheese now, I cannot taste it. I only taste the saltiness. I 
also used to love quark with blueberries.(...) If you would close your eyes and take a bite it 
just doesn’t taste the way that it used to do.’ (Nicole) 
Patients described changes in taste or smell in terms of having a reduced enjoyment of 
food. 
‘You just hope that it’s over soon, because you don’t enjoy food whatsoever. You just eat 
because you have to, but there is no pleasure in it. You just hope that it will improve 
soon.’ (Jacob) 
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Table 6.2. Template  
1.     Changes in taste 
1.1.   Reduced taste perception 
1.2.   Enhanced taste perception 
1.3.   Altered taste perception 
1.4.   Constant taste without the presence of food (phantom) 
2.     Changes in smell 
2.1.   Reduced odour perception 
2.2.   Enhanced odour perception 
2.3.   Altered odour perception 
3.     Appetite 
3.1.   Decreased appetite  
3.2.  Improved appetite 
4.     Nutritional advice (dietician) 
4.1.   Adding more fat to the diet/ eating products that contain more fat 
4.2.   Eating more protein-rich foods 
4.3.   Eating more frequently 
5.     Altered food preferences 
5.1.   Need for a more intense flavour 
5.1.1. Addition of condiments  
5.1.2. Choose products with a more distinctive flavour 
5.2.   Need for a less intense flavour  
5.2.1. Less addition of seasonings 
5.3.   Changed food choices 
5.3.1. Favouring warm food 
5.3.2. Taking into account patients’ food preferences 
5.3.3. Food for easy passage oesophagus 
5.3.3.1.          Liquid and smooth food 
5.3.3.2.          Avoiding dry and grainy food 
5.3.3.3.          Drink while eating 
5.4.   Food aversions 
5.4.1. Decreased enjoyment in eating food  
5.4.1.1.          Not liking anything anymore  
5.4.1.2.          Counting nutrients 
5.4.2. Aversion to specific foods  
5.4.2.1.          Aversion towards fried food and hot meals  
5.4.2.2.          Aversion towards meat  
6.     Practical constraints in daily life 
6.1.   Not being able to eat / drink  
6.1.1. Not being able to eat / drink cold products   
6.2.   Not being able to swallow the food  
6.3.   Planning meals and dinners  
6.4.   Adapting to what is still possible to eat  
6.4.1. Liquid and smooth food   
6.4.2. Avoiding dry and grainy food   
6.4.3. Drink while eating 
6.4.4. Trying different foods  
6.4.5. Eating more frequently   
6.4.6. Eating less (frequently)   
6.4.7. Eating smaller portions   
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7.     Social functioning in daily life 
7.1.   Eating (together) less sociable 
7.1.1. Fewer dinners with family and friends 
7.1.2. Planning of meals 
7.2.   Role of partners and family 
7.2.1. Taking into account patients’ food preferences 
7.2.2. Family is motivating (forcing?) patient to eat 
7.2.3. Change of family roles 
7.3.   Decreased pleasure in eating 
8.     Significance of chemosensory changes upon diagnosis 
8.1.   Limited impact of chemosensory changes compared to chemotherapy benefits  
8.2.   Major impact of chemosensory changes compared to chemotherapy benefits  
9.     General side effects of chemotherapy 
9.1.   Food-related side effects 
9.2.   Other side effects 
10.  Changes over time 
10.1.Exacerbation of side effects with increased number of chemotherapy cycles 
10.2.Higher intensity of side effects at start of chemotherapy 
 
Altered food preferences 
A variety of altered food preferences were experienced by patients, which are expressed 
by a need for more or less intense flavours, changed food choices and food aversions.  
To compensate for altered chemosensory perception, some patients described a need for 
more intense flavours, which was reflected by addition of condiments, like sugar, 
seasonings and salt or by choosing products with a distinctive flavour. 
‘I recognised, that during the period that I started tasting less, I used more salt and more 
products with strong flavours. I had also figured to eat herring: besides a lot of nutrients, 
it also has a strong flavour.’ (Abraham) 
Altered chemosensory perception did not always result in a preference for more intense 
stimuli, in contrast, some patients described a need for less intense flavours, specifically 
for spicy products. 
‘I need to be a bit careful not to eat spicy foods. Last Wednesday for instance, I made 
beans with a spicy curry paste and I had to pay the bill all night. That was too spicy, so I 
need to take into account not to use too much spicy herbs.’ (Nicole) 
Besides preferences for more or less intense flavours, patients sometimes needed to 
choose other types of food. Chemotherapy induced an enhanced sensitivity to cold, 
particularly a few days after oxaliplatin infusion, which resulted in a preference for warm 
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foods, the need to wear gloves to get food out of the refrigerator or an urge to put all 
foods in the microwave before consumption. 
Many patients talked about eating food that could easily pass the oesophagus. Some 
patients needed to switch to liquid foods, in order to combat weight loss and maintain 
sufficient energy intake. Some specific dry foods, like bread and meat were avoided, 
because it could not easily pass the oesophagus. 
‘It should easily slide through, it should not be too dry and it has to be tasteful.’ (Sam) 
Another way to swallow dry foods, was to drink along with food. For Wilford this was a 
way to force the food to go down.  
‘If I do not manage to get the food down, I take a glass of apple juice, and swallow the 
food along with the apple juice just to get it inside. I just have to get it inside.’ (Wilford) 
Patients often complained about food aversions, which were frequently related to aversive 
cooking aromas. These aversions could be directed at specific foods, like meat, or more 
general towards reduced enjoyment of eating. 
‘If you cook vegetarian, or just normal, it has a certain smell. (...) It gives a smell which I 
find really annoying now. It causes me to lose my appetite before eating it’ (Wilford) 
Changed food preferences were a challenge for partners and relatives, who had to take 
the altered food preferences into account during shopping and cooking.  
‘You make sure that when you cook a meal you know that he likes it (...) I used to make 
him some oven baked fish, ... but as soon as it was time to eat he looked at his plate, took 
two bites and said “That’s enough, well you don’t have to cook that for me anymore.” ’ 
(Charles’s wife)  
Practical constraints in daily life 
Patients encountered many practical constraints in daily life, mostly because of 
obstruction of the oesophagus. These pertained to not being able to eat, drink or swallow, 
consequences for the planning of meals and dinners, and adapting to what was still 
possible to eat.  
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For some patients the daily routine was changed, meals and dinners were planned at 
different times of the day. For instance for Chadd, the daily pattern was changed in order 
not to get any gastric refluxes during the night. 
‘I’ll eat as much as possible preferably in the early afternoon, around 2 pm or so. Not in 
the evening around 5 or 6 pm. Because I’ve had some of these refluxes at night, it was 
complete panic.’ (Chadd) 
Not being able to swallow the foods made patients slow down and take their time while 
consuming a meal, and therefore taking much more time.  
‘It seems as if the food does not pass that fast, as if it gets stuck. You have to slow down 
your eating, take pauses between bites.’ (Nicole) 
Patients had to adapt to what was still possible to eat, not only by choosing or avoiding 
specific types of food as previously described, but also by changing their food pattern 
into eating smaller portions, eating less frequently, or more frequently but in smaller 
portions.  
 ‘I rather eat more frequent during the day and smaller portions than once or twice a 
large meal.’ (Sam)  
Social functioning in daily life 
Changes in social functioning were presented in several ways; patients felt restricted 
because eating was less sociable, needed to be planned, and was less pleasurable. 
Furthermore, partners and family members played a role in social functioning by adjusting 
themselves to the altered food preferences which sometimes resulted in a change of roles 
within the family.  
Eating with family and friends was less sociable because it was less spontaneous and 
needed to be planned. Furthermore, patients sometimes avoided going out for dinner 
from a fear of not having the appropriate choices on a menu, or a fear for complaints 
during eating. 
 ‘But if you would say: ‘let’s go out for dinner this week with the four of us’, I would say: 
rather not, I’m not that good accompany.’ (Nixon) 
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Partners played an important role in the social aspect of eating. Relatives often tried to 
stimulate patients to eat, by taking into account patients food preferences and ensuring 
sufficient nutritional intake, which made mealtime less spontaneous.  
‘We try to do that [making decisions about dinner] together. Beforehand we think about 
meals for today or for the rest of the week. And by doing so, she [wife] takes care that it is 
not too dry and so on.’ (Sam) 
Patients sometimes tried to force themselves to eat from a feeling of guilt towards their 
partners because of their efforts into making food tasty. 
‘You are eating and think: I’ll stuff it inside, but for my wife it’s not pleasant at all because 
she is trying to make something out of it. I’ll stuff it inside, but actually for me it didn’t 
have to, because it just doesn’t taste right. (Jacob) 
The social aspect of cooking and eating was also changed by a switch of roles for patients 
and partners in the household. A partner may take over grocery shopping and cooking, 
because a patient was not able to do it anymore, or to keep a patient from losing appetite 
from cooking smells by cooking him/herself. 
Chemosensory changes influenced social aspects of eating resulting in a decreased 
pleasure in eating, where the role of a meal changed from something pleasurable into a 
compulsory way to ingest enough nutrients. 
‘Nowadays eating is a ‘necessary evil’. So I do think the social aspect is noticeable. You are 
counting the protein and nutrients and it feels like a mathematical exercise. My wife is 
thinking about the meals we shall try this time.  It is a quest to find what is possible and 
what tastes good and so on. Nutrition and taste have a whole new impact in that way, it’s 
noticeable and not for the better.’ (Sam) 
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Discussion  
This study provides insight on the impact of chemosensory and food-related changes on 
the life’s of oesophagogastric cancer patients undergoing palliative chemotherapy. We 
found a large individual variation in the intensity and impact of changes in taste or smell 
perception among patients. When patients experienced chemosensory and/or food-
related changes, this did not only result in altered food preferences, but also had practical 
implications and meaningfully influenced social life. 
In the current study, a relatively homogeneous group was interviewed, undergoing the 
same cytotoxic treatment, while other studies that examined chemosensory changes 
mainly used heterogeneous groups with respect to type of cancer and/or treatment.2 We 
found that, also in a specific, rather homogeneous group, the impact and meaning of 
chemosensory changes greatly vary. The experiences of chemosensory changes found in 
the current study, generally support existing literature on this topic with respect to altered 
food preferences and changed social aspects of eating. More specific for this particular 
group of patients with OGC are the preferences and practical constraints regarding eating 
food that would easily pass the oesophagus. 
Food preferences were influenced by chemosensory changes during chemotherapy in 
several ways. These are in concordance with previous studies where a need for both more 
and less intense flavours and food aversions to cooking aromas were described.1, 2, 21 
Typical for oxaliplatin treatment was the increased sensitivity to cold food, which resulted 
in a preference for warm food.22  
Although it seems an obvious observation that the obstruction of the oesophagus has 
consequences for food preferences and dietary patterns, there is actually little literature 
available on the experiences of this phenomenon in this patient group. Studies in OGC 
patients have mainly focussed on experiences after surgery rather than during or after 
chemotherapy.23, 24 To our knowledge, this is the first study specifically focussing on the 
experience with regard to eating in this patient group.  
Changes in social aspects of eating were reported as burdensome and entailed several 
aspects of social functioning. Similar to previous studies, mealtime acquired a new 
meaning by becoming a forced way to ingest nutrients, rather than an enjoyable part of 
the day.22, 23, 25, 26 Social consequences, like the inability to eat with family and friends and 
altered family roles, have been reported in previous studies among patients with various 
cancer sites undergoing chemotherapy.11, 22 However, changed social functioning may not 
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be solely due to chemosensory changes, as these social consequences have been 
reported in studies in oesophageal cancer patients that do not undergo chemotherapy, as 
well.23, 25 
Oesophagogastric cancer patients are susceptible to weight loss, which is associated with 
a reduced quality of life and a poor prognosis of the disease.17 The current study shows 
that OGC patients undergoing chemotherapy both have problems regarding 
chemosensory changes and difficulties with obstruction of the oesophagus, hence making 
nutritional advice more complex. Nutritional advice for this patient group therefore should 
be multidimensional and go beyond aiming for sufficient protein and energy intake, 
mainly taking into account the changed food preferences and practical constraints, and 
should aim towards enhancing the enjoyment of food. Furthermore, care strategies 
should not only be directed at the patient but should also take into account the role that 
the partner and family play in a household. Finally, health-care professionals should 
explicitly ask for chemosensory changes, as patients do not always mention these side 
effects spontaneously. Nevertheless, the results of our study show that these changes can 
have a substantial impact on daily life and therefore should not be disregarded in hospital 
practice. 
Applying template analysis as a method to explore the experiences of patients with OGC 
resulted in a rich description of the impact of chemosensory changes and altered food 
preferences on the daily life of patients and their relatives. The inclusion of a small, 
homogenous sample of study participants allowed for in-depth exploration of the lived 
experience of having OGC and suffering from chemosensory changes. We did not 
specifically select patients with previously reported taste or smell alterations, which has 
been done mostly in previous qualitative studies investigating chemosensory changes 
during chemotherapy,11, 22, 27 but instead included also patients experiencing no or little 
changes in their taste and smell perception, to gain insight into a broad range of 
experiences. However, including only patients from the Netherlands, where standard 
cytotoxic treatment for oesophagogastric cancer patients only includes oxaliplatin and 
capecitabine, may limit the transferability of our results to other treatment regimens, 
contexts or countries. In other cultures, pre-existing food preferences may be different 
from those in the Netherlands, including the addition of other spices of the use of other 
ways to prepare food. Moreover, food-related behaviours and the social rituals around 
sharing food together may differ across cultures, resulting in different practical or social 
consequences of both the anatomical changes related to tumour growth and the 
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chemosensory changes following palliative chemotherapy. Future research thus should 
include patients from different cultural backgrounds in different contexts.  
Conclusion 
The present study shows that there was a large variation in the impact of chemosensory 
and food-related changes in OGC patients. These changes had a substantial impact on 
food preferences and had various practical and social consequences in the daily life of 
patients and their relatives. Specific nutritional care for these patients should be directed 
towards higher food enjoyment and take the specific complaints due to the location of 
the tumour into account.  
Acknowledgements 
We thank the participants for their time to be interviewed in the study. Furthermore we 
thank Dieuwerke Bolhuis for her advice in the start-up phase of the study and the staff of 
the outpatient clinical of the Department of Medical Oncology of the Amsterdam Medical 
Centre for their practical help. 
6Chapter 6 
120 
be solely due to chemosensory changes, as these social consequences have been 
reported in studies in oesophageal cancer patients that do not undergo chemotherapy, as 
well.23, 25 
Oesophagogastric cancer patients are susceptible to weight loss, which is associated with 
a reduced quality of life and a poor prognosis of the disease.17 The current study shows 
that OGC patients undergoing chemotherapy both have problems regarding 
chemosensory changes and difficulties with obstruction of the oesophagus, hence making 
nutritional advice more complex. Nutritional advice for this patient group therefore should 
be multidimensional and go beyond aiming for sufficient protein and energy intake, 
mainly taking into account the changed food preferences and practical constraints, and 
should aim towards enhancing the enjoyment of food. Furthermore, care strategies 
should not only be directed at the patient but should also take into account the role that 
the partner and family play in a household. Finally, health-care professionals should 
explicitly ask for chemosensory changes, as patients do not always mention these side 
effects spontaneously. Nevertheless, the results of our study show that these changes can 
have a substantial impact on daily life and therefore should not be disregarded in hospital 
practice. 
Applying template analysis as a method to explore the experiences of patients with OGC 
resulted in a rich description of the impact of chemosensory changes and altered food 
preferences on the daily life of patients and their relatives. The inclusion of a small, 
homogenous sample of study participants allowed for in-depth exploration of the lived 
experience of having OGC and suffering from chemosensory changes. We did not 
specifically select patients with previously reported taste or smell alterations, which has 
been done mostly in previous qualitative studies investigating chemosensory changes 
during chemotherapy,11, 22, 27 but instead included also patients experiencing no or little 
changes in their taste and smell perception, to gain insight into a broad range of 
experiences. However, including only patients from the Netherlands, where standard 
cytotoxic treatment for oesophagogastric cancer patients only includes oxaliplatin and 
capecitabine, may limit the transferability of our results to other treatment regimens, 
contexts or countries. In other cultures, pre-existing food preferences may be different 
from those in the Netherlands, including the addition of other spices of the use of other 
ways to prepare food. Moreover, food-related behaviours and the social rituals around 
sharing food together may differ across cultures, resulting in different practical or social 
consequences of both the anatomical changes related to tumour growth and the 
The impact of chemosensory changes in oesophagogastric cancer patients 
121 
chemosensory changes following palliative chemotherapy. Future research thus should 
include patients from different cultural backgrounds in different contexts.  
Conclusion 
The present study shows that there was a large variation in the impact of chemosensory 
and food-related changes in OGC patients. These changes had a substantial impact on 
food preferences and had various practical and social consequences in the daily life of 
patients and their relatives. Specific nutritional care for these patients should be directed 
towards higher food enjoyment and take the specific complaints due to the location of 
the tumour into account.  
Acknowledgements 
We thank the participants for their time to be interviewed in the study. Furthermore we 
thank Dieuwerke Bolhuis for her advice in the start-up phase of the study and the staff of 
the outpatient clinical of the Department of Medical Oncology of the Amsterdam Medical 
Centre for their practical help. 
Chapter 6 
122 
References 
1. Hong JH, Omur-Ozbek P, Stanek BT, et al. Taste and odor abnormalities in cancer patients. 
The journal of supportive oncology. 2009; 7: 58-65. 
2. Gamper EM, Zabernigg A, Wintner LM, et al. Coming to your senses: detecting taste and 
smell alterations in chemotherapy patients. A systematic review. Journal of pain and symptom 
management. 2012; 44: 880-95. 
3. Foltz AT, Gaines G and Gullatte M. Recalled side effects and self-care actions of patients 
receiving inpatient chemotherapy. Oncology nursing forum. 1996; 23: 679-83. 
4. Sherry VW. Taste alterations among patients with cancer. Clinical journal of oncology 
nursing. 2002; 6: 73-7. 
5. Boltong A and Keast R. The influence of chemotherapy on taste perception and food 
hedonics: a systematic review. Cancer treatment reviews. 2012; 38: 152-63. 
6. Trant AS, Serin J and Douglass HO. Is taste related to anorexia in cancer patients? The 
American journal of clinical nutrition. 1982; 36: 45-58. 
7. Comeau TB, Epstein JB and Migas C. Taste and smell dysfunction in patients receiving 
chemotherapy: a review of current knowledge. Supportive care in cancer : official journal of the 
Multinational Association of Supportive Care in Cancer. 2001; 9: 575-80. 
8. Ravasco P. Aspects of taste and compliance in patients with cancer. European journal of 
oncology nursing : the official journal of European Oncology Nursing Society. 2005; 9 Suppl 2: S84-
91. 
9. Schiffman SS, Sattely-Miller EA, Taylor EL, et al. Combination of flavor enhancement and 
chemosensory education improves nutritional status in older cancer patients. The journal of 
nutrition, health & aging. 2007; 11: 439-54. 
10. Holmes S. Food avoidance in patients undergoing cancer chemotherapy. Supportive care 
in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1993; 1: 
326-30. 
11. Bernhardson BM, Tishelman C and Rutqvist LE. Chemosensory changes experienced by 
patients undergoing cancer chemotherapy: a qualitative interview study. Journal of pain and 
symptom management. 2007; 34: 403-12. 
12. Duffy VB, Fast K, Lucchina LA and Bartoshuk LM. Oral sensation and cancer. 2nd Edition 
ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2002. 
13. Epstein JB, Robertson M, Emerton S, Phillips N and Stevenson-Moore P. Quality of life and 
oral function in patients treated with radiation therapy for head and neck cancer. Head & neck. 
2001; 23: 389-98. 
14. Bernhardson BM, Tishelman C and Rutqvist LE. Taste and smell changes in patients 
receiving cancer chemotherapy: distress, impact on daily life, and self-care strategies. Cancer 
nursing. 2009; 32: 45-54. 
The impact of chemosensory changes in oesophagogastric cancer patients 
123 
15. Rehwaldt M, Wickham R, Purl S, et al. Self-care strategies to cope with taste changes after 
chemotherapy. Oncology nursing forum. 2009; 36: E47-56. 
16. Zabernigg A, Gamper EM, Giesinger JM, et al. Taste alterations in cancer patients receiving 
chemotherapy: A neglected side effect? Oncologist. 2010; 15: 913-20. 
17. Bozzetti F. Nutritional support in patients with oesophageal cancer. Supportive care in 
cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2010; 18: S41-
S50. 
18. Brooks J and King N. Qualitative psychology in the real world: The utility of template 
analysis. 2012 British Psychological Society Annual Conference 18th - 20th April 2012 London, 
UK2012. 
19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. American journal of clinical oncology. 1982; 5: 649-55. 
20. King N and Horrocks C. Interviews in Qualitative Research. Interviews in Qualitative 
Research. London: Sage 2010. 
21. Speck RM, DeMichele A, Farrar JT, et al. Taste alteration in breast cancer patients treated 
with taxane chemotherapy: experience, effect, and coping strategies. Supportive care in cancer : 
official journal of the Multinational Association of Supportive Care in Cancer. 2013; 21: 549-55. 
22. Boltong A, Keast R and Aranda S. Experiences and consequences of altered taste, flavour 
and food hedonics during chemotherapy treatment. Supportive care in cancer : official journal of 
the Multinational Association of Supportive Care in Cancer. 2012; 20: 2765-74. 
23. Wainwright D, Donovan JL, Kavadas V, Cramer H and Blazeby JM. Remapping the body: 
Learning to eat again after surgery for esophageal cancer. Qual Health Res. 2007; 17: 759-71. 
24. Carey S, Laws R, Ferrie S, Young J and Allman-Farinelli M. Struggling with food and eating 
- Life after major upper gastrointestinal surgery. Supportive care in cancer : official journal of the 
Multinational Association of Supportive Care in Cancer. 2013; 21: 2749-57. 
25. Watt E and Whyte F. The experience of dysphagia and its effect on the quality of life of 
patients with oesophageal cancer. European journal of cancer care. 2003; 12: 183-93. 
26. Andreassen S, Randers I, Näslund E, Stockeld D and Mattiasson AC. Patients' experiences 
of living with oesophageal cancer. J Clin Nurs. 2006; 15: 685-95. 
27. Bernhardson BM, Olson K, Baracos VE and Wismer WV. Reframing eating during 
chemotherapy in cancer patients with chemosensory alterations. European journal of oncology 
nursing : the official journal of European Oncology Nursing Society. 2012; 16: 483-90. 
 
6Chapter 6 
122 
References 
1. Hong JH, Omur-Ozbek P, Stanek BT, et al. Taste and odor abnormalities in cancer patients. 
The journal of supportive oncology. 2009; 7: 58-65. 
2. Gamper EM, Zabernigg A, Wintner LM, et al. Coming to your senses: detecting taste and 
smell alterations in chemotherapy patients. A systematic review. Journal of pain and symptom 
management. 2012; 44: 880-95. 
3. Foltz AT, Gaines G and Gullatte M. Recalled side effects and self-care actions of patients 
receiving inpatient chemotherapy. Oncology nursing forum. 1996; 23: 679-83. 
4. Sherry VW. Taste alterations among patients with cancer. Clinical journal of oncology 
nursing. 2002; 6: 73-7. 
5. Boltong A and Keast R. The influence of chemotherapy on taste perception and food 
hedonics: a systematic review. Cancer treatment reviews. 2012; 38: 152-63. 
6. Trant AS, Serin J and Douglass HO. Is taste related to anorexia in cancer patients? The 
American journal of clinical nutrition. 1982; 36: 45-58. 
7. Comeau TB, Epstein JB and Migas C. Taste and smell dysfunction in patients receiving 
chemotherapy: a review of current knowledge. Supportive care in cancer : official journal of the 
Multinational Association of Supportive Care in Cancer. 2001; 9: 575-80. 
8. Ravasco P. Aspects of taste and compliance in patients with cancer. European journal of 
oncology nursing : the official journal of European Oncology Nursing Society. 2005; 9 Suppl 2: S84-
91. 
9. Schiffman SS, Sattely-Miller EA, Taylor EL, et al. Combination of flavor enhancement and 
chemosensory education improves nutritional status in older cancer patients. The journal of 
nutrition, health & aging. 2007; 11: 439-54. 
10. Holmes S. Food avoidance in patients undergoing cancer chemotherapy. Supportive care 
in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1993; 1: 
326-30. 
11. Bernhardson BM, Tishelman C and Rutqvist LE. Chemosensory changes experienced by 
patients undergoing cancer chemotherapy: a qualitative interview study. Journal of pain and 
symptom management. 2007; 34: 403-12. 
12. Duffy VB, Fast K, Lucchina LA and Bartoshuk LM. Oral sensation and cancer. 2nd Edition 
ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2002. 
13. Epstein JB, Robertson M, Emerton S, Phillips N and Stevenson-Moore P. Quality of life and 
oral function in patients treated with radiation therapy for head and neck cancer. Head & neck. 
2001; 23: 389-98. 
14. Bernhardson BM, Tishelman C and Rutqvist LE. Taste and smell changes in patients 
receiving cancer chemotherapy: distress, impact on daily life, and self-care strategies. Cancer 
nursing. 2009; 32: 45-54. 
The impact of chemosensory changes in oesophagogastric cancer patients 
123 
15. Rehwaldt M, Wickham R, Purl S, et al. Self-care strategies to cope with taste changes after 
chemotherapy. Oncology nursing forum. 2009; 36: E47-56. 
16. Zabernigg A, Gamper EM, Giesinger JM, et al. Taste alterations in cancer patients receiving 
chemotherapy: A neglected side effect? Oncologist. 2010; 15: 913-20. 
17. Bozzetti F. Nutritional support in patients with oesophageal cancer. Supportive care in 
cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2010; 18: S41-
S50. 
18. Brooks J and King N. Qualitative psychology in the real world: The utility of template 
analysis. 2012 British Psychological Society Annual Conference 18th - 20th April 2012 London, 
UK2012. 
19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. American journal of clinical oncology. 1982; 5: 649-55. 
20. King N and Horrocks C. Interviews in Qualitative Research. Interviews in Qualitative 
Research. London: Sage 2010. 
21. Speck RM, DeMichele A, Farrar JT, et al. Taste alteration in breast cancer patients treated 
with taxane chemotherapy: experience, effect, and coping strategies. Supportive care in cancer : 
official journal of the Multinational Association of Supportive Care in Cancer. 2013; 21: 549-55. 
22. Boltong A, Keast R and Aranda S. Experiences and consequences of altered taste, flavour 
and food hedonics during chemotherapy treatment. Supportive care in cancer : official journal of 
the Multinational Association of Supportive Care in Cancer. 2012; 20: 2765-74. 
23. Wainwright D, Donovan JL, Kavadas V, Cramer H and Blazeby JM. Remapping the body: 
Learning to eat again after surgery for esophageal cancer. Qual Health Res. 2007; 17: 759-71. 
24. Carey S, Laws R, Ferrie S, Young J and Allman-Farinelli M. Struggling with food and eating 
- Life after major upper gastrointestinal surgery. Supportive care in cancer : official journal of the 
Multinational Association of Supportive Care in Cancer. 2013; 21: 2749-57. 
25. Watt E and Whyte F. The experience of dysphagia and its effect on the quality of life of 
patients with oesophageal cancer. European journal of cancer care. 2003; 12: 183-93. 
26. Andreassen S, Randers I, Näslund E, Stockeld D and Mattiasson AC. Patients' experiences 
of living with oesophageal cancer. J Clin Nurs. 2006; 15: 685-95. 
27. Bernhardson BM, Olson K, Baracos VE and Wismer WV. Reframing eating during 
chemotherapy in cancer patients with chemosensory alterations. European journal of oncology 
nursing : the official journal of European Oncology Nursing Society. 2012; 16: 483-90. 
 

Chemosensory determinants of quality 
of life after systemic therapy for breast 
cancer: the importance of trastuzumab
Y.C. de Vries, C.S. Kelfkens, E.E. Posthuma, S. Boesveldt, 
M.M.G.A. van den Berg, J.Th.C.M de Kruif, A. Haringhuizen, 
D. Sommeijer, N. Buist, S. Grosfeld, C. de Graaf, 
H.W.M. van Laarhoven, E. Kampman, R.M. Winkels
Submitted
Chapter 7
Chapter 7 
126 
Abstract 
Background: Altered taste and smell function are frequently observed during 
chemotherapy. However, little is known about the relationship between taste and smell 
changes and quality of life (QoL), especially after chemotherapy has ended. 
Aim: To assess self-reported taste and smell perception after chemotherapy in breast 
cancer patients, compared to women without cancer, and to determine the association 
between taste and smell perception and QoL after the end of chemotherapy. 
Methods: We included 135 newly diagnosed breast cancer patients that completed 
chemotherapy and 114 women without cancer. Questionnaires on taste, smell and QoL 
were completed shortly after and 6 months after chemotherapy (patients) or at two 
moments that were 6 months apart (controls). 
Results: Self-reported taste and smell perception were significantly lower in patients 
shortly after chemotherapy compared to the control group. Most patients recovered 6 
months after chemotherapy, but patients treated with trastuzumab reported a lower taste 
and smell perception compared to patients not receiving trastuzumab. A lower self-
reported taste and smell was significantly associated with a worse QoL, social, emotional 
and role functioning shortly after chemotherapy. Six months after chemotherapy, taste 
and smell were still significantly associated with QoL, social and role functioning, but only 
in patients treated with trastuzumab. 
Conclusions: Most taste and smell alterations recover within six months after the end of 
chemotherapy for breast cancer, except for patients receiving trastuzumab. These results 
highlight the importance of monitoring taste and smell alterations during treatment with 
chemotherapy and trastuzumab, as they have an impact on quality of life. 
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Introduction 
Taste and smell alterations are amongst the most distressing side effects of chemotherapy 
treatment in cancer patients and may seriously impact everyday life of cancer patients.1 
Qualitative studies show that taste and smell alterations during chemotherapy have an 
impact on patient’s lives in terms of household roles (e.g. partners that take over grocery 
shopping and cooking) and social interactions (e.g. not eating out or inviting friends for 
dinner).2, 3 Quantitative studies have also shown that cancer patients with an altered taste 
and/or smell during chemotherapy, have a lower quality of life.4-7 
Previous research has shown that taste and smell alterations are largely transient, and 
usually recover within the first three months after the end of chemotherapy.8-10 However, 
some studies suggest that taste and smell may be distorted well beyond the end of 
chemotherapy.11-13 To date, there is not much known about clinical factors that influence 
taste and smell perception after the end of chemotherapy, but the subsequent treatment 
that patients receive, may be of potential interest. E.g breast cancer patients treated with 
neo-adjuvant chemotherapy may still undergo surgery and/or radiotherapy, about 60-
75% of patients receive hormonal therapy14 and approximately 30% of patients receives 
trastuzumab.15, 16 It is currently unknown however if, and to what extent, these factors 
relate to taste and smell perception, and whether it is related to quality of life after the 
end of chemotherapy.   
To understand more about the nature and impact of taste and smell changes after 
chemotherapy treatment, the aim of the current study was twofold. First, we assessed 
reported taste and smell changes shortly after, and 6 months after chemotherapy in 
breast cancer patients compared to a group of women without breast cancer. Second, we 
aimed to determine the association between taste and smell perception and quality of life 
(QoL) shortly after and 6 months after chemotherapy. 
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Materials and methods 
Participants 
This study is part of the COBRA-study17, an observational multi-center study among breast 
cancer patients during chemotherapy and a control group of women without cancer of 
similar age. Women with newly diagnosed, stage I-IIIB, operable breast cancer, who were 
scheduled for 2nd or 3rd generation chemotherapy were compared to women without 
cancer of similar age. Eligible participants were at least 18 years old and able to 
communicate in Dutch. Exclusion criteria were: history of cancer, previous treatment with 
chemotherapy, pregnancy or the intention to get pregnant during the study period, 
dementia or other mental conditions that made it impossible to comply with study 
procedures. The protocol was approved by the Medical Ethical Committee of 
Wageningen University (ABR NL40666.081.12). All participants provided written informed 
consent before enrolment. 
Study design 
We assessed self-reported taste and smell perception and quality of life at two moments. 
For breast cancer patients this was within one month after the last chemotherapy cycle 
(T1) and approximately 6 months after the last chemotherapy cycle (T2). In the control 
group this was at two moments that were approximately 6 months apart. In total 135 
patients and 114 controls were included in the analyses. Patients that did not fill in the 
questionnaires within one month after the last chemotherapy cycle (T1), or did not fill in 
the questionnaires within 5-8 months after the last chemotherapy cycle (T2) were 
excluded from the analyses (n=7). On average, the time between the first and second 
measurement was 207±18  days (patients) and 194±17 days (controls). 
Measurements 
Self-reported taste and smell 
The Appetite, Hunger feelings and Sensory Perception (AHSP) questionnaire was used to 
assess self-judgement of taste and smell perception.18 The questionnaire consists of 
questions answered on a 5 point Likert scale. For this study, we used the taste (8 items, 
score range 8-40) and smell (6 items, range 6-30) scale. A higher score corresponds to a 
more positive judgement about current taste and smell perception. 
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To assess the prevalence of taste and smell changes in patients, two questions were 
added from the 16-item taste and smell questionnaire.19 1. “Have you noticed any changes 
in your sense of taste compared to before chemotherapy?” and 2. “Have you noticed any 
changes in your sense of smell compared to before chemotherapy?” Answer possibilities: 
no, it is the same; yes, it is better; yes, it is worse.  
Quality of life 
The EORTC QLQ-C30 was used to assess health related quality of life (QoL).20 For this 
study we used the scales for global QoL, and the functional scales for social, role and 
emotional functioning. Questions were asked on a 4-point Likert scale, and were 
transformed to scales from 0-100 according to the questionnaire guidelines.21 For all QoL 
scales, a higher score corresponds to a better QoL or level of functioning. 
Demographic and clinical characteristics 
All participants filled out a general questionnaire for demographic information which 
included age, smoking status (current, former, never), educational level (low, middle, high) 
and living situation (alone, with partner and/or children). Information on the stage of 
disease at diagnosis (stage I, II or III) and treatment (neo- or adjuvant chemotherapy, type 
of chemotherapy, hormone treatment yes/no, trastuzumab yes/no) was obtained from 
the patients’ medical records. Chemotherapy regimens were categorized to combined 
and sequential regimes. Combined regimes included schemes where all different 
components were administered together during all cycles, such as TAC (6x docetaxel, 
doxorubicine and cyclofosfamide every 3 weeks). Sequential regimes included schemes 
where different components were administered in different cycles such as ACP (ACP: 4 x 
adriamycine and cyclofosfamide every 3 weeks  followed by 12 x paclitaxel weekly). 
Data analysis 
Demographic, clinical variables and prevalence of taste and smell changes are presented 
as mean ± SD or n (%). We used a linear mixed model analysis to assess differences in the 
AHSP subscales for taste and smell and quality of life outcomes over time and between 
groups. Time (T1 and T2) and group (patient and controls) were included in the model as 
fixed factors and participants as random factor.  
Analysis of covariance was used to assess associations between demographic, clinical 
variables (stage of disease, adjuvant/neo-adjuvant treatment, type of chemotherapy, 
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scales, a higher score corresponds to a better QoL or level of functioning. 
Demographic and clinical characteristics 
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and living situation (alone, with partner and/or children). Information on the stage of 
disease at diagnosis (stage I, II or III) and treatment (neo- or adjuvant chemotherapy, type 
of chemotherapy, hormone treatment yes/no, trastuzumab yes/no) was obtained from 
the patients’ medical records. Chemotherapy regimens were categorized to combined 
and sequential regimes. Combined regimes included schemes where all different 
components were administered together during all cycles, such as TAC (6x docetaxel, 
doxorubicine and cyclofosfamide every 3 weeks). Sequential regimes included schemes 
where different components were administered in different cycles such as ACP (ACP: 4 x 
adriamycine and cyclofosfamide every 3 weeks  followed by 12 x paclitaxel weekly). 
Data analysis 
Demographic, clinical variables and prevalence of taste and smell changes are presented 
as mean ± SD or n (%). We used a linear mixed model analysis to assess differences in the 
AHSP subscales for taste and smell and quality of life outcomes over time and between 
groups. Time (T1 and T2) and group (patient and controls) were included in the model as 
fixed factors and participants as random factor.  
Analysis of covariance was used to assess associations between demographic, clinical 
variables (stage of disease, adjuvant/neo-adjuvant treatment, type of chemotherapy, 
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hormone treatment and trastuzumab) and taste and smell, on both time points 
separately. Analysis of covariance was also used to assess the association between taste, 
smell and quality of life. Relevant covariates were included in the models based on 
literature and change of the regression coefficient. Variables changing the regression 
coefficient ≥ 10% in the adjusted model compared to the crude model were included in 
the final model. Final models were adjusted for age. Possible effect modifiers were 
assessed by including interactions in the model. Variables assessed as effect modifiers 
were: adjuvant/neo-adjuvant treatment, type of chemotherapy (combined vs sequential), 
hormone treatment (yes vs no) and trastuzumab (yes vs no). Statistical analyses were 
performed using SPSS statistics version 23 (IBM Corporation, Armonk, New York, USA). A 
p-value <0.05 was considered statistically significant. 
Results 
Demographic and clinical characteristics of the patient and the control group are shown 
in table 7.1. The breast cancer patients had a slightly lower age and higher BMI than the 
women without breast cancer. Furthermore, the patient group had more current smokers 
and fewer former smokers than the control group. The groups were similar in education 
level and living situation. Most patients had a stage II tumor and were treated with 
adjuvant chemotherapy.  
Taste and smell perception over time 
At T1 (shortly after chemotherapy), 65% of patients reported their taste perception as 
worse compared to before chemotherapy, 3% reported a better taste perception and 32% 
reported their taste perception as unchanged. Six months later (T2), 16% of patients 
reported a worse taste perception, 8% a better taste perception and 76% reported their 
taste to be the same as before chemotherapy.  
For smell at T1, 19% of patients reported their smell perception to be worse, 16% reported 
a better smell perception and 65% reported their smell to be the same as before 
chemotherapy. Six months later (T2), only 3% reported a worse smell perception, 12% 
better, and 85% reported their smell perception to be the same as before chemotherapy. 
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Table 7.1. Demographic and clinical characteristics of the participants in the study presented as 
mean (SD) or n (%). 
Control 
n= 114 
Patients 
n= 135 
Demographic characteristics 
Age (years) 55.4 (10.2) 52.5 (9.1) 
BMI (kg/m2) 24.9 (3.5) 26.0 (4.0) 
Smoking* 
 Current 
 Former 
 Never 
10 (9) 
62 (54) 
42 (37) 
21 (15) 
56 (42) 
57 (43) 
Education* 
 Lower 
 Middle 
 Higher 
9 (8) 
32 (28) 
73 (64) 
12 (9) 
42 (31) 
80 (60) 
Living situation* 
 Alone 
 With partner and/or children 
15 (13) 
99 (87) 
16 (12) 
118 (88) 
Clinical characteristics 
Adjuvant chemotherapy 
Neo-adjuvant chemotherapy 
83 (61) 
52 (39) 
Stage 
 I 
 II 
 III 
36 (27) 
79 (59) 
19 (14) 
Chemotherapy 
Combined treatment  
Split treatment 
62 (46) 
73 (54) 
Hormone treatment* 
Yes  
No 
104 (78) 
30 (22) 
Trastuzumab 
Yes 
No 
31 (23) 
104 (77) 
* 1 missing for patient group
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Both shortly after chemotherapy (T1) and half a year after chemotherapy (T2), breast 
cancer patients reported a lower taste perception compared to the control group (figure 
7.1a). However, in the patient group, self-reported taste perception improved over time, 
while the control group remained stable. Results were similar for self-reported smell 
perception (figure 7.1b), although there was no significant difference between patient and 
control group for smell perception at T2. 
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Figure 7.1. Taste and smell scores (mean ± SD) of the AHSP questionnaire over time for the patient 
and control group. T1 represents the first measurement (control) and shortly after chemotherapy 
(patients), T2 represents 6 months after the first measurement (control) or after chemotherapy 
(patients). * indicates a significant difference at p<0.05. 
Determinants of self-reported taste and smell in breast cancer patients 
Both shortly after (T1) and half a year after chemotherapy (T2), the following parameters 
were not significantly associated with self-reported taste or smell; age, BMI, smoking 
status, living situation, education level, stage of disease, receiving adjuvant or neo-
adjuvant treatment, type of chemotherapy and receiving hormone treatment. Only 
trastuzumab showed an association with self-reported taste and smell half a year after 
chemotherapy (T2), but not shortly after chemotherapy (T1). At T2, breast cancer patients 
that received trastuzumab scored 2.6 points lower on the taste scale (β=-2.6, 95%CI: -4.17 
; -1.08, p=0.001) and 2.0 points lower on the smell scale (β=-2.0, 95%CI: -3.12 ; -0.87, 
p=0.001) compared to patients that were not treated with trastuzumab. 
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Quality of Life over time 
Global QoL was significantly lower in the patient group compared to the control group at 
both time points (figure 7.2a), but significantly improved half a year after chemotherapy.  
These patterns between groups and over time were similar for role functioning and social 
functioning (figure 7.2b-c). For emotional functioning, patients scored lower compared to 
the control group at T1 and T2, and this did not improve half a year after chemotherapy 
(figure 7.2d). 
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Figure 7.2. Global Quality of Life (a) and Function scales (b. social, c. role and d. emotional 
functioning) of the EORTC-QLQ-C30 (mean ± SD) over time for the patient and control group. T1 
represents the first measurement (control) and shortly after chemotherapy (patients), T2 represents 
6 months after the first measurement (control) or after chemotherapy (patients). * indicates a 
significant difference at p<0.05. 
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Associations between taste, smell and quality of life shortly and half a year 
after chemotherapy 
In patients, shortly after chemotherapy, a better reported taste and smell was significantly 
associated with better global quality of life, role functioning, social functioning and 
emotional functioning (table 7.2). 
Table 7.2. The association between taste, smell and quality of life outcomes in breast cancer 
patients shortly after chemotherapy (T1), adjusted for age. β represents the difference in QoL 
outcome per 1 unit higher score within the AHSP category. 
Taste β SE p-value 95% CI 
0.99 0.26 <0.001 0.47 ; 1.51 
1.74 0.36 <0.001 1.03 ; 2.44 
1.14 0.32 <0.001 0.51 ; 1.77 
Global QoL 
Role functioning  
Social functioning  
Emotional functioning 0.79 0.28 <0.005 0.24 ; 1.35 
Smell β SE p-value 95% CI 
1.09 0.44 0.02 0.21 ; 1.96 
1.50 0.62 0.02 0.27 ; 2.74 
1.69 0.52 <0.01 0.65 ; 2.72 
Global QoL 
Role functioning  
Social functioning  
Emotional functioning 1.23 0.46 <0.01 0.32 ; 2.14 
The association between  taste, smell and global quality of life, role functioning and social 
functioning, was different for patients receiving trastuzumab compared to patients not 
receiving trastuzumab (table 7.3). Only in patients that received trastuzumab, both a 
better reported taste and smell perception were significantly associated with a better 
global QoL, role functioning and social functioning.  
Self-reported taste and smell perception were not significantly associated with emotional 
functioning half a year after chemotherapy (Taste: β=0.82, 95%CI: -0.15 ; 1.78, p=0.10, 
Smell: β=0.91, 95%CI: -0.42 ; 2.24, p=0.18). 
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Discussion 
In this study we aimed to assess reported taste and smell changes shortly after, and 6 
months after chemotherapy in breast cancer patients compared to a group of women 
without breast cancer. Furthermore, we aimed to determine the association between taste 
and smell perception and quality of life (QoL) shortly after, and 6 months after 
chemotherapy. 
In line with previous studies in breast cancer patients, we show that taste and smell 
perception are altered shortly after the end of chemotherapy, but mostly recover within 
six months after the end of treatment.8, 9 The prevalence of taste (68%) and smell (35%) 
alterations shortly after chemotherapy are also within the range described in previous 
literature for taste (45-84%) and smell (5-60%).22 Interestingly, half a year after 
chemotherapy self-reported taste and smell perception were lower in patients receiving 
trastuzumab compared to patients not treated with trastuzumab. This finding is especially 
relevant, because half a year after chemotherapy, these patients also had a lower quality 
of life, social functioning and role functioning.  
We found that a lower taste and smell perception was associated with a lower quality of 
life, which is in line with previous studies in cancer patients during chemotherapy.4, 5, 23 In 
addition, role and social functioning were affected by a worsened taste and smell 
perception. In daily life, the sense of taste and smell play an important role in eating, but 
also for social communication, personal hygiene and detection of environmental 
hazards.24 For instance, women with good smell function tend to have more active social 
lives than those with diminished smell function.25 In addition, problems with cooking are 
commonly reported in patients with olfactory dysfunction, as they have difficulties with 
smelling whether food is spoiled.24, 26 Furthermore, in cancer patients, role functioning 
may be affected because a partner needs to take over cooking tasks, because cooking 
smells are offensive or nauseating.2, 23 
To our knowledge, this is the first study that assessed taste or smell changes as a primary 
outcome measure in combination with trastuzumab as a factor. Patients treated with 
trastuzumab had a lower taste and smell perception half a year after chemotherapy 
compared to patients not treated with trastuzumab. However, more research is needed to 
confirm our findings. Furthermore, there are several factors that require further 
investigation in the future. Firstly, it is necessary to assess the nature and prevalence of 
taste and smell alterations over the whole treatment trajectory of trastuzumab. For 
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chemotherapy, alterations are the worst early in the chemotherapy cycle, and generally 
recover after chemotherapy has ended. Therefore, assessments of taste and smell 
perception are necessary before, at several moments during, and after the end of 
treatment with trastuzumab. This will give insight as to whether these alterations might 
diminish or worsen over the trajectory, and whether these alterations recover after the 
end of treatment with trastuzumab. Secondly, the possible mechanism how trastuzumab 
can impact taste and smell perception needs investigation. For chemotherapy, the general 
hypothesis is that it acts on rapidly dividing cells, and therapy may therefore also impact 
the taste and smell receptor cells that have a turnover rate of 1 week to a month.27, 28 
Objective measurements of taste and smell function could help to elucidate whether 
these alterations are due to actual dysfunction of the sense of taste and/or smell. 
However, the mechanism of trastuzumab on chemosensory perception is yet unclear. 
Thirdly, research has shown that a lower taste perception during chemotherapy in breast 
cancer patients is associated with a lower energy intake, specifically for protein and fat 
intake.17 Potentially, patients that are treated with trastuzumab and report a lower taste 
perception, have a lower energy intake as well, which might have an impact on their 
nutritional status.  
Unfortunately, there are currently no effective interventions for taste and smell alterations 
in cancer patients. Still, it is important to monitor these alterations over the treatment 
trajectory in breast cancer patients, in particular given the impact on quality of life and the 
potential nutritional consequences. After chemotherapy has ended, specifically patients 
that are treated with trastuzumab are a group of interest that warrant the attention of 
clinicians. 
In conclusion, this study shows that most taste and smell alterations recover after 
chemotherapy for breast cancer, but importantly, not for patients that receive 
trastuzumab. These results highlight the importance of monitoring taste and smell 
alterations during treatment with chemotherapy and trastuzumab, as they have an impact 
on quality of life. 
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General discussion 
Where did we start? 
The starting point of this thesis was the observation that breast cancer patients seem to 
gain weight during and after chemotherapy1, 2, which is characterized by a change in body 
composition, with an increase in fat mass, and a decrease, or no change in lean mass.3, 4 
Potentially, taste and smell changes during chemotherapy could play a role in this change 
in weight and body composition in breast cancer patients, by changing food preferences 
and food intake (figure 8.1).  
 
  
Figure 8.1 Hypothetical chain of events for how taste and smell changes could contribute to weight 
change and body composition.  
 
Furthermore, changed taste and smell perception may not only impact patients through 
changed food preferences and food intake, but can also play an important role in 
everyday functioning and quality of life. This thesis assessed the influence of 
chemosensory changes on food preferences, food intake and quality of life in breast 
cancer patients. To get insight in whether chemosensory changes and their consequences 
during chemotherapy are similar or different in specific cancer populations, this thesis also 
focussed on advanced oesophagogastric cancer patients, as these patients probably have 
a poorer nutritional status upon start with chemotherapy compared to breast cancer 
patients. 
The following research questions were addressed in this thesis: 
1. How can we systematically measure food preferences in terms of macronutrients 
and tastes? 
2. How do (objective and subjective) taste and smell perception change over the 
course of chemotherapy? 
3. How do food preferences and food intake change over the course of 
chemotherapy, and are they related to taste and smell perception? 
4. What are the consequences of chemosensory changes during chemotherapy for 
daily life and quality of life? 
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This final chapter starts with answers to these research questions based on the work 
presented in this thesis, after which methodological considerations are discussed. 
Subsequently the potential role for chemosensory changes in weight change during 
chemotherapy will be discussed, as well as the impact and relevance of these findings for 
clinical practice, and suggestions for future research. This discussion will end with an 
overall conclusion. 
How can we systematically measure food preferences in terms of 
macronutrients and tastes?  
In chapter 2, the development and validation of the Macronutrient and Taste Preference 
Ranking Task (MTPRT) was described.5 The study showed that the MTPRT can detect shifts 
in preferences for both tastes (sweet, savoury) and macronutrients (high-fat, high-
carbohydrate, high-protein and low-energy) upon sensory specific satiety induced by a 
standardized sweet or savoury meal. Furthermore, these results were reproducible under 
similar conditions, demonstrating that the MTPRT is a reliable method to measure 
changes in preferences for macronutrients and tastes. 
How do (objective and subjective) taste and smell perception change over 
the course of chemotherapy? 
We assessed changes in taste and smell breast cancer patients (chapter 4) and 
oesophagogastric cancer patients (chapter 3) undergoing chemotherapy. In both patient 
groups, objectively measured taste function was decreased during chemotherapy. Results 
in breast cancer patients also indicated that this deteriorated taste function was recovered 
half a year after chemotherapy. For objectively measured olfactory function, there was a 
small decrease during chemotherapy in breast cancer patients, but no change in 
oesophagogastric cancer patients.  
Considering subjective measures of taste and smell perception, breast cancer patients 
reported a worsened taste and smell perception during (chapter 4, 5) and shortly after 
chemotherapy (chapter 4, 7), which mostly recovered half a year after chemotherapy 
(chapter 4, 7). However, breast cancer patients receiving trastuzumab, reported a poorer 
taste and smell perception half a year after the end of chemotherapy. In 
oesophagogastric cancer patients, the quantitative study (chapter 3) showed no changes 
in  subjective taste and smell perception, while the qualitative study (chapter 6) did show 
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that oesophagogastric cancer patients experience taste and smell changes during 
chemotherapy. 
Overall, the studies in this thesis show that chemotherapy induces a transient decrease in 
taste and smell perception, which is most pronounced for taste. However, both in breast 
and oesophagogastric cancer patients, subjective taste measures were not associated with 
objective taste measures, indicating that these measures encompass different aspects of 
taste perception. 
How do food preferences and food intake change over the course of 
chemotherapy, and are they related to taste and smell perception? 
Breast cancer patients liked high-protein, high-fat, sweet and savoury products less during 
chemotherapy, as measured with the MTPRT (chapter 4). In contrast, the relative 
preferences (ranking scores) for macronutrients did not shift during chemotherapy. 
Relative preference for savoury products over sweet products was higher during 
chemotherapy in breast cancer patients, but these results could not completely be 
attributed to chemotherapy, as the control group also shifted their taste preferences 
similarly over the study period. The dietary intake during chemotherapy (chapter 5) was in 
line with the changed macronutrient preferences (chapter 4), as breast cancer patients 
had a lower total energy intake, expressed in a lower protein, fat and alcohol intake 
during chemotherapy compared to a control group of women without cancer.  
In oesophagogastric cancer patients, the quantitative study did not show changes in food 
preferences as measured with the MTPRT. However, in the qualitative study  patients do 
report to have altered preferences, for instance to prefer more or less intense flavours, 
specific aversions, avoiding cold food and to prefer food that could easily pass the 
oesophagus.  
In both breast and oesophagogastric cancer patients, objective measures of taste and 
smell were not correlated with food preferences, but self-reported measures were. A 
lower self-reported taste perception was associated with a lower preference or liking for 
high-protein (both patient groups), low-energy, savoury and sweet products (only breast 
cancer patients). Furthermore, a lower self-reported taste perception was associated with 
a lower dietary intake in breast cancer patients (chapter 5). 
Overall, the results show that changed food preferences during chemotherapy are 
macronutrient specific but not taste specific in breast cancer patients, but do not change 
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for macronutrient or tastes in oesophagogastric cancer patients. Only subjective measures 
of taste and smell were associated with food preferences and food intake. 
What are the consequences of chemosensory changes during 
chemotherapy for daily life and quality of life?  
In both oesophagogastric cancer patients (chapter 6) and breast cancer patients (chapter 
7), we showed that taste and smell changes had a negative impact on social and role 
functioning in daily life and quality life. In the qualitative study oesophagogastric cancer 
patients described a substantial impact of chemosensory and food-related changes on 
daily life (by changing daily routines), social life (eating being less sociable) and roles in 
the household (changing roles in cooking and grocery shopping). The quantitative study 
in breast cancer patients showed similar results, with a worse taste and smell perception 
being related to a worse global quality of life, role, social and emotional functioning 
shortly after chemotherapy. In patients treated with trastuzumab, a worse taste and smell 
perception was still associated with quality of life, social and role functioning half a year 
after chemotherapy had ended. 
Overall, our studies showed that in both patient groups, taste and smell changes have a 
significant impact on quality of life and daily life through changed social and role 
functioning. 
Methodological considerations 
Objective versus subjective taste and smell perception 
In this thesis, chemosensory perception was assessed both objectively and subjectively, in 
breast cancer patients and oesophagogastric cancer patients. Although in both patient 
groups objective taste function declined, this did not correlate with subjective experience 
of taste perception, thereby confirming that humans are not well able to rate their actual 
taste or smell function.6-8 However, the factors that influence subjective taste and smell 
perception in cancer patients are not quite clear. Subjective taste perception is likely to be 
related to overall flavour perception, which is influenced by olfactory, gustatory, and 
somatosensory signals.9 Furthermore, it has also been suggested that reported taste 
changes are more hedonic in nature, meaning one refers to food not tasting good 
anymore, which is interpreted as a changed taste perception.10, 11 However, what makes 
food not taste good anymore should be investigated in further research. It has been 
reported in qualitative studies that cancer patients undergoing chemotherapy report to 
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that oesophagogastric cancer patients experience taste and smell changes during 
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be more sensitive to specific odours, or to prefer more or less intense flavours.12, 13 This 
could be further investigated by studying both supra-threshold tastes and odours with 
varying intensities, and assessing these on both perceived intensity and liking. This will 
give insight in whether patients perceive tastes and/or smells as more or less intense, and 
whether that is related to preferences of these tastes and smells. For odours, stimuli 
should be chosen to represent different food categories like in the MTPRT, based on 
macronutrients and tastes, to assess whether the decreased liking we found in breast 
cancer patients is related to the olfactory perception of these food categories.  
Food preferences 
To assess food preferences for macronutrients and tastes, we developed the MTPRT, 
which was described in chapter 2. It was shown that this is a reliable tool when using it in 
an experimental setting by inducing sensory specific satiety. In our studies in cancer 
patients, we used the MTPRT in an observational setting, which clearly has consequences 
for standardization of the testing procedures within and between patients. Ideally, all test 
sessions for all participants would have been at the same time of day, but in practice it 
was only possible to schedule sessions generally at the same part of day (morning or 
afternoon). The rankings of the MTPRT might be more susceptible for daily fluctuations, 
while rating of liking might be less prone to this. This is supported by a series of studies of 
Kramer et al14, who showed that the appropriateness of foods in an eating context did not 
affect liking ratings, but they concluded that including choice in their studies would have 
reflected appropriateness. Possibly, because of the variety in test contexts in the 
observational studies described in this thesis (e.g. different times of day), it was not 
possible to detect systematic shifts in macronutrient or taste preferences in the rankings 
of the MTPRT. Future studies should investigate how factors like time of day, meal 
context, hunger feelings and personal characteristics in a large group of healthy 
participants are of influence on the MTPRT liking and ranking outcomes to substantiate 
this hypothesis.  
Qualitative versus quantitative research 
In chapter 6 we used a qualitative approach to explore the experiences of chemosensory 
and food-related changes in oesophagogastric cancer patients undergoing 
chemotherapy, and its impact on daily life. Qualitative research allows to gain insight in 
the variety of experiences that patients have, but is not designed to quantify the 
frequency of observed experiences. By using qualitative research, is it possible to grasp 
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experiences and nuances that quantitative measures might not capture.15 The qualitative 
study did show that oesophagogastric cancer patients experienced changes in taste, smell 
and food preferences, while self-reported taste and smell and food preferences did not 
seem to change in the quantitative study. Possibly, the quantitative methods were not 
sensitive enough to detect these changes, but it is also possible that some these changes 
were already experienced before the start of chemotherapy. However, the MTPRT was 
designed to measure food preferences for macronutrients and tastes, and it is therefore 
not surprizing that the MTPRT did not detect preferences for more or less intense flavours 
and foods that could easily pass the oesophagus. 
A potential role for chemosensory perception, food preferences and food 
intake in weight change during chemotherapy? 
It was hypothesized that chemosensory changes could have a role in weight gain and 
changing body composition of breast cancer patients, through a shift in food preferences 
from savoury, protein-rich products towards a preference for sweet, carbohydrate and 
fat-rich products. This could subsequently influence dietary intake in terms of lower 
protein intake, higher carbohydrate and fat intake and thereby potentially influence body 
weight and body composition. However, our findings could not confirm this proposed 
sequence of events in breast cancer patients (as summarized in figure 8.2).  
 
 
Figure 8.2. Findings and (hypothetical) associations based on results in breast cancer patients in 
this thesis 
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The results of the breast cancer studies in this thesis suggest that if patients experience 
taste changes, it is more likely that they like high-fat and high-protein products less, 
resulting in a lower total energy, fat and protein intake. Thus, the results do not suggest a 
role for chemosensory changes and diet in weight gain, but more likely in weight loss. 
That is, when other factors that affect energy balance, such as  physical activity, would 
stay the same, but that is probably not the case. Physical activity has been found to be 
lower during chemotherapy in breast cancer.3, 16 However, there is currently an increasing 
focus on staying physically active during treatment, as it has been shown to be beneficial 
for physical functioning, fatigue and side effects like nausea, vomiting and pain.17, 18 
Therefore it is essential to study factors, besides nutritional intake, that could have an 
impact on weight change during chemotherapy. A recent meta-analysis concluded that 
weight gain in breast cancer patients undergoing chemotherapy actually has decreased 
over time19; weight gain was most pronounced in patients treated with CMF regimes, 
which is seldom used in breast cancer patients currently.20 Part of this thesis was 
performed within the COBRA-study, which currently investigates to what extent weight 
gain and changes in body composition during chemotherapy are still occurring with 
current chemotherapeutic regimes in the Netherlands. Our results in breast cancer 
patients may show, that patients who experience no, or mild chemosensory changes, 
might be the patients who stay stable in weight, or gain weight, as suggested by a recent 
qualitative study.21 However, this association has shown mixed results in previous studies, 
by both showing an association between taste and smell changes and weight loss13, but 
also no associations.22, 23 Therefore this should be further investigated in future analyses in 
the COBRA-study, in combination with other factors that may have an influence on weight 
change. 
The results in oesophagogastric cancer patients were in line with findings in breast cancer 
patients, as worse self-reported taste perception was associated with lower preference for 
high-protein products. However, the oesophagogastric cancer patients did not have 
changed subjective taste and or smell perception, or changed food preferences during 
chemotherapy as measured chapter 3. This suggest that the relation between taste 
perception and food preferences might not depend on changes during chemotherapy. 
However, this should be further investigated with studies that also include patients that do 
not undergo chemotherapy. 
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Taste and smell changes during chemotherapy: (why) should we care? 
As mentioned in the previous section, possibly patients who experience no, or mild 
chemosensory changes, might be the patients who stay stable in weight, or gain weight. 
Thus, patients who do experience chemosensory changes, may have a decreased dietary 
intake and are potentially at risk for malnutrition. This already highlights the importance of 
attention for these complaints from a nutritional point of view. Moreover, our results show 
that the impact of chemosensory changes goes beyond nutrition, by having a negative 
impact on daily life and quality of life. Patients are not always specifically informed about 
chemosensory changes and their consequences prior to commencement of 
chemotherapy.22 Being well informed about these alterations may prepare patients about 
this issue and thereby also lead to less discomfort during treatment.24  
It can be beneficial to monitor chemosensory changes during chemotherapy, especially in 
patients who are at risk for malnutrition, like elderly patients and patients with cancer in 
the gastrointestinal tract.25, 26 Malnutrition in cancer patients can in turn lead to poorer 
response to chemotherapy, a longer hospital stay and survival.26, 27 Monitoring taste and 
smell changes may help to signal potential malnutrition in an early stage and may help to 
tailor dietary advice, according to the needs and complaints of cancer patients. Moreover, 
it is important to explicitly ask for these changes, as we found in oesophagogastric cancer 
patients that they do not spontaneously talk about these changes. The studies presented 
in this thesis do not suggest an added value of objective measurement of taste and smell 
perception over subjective taste and smell perception.  
Although currently there are no evidence based interventions or treatments to alleviate 
chemosensory alterations during treatment, in the future these could be designed. These 
interventions should aim to enhance enjoyment of eating, which could possibly be 
designed based on the management strategies that patients report. Furthermore, it is 
important to involve patients’ family and carers in these interventions, as they often take 
over roles within the households. 
Taste and smell changes during chemotherapy: now what? 
Several suggestions for future research were made in the chapters of this thesis and 
throughout this discussion. Here some additional suggestions  are discussed. 
First, there is need for further insight in the mechanisms of taste and smell alterations 
during chemotherapy. Mechanistic work in animal models, investigating the influence of 
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chemotherapy on the gustatory and olfactory epithelium can provide more understanding 
why and how chemotherapy affects chemosensory function. Recently, it was shown that a 
specific signalling pathway (Hedgehog signalling pathway) is essential for taste organ 
maintenance and function.28, 29 This same pathway is inhibited by specific 
chemotherapeutic agents used in basal cell carcinoma30, which explains why patients 
treated with these agents can experience taste disturbances. In addition, animal studies 
suggest that cyclophosphamide induces disruption of umami and salt taste and the taste 
and olfactory epithelium.31-33 Moreover, these studies also showed the temporality of taste 
and which may explain why these changes are cyclic and temporal in humans.22, 34 Animal 
studies thus far are mostly addressing one cytotoxic agent and one specific taste, while 
often cytotoxic agents are used in combinations. Therefore, similar studies using 
combinations of agents with several tastes are needed to provide a better insight how it 
works in humans.  
Furthermore, studies in humans can also give more insight in mechanisms of 
chemosensory changes during chemotherapy in cancer patients. For instance by 
quantification of taste buds, taking papillae biopsies and assessing taste gene 
expression.35, 36 Neuroimaging techniques could also be used during chemotherapy, to 
get insight whether gustatory and  olfactory processing in the brain is different. Doing this 
with different types of stimuli that represent different macronutrients and tastes, as 
proposed under methodological considerations, this can give understanding why certain 
products are more or less liked upon chemotherapy. Furthermore, the role of salivary flow 
on chemosensory perception would be of interest to explore. Saliva acts as a carrier to 
transport taste substances to taste receptors and plays a role in the aroma release in the 
mouth, and thereby contributes to flavour perception.37 A dry mouth and less saliva are 
often reported as a side effect of chemotherapy38, which we also observed in chapter 5 in 
breast cancer patients.39 Potentially, a reduced salivary flow during chemotherapy can 
result in a decreased taste function.40 Finally, it would be of interest to assess the 
similarities and differences between chemosensory changes and food preferences during 
chemotherapy with women during pregnancy. Just like cancer patients during 
chemotherapy, pregnant women frequently report chemosensory changes and food 
aversions.41, 42 Insight in whether the experiences are of similar, or different nature, may 
give information whether these changes have similar aetiologies.  
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Conclusions 
From this thesis we can conclude that chemotherapy affects mainly taste perception, 
which is associated with a lower preference for food products and lower dietary intake. 
Furthermore, chemosensory changes can have a substantial impact on cancer patients’ 
lives, in a practical way by changing daily patterns of eating, but also socially and in roles 
in the household. Our results indicate that it is not necessarily an actual change in the 
sense of taste or smell that has an impact on patients, but flavour perception as a whole 
and possibly a lower enjoyment of food. Worsened chemosensory perception during 
chemotherapy could lead to a worsened nutritional status, and could thereby negatively 
impact the response to chemotherapy. Therefore chemosensory perception should be 
monitored during chemotherapy. Future studies should investigate the mechanisms 
behind chemosensory changes during chemotherapy in more detail, which factors 
contribute to the subjective perception of taste and smell, and possible interventions to 
alleviate chemosensory disturbances during chemotherapy. 
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Summary 
Taste and smell changes are common side effects during chemotherapy in cancer patient 
and may have an impact on food preferences, food intake and quality of life. However, 
these relations have hardly been studied systematically in specific cancer populations. The 
overall aim of this thesis was to assess how the sense of taste and smell change upon 
treatment with chemotherapy in breast cancer and oesophagogastric cancer patients, and 
to investigate their consequences in terms of food preferences, food intake and quality of 
life.  
To measure food preferences for both macronutrients and tastes, the Macronutrient and 
Taste Preference Ranking Task (MTPRT) was developed. in chapter 2, it was shown that by 
inducing sensory specific satiety for a standardized sweet and savoury meal, it is possible 
to detect shifts in preferences for both tastes and macronutrients with the MTPRT, and 
that these results are reproducible. 
In chapter 3 we studied objective and subjective taste and smell perception and food 
preferences in advanced oesophagogastric cancer patients undergoing palliative 
chemotherapy. The result showed that only objective taste function decreases during 
chemotherapy, but other chemosensory measures were unchanged. A lower subjective 
taste perception was related to a lower preference for high-protein products. Therefore it 
is important to consider patients’ taste perception, when providing dietary advice to OGC 
patients 
Chapter 4 describes a study with similar outcome measures as chapter 3, but in breast 
cancer patients at several time points during and after chemotherapy, and compared to a 
healthy control group. The study showed that breast cancer patients like high-protein, 
high-fat, sweet and savoury products less during chemotherapy, thus showing altered 
preferences for macronutrients, but not for tastes. Furthermore, results showed a 
temporary decrease in taste and smell perception during chemotherapy. These findings 
show that patients should be informed prior to treatment on chemosensory changes, and 
that these changes should be monitored during treatment due to the consequences for 
nutritional intake and quality of life 
In chapter 5 we assessed the dietary intake of breast cancer patients before and during 
chemotherapy compared to a healthy control group, and associations with experienced 
symptoms during chemotherapy. It was shown that symptoms induced by chemotherapy 
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were associated with lower total energy, protein and fat intake, which was manifested by a 
lower intake of specific food groups. Therefore, to ensure an optimal dietary intake during 
chemotherapy, it is important to monitor nutritional status and symptom burden during 
chemotherapy in breast cancer patients. 
To better understand the impact of chemosensory changes during chemotherapy on daily 
life, 13 advanced oesophagogastric cancer patients were interviewed (see chapter 6). 
Patients described a substantial impact of chemosensory and food-related changes on 
daily life (by changing daily routines), social life (eating being less sociable) and roles in 
the household (changing roles in cooking and grocery shopping). 
Finally, in chapter 7, we assessed the association between self-reported taste and smell 
perception and quality of life in breast cancer patients. A worse taste and smell perception 
was associated with a worse global quality of life, role, social and emotional functioning 
shortly after chemotherapy. In patients treated with trastuzumab, a worse taste and smell 
perception was still associated with quality of life, social and role functioning half a year 
after chemotherapy had ended. 
From the studies in this thesis we can conclude that chemotherapy mainly affects the 
sense of taste. The subjective perception of taste was associated with a lower preference 
for food products and lower energy intake. This indicates that it is not necessarily an 
actual change in the sense of taste or smell that has an impact on patients, but flavour 
perception as a whole and potentially a lower enjoyment of food. Moreover, these 
perceived changes in taste and smell can have a substantial impact on cancer patients’ 
lives, in a practical way by changing daily patterns of eating, but also socially and in roles 
in the household. A changed chemosensory perception during chemotherapy may lead to 
a worsened nutritional status, and could thereby negatively impact the response to 
chemotherapy. Therefore chemosensory perception should be monitored during 
chemotherapy. Future studies should further investigate the mechanisms behind 
chemosensory changes, factors that contribute to subjective taste perception and possible 
interventions to alleviate chemosensory changes during chemotherapy. 
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Dit is het dan, mijn proefschrift is klaar. Ik heb (letterlijk) bergen beklommen en ben ook 
wel door een paar dalletjes gegaan, maar ik ben ontzettend trots op het resultaat. Het tot 
stand komen van dit proefschrift was niet mogelijk geweest zonder een aantal personen 
die direct of indirect een bijdrage hebben geleverd. Dit dankwoord is ongetwijfeld te lang, 
maar hé, het is eigenlijk één van de weinige hoofdstukken die men daadwerkelijk leest, 
dus geniet ervan! 
Allereerst mijn copromotoren, Renate en Sanne. Renate, het was fijn om jou als 
begeleider te hebben. Bedankt voor je interesse in de wereld van reuk en smaak in 
kankerpatiënten, ook al was dat niet je expertise. Je kon altijd tijd vrijmaken wanneer ik 
weer eens langskwam met de vraag ‘heb je even?’ Dank voor je positieve houding en dat 
je deur altijd openstond wanneer het nodig was, zelfs na je verhuizing naar de Verenigde 
Staten. Sanne, ik ben echt ontzettend blij dat je alsnog bij mijn promotie betrokken werd. 
Ik heb altijd veel gehad aan onze uitgebreide discussies over mijn resultaten, het heeft me 
echt geholpen om ‘mijn mening’ over het veld te bepalen. Ook jouw deur stond altijd 
open. Bedankt voor je altijd eerlijke en directe feedback, en voor het geven van mijn 
meest begeerde award als Best Female-Female Photo Contest winner bij Achems 2016, 
samen met Johanna natuurlijk. 
Dan mijn promotoren, Kees en Hanneke. Kees, bedankt voor je betrokkenheid bij mijn 
promotie, je was er altijd op de momenten dat het nodig was. Jouw jarenlange expertise 
in het sensoriekveld was erg belangrijk om richting te geven aan mijn onderzoek. Onze 
discussies heb ik altijd gewaardeerd en je hebt altijd veel vertrouwen in mij gehad, 
bedankt daarvoor! Hanneke, het was fijn om zowel binnen de COBRA-studie als de 
GUSTO-studie met je samen te werken. Jouw expertise zorgde voor dat extra stukje: ‘wat 
moeten we hier nou mee in de kliniek?’ Je feedback op mijn stukken was altijd op tijd en 
positief geformuleerd, dat heeft me erg gemotiveerd, bedankt!  
Ellen, ook al sta je niet officieel als promotor op mijn boekje, je bent altijd betrokken 
geweest bij mijn proefschrift. Je wist me af en toe op scherp te zetten wanneer er even 
een schepje bovenop moest, en het fijne was dat je meestal ook zag dat er een schepje 
bovenop gedaan was. Ik heb van jou geleerd dat ik met een doordacht plan en duidelijke 
argumentatie mijn eigen plannen kon uitvoeren en zo er ook echt ‘mijn proefschrift’ van 
te maken. Bedankt! 
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Hereby I would also like to thank my thesis committee prof. Lisette de Groot, dr. Sabine 
Boesen Mariani, dr. Ellen Kramer and prof. Thomas Hummel for reading my thesis and 
being present at my defence. 
Een groot deel van mijn tijd heb ik besteed aan de COBRA-studie, die ik gelukkig niet in 
mijn eentje heb hoeven draaien. Allereerst wil ik mijn mede-COBRA-promovendi 
bedanken. Maaike, we zijn een groot deel van onze AIO-tijd kamergenootjes geweest 
waar we lief en leed hebben gedeeld. Ik kijk nog met plezier terug naar hoe we samen de 
Alpe d’Huez hebben beklommen om zo ons steentje bij te dragen aan toekomstig 
kankeronderzoek. Ik waardeer jouw eindeloze inzet om de COBRA-studie en je eigen 
proefschrift tot een succes te maken! Anja, wat heb ik veel geleerd van onze 
samenwerking binnen de COBRA-studie, ik denk dat er weinig mensen zijn met zoveel 
passie voor kwalitatief onderzoek. Succes met het afronden van jouw proefschrift! De 
COBRA-studie had nooit goed kunnen lopen zonder alle hulp van 
onderzoeksmedewerkers Lisette, Celine, Liesbeth en Monique. Lisette, jij wist altijd de rust 
te bewaren, wanneer het soms een kippenhok kon zijn, bedankt! Celine, bedankt voor je 
gezelligheid en het doen van vele sensorische testen. Liesbeth, bedankt voor je 
enthousiasme en altijd positieve blik. Monique, bedankt voor jouw interesse in het 
onderzoek, maar ook vooral in de mensen om je heen. Uiteraard ook dank aan het 
begeleidingsteam van de COBRA-studie, bedankt Jeanne, Marjolein en Marjan voor de 
support en discussies tijdens projectmeetings en dank aan de diëtisten Pauline en Renske 
voor het doen van alle 24h-recalls en het coderen van alle voedingsdata.  
Esther, met het kwalitatieve artikel van de GUSTO-studie heb ik veel met je 
samengewerkt, dank dat je me wegwijs heb gemaakt in het kwalitatieve onderzoek en de 
tijd wilde nemen om er een mooi paper van te maken. 
Geen onderzoek zonder deelnemers, bedankt dat jullie bereid waren om mee te doen 
met de COBRA, GUSTO en FANCY-studie. Mijn speciale dank gaat uit naar de COBRA-
deelneemsters die naast alle ‘standaard COBRA-metingen’ ook nog bereid waren om mee 
te doen aan de sensorische metingen. Veel van jullie heb ik persoonlijk ontmoet, bedankt 
dat jullie je verhaal wilden delen tijdens metingen. Het doen van onderzoek is zoveel 
meer dan getallen die uit metingen komen. 
Ook de artsen en verpleegkundigen van de deelnemende ziekenhuizen ben ik zeer 
dankbaar voor de hulp met het werven van deelnemers voor de COBRA en GUSTO-
studie, zonder jullie betrokkenheid en interesse in ons onderzoek was het nooit gelukt.  
Mijn onderzoek was onderdeel van het TIFN project ‘Sensory & Liking’. Bedankt mede-
promovendi Swetlana, Iris, Irene, Heleen en Jelle voor jullie gezelligheid en betrokkenheid 
binnen het project. Daarnaast wil ik ook alle andere TIFN collega’s bedanken voor de 
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Geen onderzoek zonder deelnemers, bedankt dat jullie bereid waren om mee te doen 
met de COBRA, GUSTO en FANCY-studie. Mijn speciale dank gaat uit naar de COBRA-
deelneemsters die naast alle ‘standaard COBRA-metingen’ ook nog bereid waren om mee 
te doen aan de sensorische metingen. Veel van jullie heb ik persoonlijk ontmoet, bedankt 
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meer dan getallen die uit metingen komen. 
Ook de artsen en verpleegkundigen van de deelnemende ziekenhuizen ben ik zeer 
dankbaar voor de hulp met het werven van deelnemers voor de COBRA en GUSTO-
studie, zonder jullie betrokkenheid en interesse in ons onderzoek was het nooit gelukt.  
Mijn onderzoek was onderdeel van het TIFN project ‘Sensory & Liking’. Bedankt mede-
promovendi Swetlana, Iris, Irene, Heleen en Jelle voor jullie gezelligheid en betrokkenheid 
binnen het project. Daarnaast wil ik ook alle andere TIFN collega’s bedanken voor de 
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samenwerking de afgelopen jaren: Gert, Remco, An, Monicque, Luca, René, Manon, 
Martijn, Sanne, Geja, Sarah, Pascalle, Ben, Annelies, Hugo, Erik, Marion, Corine en Aafke. 
Ik heb een heel aantal enthousiaste BSc en MSc studenten mogen begeleiden de 
afgelopen jaren. Margreet, Helen, Judith, Vera, Gwen, Matty, Ronne, Marlou, Lisette, 
Karen, Lorin en Christel: ik heb jullie met veel plezier begeleid. Bedankt voor het werk dat 
jullie hebben verzet in de verschillende studies en voor de leuke gesprekken, al dan niet 
over jullie thesis. 
De collega’s in het Agrotechnion, Biotechnion, Helix en Futurum hebben veel gezelligheid 
toegevoegd aan mijn promotietijd. Moniek, bedankt voor de gezellige, vaak iets te lange, 
‘netwerkpauzes’. Tijdens de lunches in het Restaurant van de Toekomst en koffiepauzes 
met chocola hebben we een heel hecht netwerk opgebouwd. Superleuk dat je me wilt 
bijstaan als paranimf! En dan mijn andere paranimf, Guido, tegen jou kon ik onbeperkt 
ongenuanceerde opmerkingen maken. Bedankt voor de afleiding in ons Helixkantoor met 
de drone, je sarcastische grappen en toch ook een luisterend oor. Ik vind het echt knap 
hoe jij alle ballen hoog weet te houden in je drukke leven. Supertof dat je me ook nog wilt 
bijstaan als paranimf! 
Gezellige, positieve en altijd behulpzame Suzanne, onze samenwerking was zoals onze 
communicatie: lekker duidelijk, en daardoor heel plezierig. Naast onze samenwerking was 
het ook fijn om ons laatste jaar kamergenootjes te zijn en samen door de laatste loodjes 
te gaan. 
Jet, de stelling ‘stickers motivate to do a good job’ heeft het helaas niet gehaald als 
stelling. Toch heeft onze partnership als ‘sticker en deadlinebuddy’ er wel voor gezorgd 
dat iedereen die mijn proefschrift ontvangt daar ook een paar motiverende stickers bij 
krijgt. De mini-deadlines zorgen ervoor dat ik toch vooruitkwam op dagen dat het niet zo 
makkelijk ging. Bedankt voor alle coole plaatjes! 
Mijn tijd in het Helix was nooit zo gezellig geweest zonder de kamergenootjes die ik nog 
niet genoemd heb, Irene, Ilse, Kamalita en Rachelle. Bedankt voor de gezelligheid, de 
leuke verhalen en het aanhoren van mijn frustraties. Irene, bedankt voor jouw altijd 
verrassende verhalen, ik ga ze echt missen!  
Ik heb goede herinneringen aan het Agrotechnion, niet per se aan het lekkende gebouw, 
maar vooral aan de collega’s op de 3e en 4e verdieping. Bedankt Janne, Laura, Agnes, 
Marije, Agnes, Anouk, Rieneke, Pim, Martin, Nikkie en Mirthe voor de koffiebreaks, 
gezellige lunchpauzes, etentjes en borrels natuurlijk. 
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De afgelopen jaren stond ik met 1 been in de sensoriekgroep, en de andere in de voeding 
& kankergroep. Bedankt Monica, Gerry, Paul, Marcus, Astrid, Janet, Korrie, Victoire, Eva, 
Roelien, Patricia, Cristina, Johanna, Elbrich, Santiago, Marielle, Apple, Janneke, Dieuwertje, 
Fränzel, Klaske, Moniek, Merel (2x), Harm, Jesca, Rogier, Anne en Suzanne voor de 
Eetclubs, Tasty Talks, Journal Clubs en gezellige groepsuitjes.  
Gea, Jasmijn, Jacqueline, Karen, Didi en Cornelia, bedankt voor jullie hulp bij allerhande 
zaken die toch essentieel zijn.  
Lieve vrienden en (schoon)familie, jullie zijn altijd geïnteresseerd geweest in wat ik de 
afgelopen jaren heb gedaan. De Friezen, Alie, Johannes, Sybren, Klaas-Thomas en 
Tryntsje: Hulde! De sensory club, Jacco, Roos, Daan, Alard, Linda en Maria: bedankt voor 
de gezellige spontane borrels en barbecues! Lieve Marjan, we hebben elkaar zo’n 10 jaar 
geleden ontmoet als AID-zusjes, nu zijn we nog steeds goede vriendinnen, bedankt voor 
de leuke weekendjes Concert at Sea en de vele etentjes en borrels! 
Lieve ‘Bakkers’, Bart, Riet, Andrea, Lars, Ineke, Paco, Marieke, Jaco en alle kids, de tripjes 
naar Middelharnis, Den Haag, Ouddorp en Kinderdijk zijn altijd vol gezelligheid. Ik voel 
me ontzettend thuis in de familie. 
Lieve Jolijn en Ilse, er gaat weinig boven een dag vol zussenpraat, al maken de mannen 
Vitho en Bernd en natuurlijk mijn lieve nichtjes Fardau en Lieke het nóg leuker!  
Lieve pap en mam, bedankt dat jullie er altijd voor me zijn en altijd vertrouwen in me 
hebben. Een weekendje Friesland was en is nog steeds altijd ontspannend door de fijne 
gesprekken, de wandelingen, het werken in de tuin en de uitgebreide diners. Ik ben blij 
dat we straks weer wat dichter bij elkaar wonen. 
Dan als laatste, allerliefste Albert, ik weet het, ‘het is maar werk’. Je hebt er vol van kunnen 
meegenieten de afgelopen jaren. Bedankt dat je me elke keer weer met mijn benen op de 
grond zet en me laat beseffen dat er zoveel dingen belangrijker zijn dan werk. Jouw 
onvoorwaardelijke steun geeft me de rust die ik nodig heb. Ik kan niet wachten op onze 
nieuwe, toekomstige avonturen! 
Dit was het, mijn decennium in Wageningen zit erop. 
Doei, tabée en de groeten, 
Yfke 
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